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ABSTRACT: THE RISE AND FALL OF THE BOVINE CORPUS LUTEUM
Heather A. Talbott, Ph.D.
University of Nebraska, 2017
Supervisor: John S. Davis, Ph.D.
This dissertation describes a study of the mechanisms regulating the genesis and subsequent
involution of the temporary endocrine structure, the corpus luteum (CL), through the use of a
bovine model. The CL is essential for maintaining a suitable uterine environment for embryo
implantation and early development through secretion of the steroid hormone progesterone. The
“Rise and Fall” of the CL occurs within each estrous cycle whereby the CL must form from the
ruptured follicle, secrete sufficient progesterone for uterine maturation, and at the end of the cycle
(or pregnancy) regress to allow new follicular development. During the rise of the CL, the
composition and regulation of lipid droplets (LDs) were studied and it was determined that LDs
are a common luteal cell structure formed by day 3 post-ovulation, and store both cholesteryl
esters and triglycerides. Additionally, the LD-associated proteome was examined and established
that steroidogenic enzymes are enriched in purified LD fractions. Demonstrating that luteal LDs
may serve as critical mediators of steroidogenesis by storing steroid precursors in close
association with steroidogenic enzymes. At the fall of the CL, alterations in the luteal
transcriptome revealed changes consistent with early activation of cytokine signaling. One such
cytokine, C-X-C motif chemokine ligand 8 (previously IL-8), was assessed for its ability to
regulate luteal cell function. CXCL8 expression was determined to be induced in bovine luteal
cells via p38 and JNK signaling and could induce bovine neutrophil migration. However,
neutrophils had no effect on progesterone secretion unlike activated peripheral blood
mononuclear cells which could inhibit luteal cell progesterone secretion. In total, the studies
described herein indicate that both LDs and cytokines play important roles in CL development,
function, and regression.
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GRAPHICAL ABSTRACT

The Rise and Fall of the Bovine Corpus Luteum
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Diagram depicting the rise (left) and fall (right) of the bovine corpus luteum (CL).
Development of the CL begins from a mature follicle (bottom left) with a well vascularized
theca layer and multi-layered mural granulosa cells. Ovulation of the follicle begins the
transformation into a functional CL (top) through angiogenic growth into the granulosa layer
and differentiation of granulosa and theca cells into large and small luteal cells. During CL
development, lipid droplets (LDs) form and store cholesteryl esters. These LDs maybe an
important source of luteinizing hormone (LH)-stimulated progesterone synthesis. At the end
of the estrous cycle, prostaglandin F2alpha (PGF2α) released from the bovine uterus will
trigger luteal regression, in part through stimulation of cytokine and cytokine signaling events.
These processes result in decreased progesterone production and involution of the CL.
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CHAPTER 1: INTRODUCTION
Luteal Lipid Droplets and Metabolic Pathways
Regulate Steroidogenesis in the Corpus Luteum *
Abstract
This review focuses on recent advances in the understanding of metabolic processes used by
the corpus luteum to control steroidogenesis and other cellular functions. The corpus luteum (CL)
has abundant lipid droplets that are believed to store cholesteryl esters and triglycerides. Recent
studies in other tissues indicate that cytoplasmic lipid droplets serve as platforms for cell
signaling and interactions with other organelles. Lipid droplets are also critical organelles for
controlling cellular metabolism. Emerging evidence demonstrates that luteinizing hormone (LH)
via activation of the cAMP and the protein kinase A (PKA) signaling pathway stimulates the
phosphorylation and activation of hormone-sensitive lipase (HSL) an enzyme that hydrolyzes
cholesteryl esters stored in lipid droplets to provide cholesterol for steroidogenesis and fatty acids
for utilization by mitochondria for energy production. The energy sensor adenosine
monophosphate (AMP)-activated protein kinase (AMPK) can inhibit steroidogenesis by
interrupting metabolic pathways that provide cholesterol to the mitochondria or the expression of
genes required for steroidogenesis. In addition to lipid droplets, autophagy also contributes to the
regulation of the metabolic balance of the cell by eliminating damaged organelles and providing
cells with essential nutrients during starvation. Autophagy in luteal cells is regulated by signaling
pathways that impact AMPK activity and lipid droplet homeostasis. In summary, a number of
signaling pathways converge on luteal lipid droplets to regulate steroidogenesis and metabolism.
Knowledge of metabolic pathways in luteal cells is fundamental to understanding events that
control the function and life span the corpus luteum.

The material presented in this chapter was previously published: Talbott and Davis. Lipid Droplets and
Metabolic Pathways Regulate Steroidogenesis in the Corpus Luteum. The Life Cycle of the Corpus Luteum
2017 161
*
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Recent research has provided great insight into mechanisms contributing to corpus luteum
formation, function, and regression. Many of these studies have focused on changes in gene and
protein expression and activity. The availability of new techniques for metabolomics, lipidomics,
and proteomics has renewed interest in determining how cellular metabolic events control
steroidogenesis. Specifically, there is an interest in understanding how lipids are stored and
utilized during the lifespan of the corpus luteum. One of the notable features observed during
luteal development is the acquisition of cytoplasmic lipid droplets (LDs). These unique organelles
are surrounded by a phospholipid monolayer which coats a core of neutral lipids including
cholesteryl esters and triglycerides. Lipid droplets have been most extensively studied in
adipocytes and preadipocytes, for their pivotal role in energy conservation and homeostasis 1,2,
however, LDs have been observed in nearly all cell types, from prokaryotes 3 to hepatocytes 4,
cardiac myocytes 5, macrophages 6, and steroid-secreting cells 7,8. In many of these cells, LDs are
a sign of pathological stress because of an overabundance of environmental lipids (e.g., the foamy
macrophage seen in atherosclerotic lesions 6). However, LD formation and presence in
steroidogenic tissues such as the ovarian follicle and corpus luteum appears to be nonpathological and required for healthy, fully-functional steroidogenic ovarian cells.
1.1. Lipid droplets
Recent reviews point to cytoplasmic LDs as critical mediators of metabolic health and disease
1,9,10

. Intracellular LDs store triglycerides and cholesteryl esters as reservoirs for energetic

substrates (fatty acids) or cholesterol for membrane biosynthesis or sterol production 11,12. They
also serve to protect cells from lipotoxicity 13. The key to understanding LD size and activity is
the presence or absence of specific LD coat proteins 14. The family of perilipin (PLIN) proteins
(PLIN1-5) serves as LD coat proteins and organizing centers for enzymes and transporters in lipid
metabolism 15–17. The PLIN family of proteins is composed of PLIN1 (also called perilipin),
PLIN2 (adipophilin or ADRP), PLIN3 (previously Tip47), PLIN4 (previously S3-12) and PLIN5
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(previously OXPAT). PLIN1 and PLIN4 are highly expressed in white adipose 16; whereas
PLIN2, PLIN3 and PLIN4 are widely expressed; PLIN2 is abundant in liver and PLIN5 is found
in oxidative tissues like heart and brown adipose 18. Plin1 null mice have a distinct phenotype of
reduced fat mass, increased lipolysis and increased β-oxidation 19. Plin2 null mice are resistant to
high fat diet-induced obesity 20, and Plin3 compensates for the loss of Plin2 in these mice 21.
Inactivation of Plin4 down-regulates Plin5 and reduces cardiac lipid accumulation in mice 22. It
seems, therefore, that the level of PLIN proteins in specific cell types regulates lipolysis in target
tissues. Reports in the monkey 23 and mouse 24 indicate that the ovary expresses PLIN2, an LD
coat protein associated with cholesteryl ester storage 25. We have found that the bovine corpus
luteum predominantly expresses mRNA for PLIN2 and PLIN3 with low levels of PLIN1, a
different pattern of PLIN transcript expression when compared to adipose tissue (Figure 1-1 A).
Bovine large and small luteal cells express comparable levels of PLIN2 and PLIN3 mRNA but
different levels of PLIN1 and PLIN4 mRNA (Talbott, Krauss, and Davis, unpublished). Exactly
how the LD-associated PLINs impact luteal LDs and steroidogenesis are subjects of current
investigation.
Hormone-sensitive lipase (HSL) is a key cytosolic enzyme in the regulation of lipid stores in
adipocytes that translocates to the LD in response to catecholamine stimulation 26–28. A current
view of the mechanisms regulating lipolysis in adipose tissue suggests that the LD-associated
PLIN1 coats the LD and functions as a scaffold in the regulation of lipolysis 16,29,30. Under basal
conditions, PLIN1 acts as a barrier to the hydrolysis of lipids within the LD by preventing access
of adipose triglyceride lipase (ATGL) and HSL, the major lipases in adipose cells. Following βadrenergic stimulation of cAMP and protein kinase A (PKA) signaling, PLIN1 and HSL are
phosphorylated, which leads to the movement of HSL from the cytosol to the LD 31. The
phosphorylation of HSL facilitates its association with the LD and with lipid substrates once
associated with the LD 32 permitting lipid hydrolysis to proceed. Phosphorylation of HSL by PKA
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occurs on multiple sites, including Ser‐563 and Ser‐660, which stimulate catalytic activity and
translocation of HSL to LDs 33–36. Phosphorylation of HSL also occurs at Ser-565, a non‐PKA
site, which is a negative regulator of HSL activity and is believed to be mutually exclusive with
phosphorylation on the Ser‐563 site 37. Thus, hormonal cues that signal for elevations in systemic
energy stimulate PKA to phosphorylate HSL which contributes to lipolysis to maintain energy
homeostasis.
The presence of both PLIN coat proteins 38 and HSL 39 in the ovary suggests that LH via a
cAMP/PKA signaling pathway may regulate the phosphorylation of PLINs and HSL to hydrolyze
cholesteryl esters stored in luteal LDs to produce substrate for synthesis of steroids such as
progesterone, which is an obligate precursor of all biologically active steroids. Studies with HSLnull mice revealed that knockout of HSL resulted in decreased steroidogenesis in the adrenals and
inhibited sperm production in the testis 40,41. These findings suggest that HSL is involved in the
intracellular processing and availability of cholesterol for adrenal and gonadal steroidogenesis.
Manna et al. recently reported that activation of the PKA pathway in MA-10 mouse Leydig cells,
the testosterone-producing cells of testes, enhanced expression of HSL and its phosphorylation at
Ser-563 and Ser-660 42. Inhibition of HSL activity suppressed cAMP-induced progesterone
synthesis and resulted in increased cholesteryl ester levels in MA-10 cells. Also of interest is a
report 43 demonstrating an interaction between StAR (steroidogenic acute regulatory protein) and
HSL in the rat adrenal following treatment with adrenocorticotropic hormone. Co-expression of
StAR and HSL resulted in elevated HSL activity and mitochondrial cholesterol content. These
observations suggest that the proteins that produce and transport cholesterol may co-localize in
LDs and mitochondria. Furthermore, we have observed that mitochondria are closely associated
with cytoplasmic LDs in bovine luteal cells (Figure 1-1 B) indicating that luteal LDs and
mitochondria may interact to facilitate steroidogenesis. While the evidence points to an important
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role for HSL in steroidogenesis, there is little information concerning the LD and the events that
control these early steps in ovarian steroidogenesis 44.
Despite the renewed interest in cytoplasmic LD as platforms for cell signaling, interactions
with other organelles, and metabolic control 45,46, few studies have characterized the protein and
lipid composition of the LD. The LD proteome has been characterized to varying degrees in a few
mammalian tissues or cell lines [mouse mammary epithelial cells 47 and 3T3-L1 adipocytes 48,49,
rat liver and mouse muscle tissue 50,51, and human cell lines 52–54]. Khor et al. compared the
proteome of LDs from rat granulosa cells treated in vitro with either high-density lipoproteins or
fatty acids to enrich cytoplasmic LDs with cholesteryl esters or triacylglycerides, respectively 55.
When comparing the LD proteomes a large number of proteins (278) were common to the LDs
prepared from either treatment. These proteins included PLIN2 and were similar to other studies
on LD proteomes. They also identified 61 proteins unique to the cholesteryl ester-rich LDs and 40
unique proteins unique to triacylglycerol-rich LDs. Notably, they identified steroidogenesis
associated proteins, Hsd3b1, vimentin, and voltage-dependent anion channel (Vdac1) proteins
enriched in the cholesteryl ester-rich LDs. Recent reports on the proteomic analysis of LD
isolated from the mouse Leydig tumor cell line MLTC-1 56, and mouse testes 57 also revealed the
presence of PLIN family proteins and enzymes involved in the synthesis of steroid hormones.
Despite the recent work on characterization of the LD proteome in various tissues, there is still a
lack of information about the protein composition of luteal LDs and the effects of hormones or
metabolic alterations on luteal LD properties. In our studies (Talbott, Krauss, and Davis,
unpublished) the LDs isolated from bovine luteal tissue predominantly contain PLIN2 and PLIN3
coat proteins, as well as HSL, HSD3B1, CYP11A1, and StAR. Collectively, these studies
indicate that the LD may serve as a novel hormonally-responsive platform that is essential for
steroidogenesis.
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Comprehensive analysis of the lipid composition of LDs in other tissues is just beginning to
be evaluated 58. The protein composition of LDs, particularly the PLIN family of LD coat proteins
is believed to influence the type of lipids stored in LDs and metabolic activity of tissues 1,59. The
lipid composition of ovarian LDs and the effects of hormones on the lipids contained therein are
currently unknown. Our preliminary studies indicate that compared to granulosa and theca cells,
the total lipid content of luteal cells is increased. Several studies reported the types and changes
of lipids in the intact corpus luteum of rats 60, pigs 61,62, sheep 63 and humans 64. These studies
reported that cholesteryl esters and free fatty acids remain relatively constant during the
functional phases of the luteal lifespan while triglycerides accumulated in the regressing corpus
luteum. The increased lipid content of luteal cells is likely to be stored exclusively within the
LDs; however, this remains to be shown experimentally. Additional studies are needed to
determine the role and fate of lipids in LDs during both function and regression of the corpus
luteum.
Bovine and ovine corpora lutea have two distinct steroidogenic cells, large and small luteal
cells, with different abilities to produce progesterone 65–67. The small luteal cells respond to LH
with large increases in progesterone secretion while the large luteal cells have a high basal rate of
progesterone secretion and respond to LH with a comparatively modest fold increase in
progesterone secretion. The luteal tissue of women, monkeys, pigs, and rodents also possess large
and small luteal cells, although the basal and LH-stimulated progesterone secretion differ from
the bovine corpus luteum 68. Our preliminary data indicate that bovine large and small luteal cells
have LDs with distinctive morphology. As indicated by BODIPY 493/503 staining of neutral
lipids (green) and the LD protein ATGL small luteal cells have large LDs, whereas large cells
have abundant dispersed small LDs (Figure 1-1 C & D). Whether and how the LDs in either cell
type contribute to the ability to respond to LH or to the basal rate of progesterone secretion is
currently unknown. Studies in other tissues indicate that PKA-dependent phosphorylation of
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PLIN1 induces dispersion of clustered LDs in HEK293 cells, fibroblasts, and 3T3L1 adipocytes
69,70

. Based on these findings it seems possible that the dispersed LDs observed in bovine large

luteal cells may be the result of constitutive PKA activity reported to be present in large luteal
cells 71.
Fatty acids (either synthesized de novo or provided by the hydrolysis of stored cholesteryl
esters, triglycerides or phospholipids) are essential for energy production and the synthesis of
most lipids, including those found in membranes and lipids involved in cellular signaling. Despite
their fundamental physiological importance, an oversupply of non-esterified fatty acids can be
detrimental to the cellular function 10. Fatty acids are transported across the outer mitochondrial
membrane by carnitine palmitoyltransferase I (CPT1A), the rate-limiting step in fatty acid
oxidation. Fatty acids are consumed by mitochondria through β-oxidation to produce acetyl-CoA
and nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) for use
in the electron transport chain to produce adenosine triphosphate (ATP) 72. The hydrolysis of
cholesteryl esters by HSL liberates cholesterol and fatty acids (Figure 1-2). The fatty acids are
either re-esterified and stored in LDs or membranes or used for β-oxidation producing reducing
equivalents and acetyl-CoA for the citric acid cycle 72. Although little is known about the role of
fatty acid β-oxidation in luteal cells, recent studies indicate that fatty acid β-oxidation plays a key
role in cumulus-oocyte complex metabolism and oocyte maturation 73,74. These studies found that
promoting β-oxidation with L-carnitine improved embryo development and pharmacologic
inhibition of fatty acid β-oxidation with etomoxir, a CPT1A inhibitor, impaired oocyte maturation
and embryo development. Steroidogenic tissues use glycolysis to support steroidogenesis 75,
however, it seems likely that the production of large quantities of progesterone by luteal cells
would also require β-oxidation of fatty acids to provide the energy needed for optimal
steroidogenesis under basal conditions, but this remains to be critically evaluated. It seems likely
that large and small luteal cells may have different energy processing requirements, based on the
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pronounced differences in the ability of large and small luteal cells to produce progesterone under
basal and stimulated steroidogenesis. Our preliminary studies indicate that CPT1A mRNA
expression in large luteal cells is 5.6 fold greater than in granulosa cells, whereas no difference in
CPT1A mRNA expression was observed between theca and small luteal cells. This data supports
our idea that β-oxidation may play an important role in the metabolic regulation of large luteal
cells. Given the intense interest in pathologies that result in lipid accumulation and conditions
(i.e. obesity, diabetes, metabolic syndrome) that elevate free fatty acids and alter metabolism,
understanding how LDs, glycolysis, and β–oxidation are regulated in the corpus luteum may
provide clues for improving ovarian function, treating ovarian disorders, and enhancing fertility.
1.2. AMP-activated protein kinase
AMP-activated protein kinase (AMPK) is a master regulator of cellular metabolism 72,76. The
AMPK complex is a heterotrimer consisting of an α catalytic subunit, and non-catalytic β and γ
regulatory subunits 77. Studies from a number of investigators demonstrated that AMPK is present
in the oocyte, granulosa and theca cells as well as luteal cells [reviewed in Bertoldo et al. 78]. As
its name suggests, AMPK is allosterically activated by adenosine monophosphate, AMP. The
enzyme is activated by increases in AMP : ATP or ADP : ATP ratios, which occur when cellular
energy status has been compromised by metabolic stresses that either interfere with ATP
production or that accelerate ATP consumption 79. AMPK acts to restore energy homeostasis by
activating alternate catabolic processes generating ATP while inhibiting energy-consuming
processes, e.g., protein, carbohydrate, and lipid biosynthesis, as well as cell growth and
proliferation (Figure 1-3). AMPK acts via direct phosphorylation of metabolic enzymes, and by
longer-term effects via phosphorylation of transcription regulators 80,81.
AMPK can be activated by a number of synthetic allosteric effectors (A-769662, 991, MT
63-78) identified by Abbott laboratories using high throughput screens for AMPK. Other
allosteric effectors are salicylate, the major breakdown product of aspirin, and pro-drugs: 5-
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amino-imidazole-4-carboxamide riboside (AICAR) and C13, which are converted into AMP
analogs following cellular uptake. For example, AICAR, a widely used AMPK activator, is taken
into cells and then converted to the monophosphorylated derivative ZMP, which mimics the
effect of AMP both on the allosteric activation of the kinase and inhibition of the
dephosphorylation of Thr-172 on AMPK. Pharmacological AMPK activators (e.g., metformin,
berberine, resveratrol, and hydrogen peroxide) are typically viewed as metabolic poisons that
inhibit ATP synthesis and stimulate AMPK indirectly by increasing cellular AMP levels 79.
Activation of AMPK by upstream kinases occurs by phosphorylation of a conserved threonine
within the ‘activation loop’ of the kinase domain (Thr-172). The primary upstream kinases that
phosphorylate Thr-172 are the tumor suppressor liver kinase B1 (LKB1) (also known as serine
and threonine kinase 11 or STK11), and the calcium/calmodulin-dependent protein kinase kinase
2, CAMKK2. The latter is activated when intracellular Ca2+ is increased by the action of
hormones.
The AMPK likely controls multiple aspects of metabolism in ovarian cells. AMPK
phosphorylates and inactivates acetyl-CoA carboxylase (ACC) and 3-hydroxy-3-methylglutarylCoA reductase (HMGCR), key enzymes involved in regulating de novo biosynthesis of fatty
acids and cholesterol (Figure 1-3). Activation of AMPK also blocks the activation of the
mechanistic target of rapamycin (MTOR) and protein synthesis by phosphorylating the key
regulatory proteins, raptor and tuberous sclerosis proteins 81. Another immediate consequence of
enhanced AMPK activity is the phosphorylation of HSL at Ser‐565, which precludes activation of
HSL by PKA 82. Conversely, conditions that stimulate PKA‐induced phosphorylation of HSL at
Ser‐660 and Ser‐563 suppress the phosphorylation of HSL at the AMPK site Ser‐565. In vitro
kinase assays using purified PKA and AMPK support the notion that phosphorylation of HSL at
Ser‐563 and Ser‐565 is mutually exclusive. Thus, in steroidogenic tissues, activation of AMPK
can inhibit HSL-mediated hydrolysis of cholesteryl esters and prevent the release of free

10

cholesterol for steroidogenesis 83. The observation that HSL is a key enzyme in adipocytes and
steroidogenic cells strategically positions AMPK to control the expression of genes required for
steroidogenesis and the availability of cholesterol for ovarian progesterone synthesis (Figure 1-4).
Reports from the DuPont laboratory 84,85 demonstrate that AMPK activators metformin and
AICAR inhibit the secretion of progesterone and/or estradiol by granulosa cells in a manner
dependent on the state of cellular differentiation and the species investigated 78,84,86. In rat and
bovine granulosa cells, AMPK activation induced by metformin reduced the expression of
mRNA for key enzymes required for progesterone synthesis, HSD3B1, CYP11A1 and StAR 85,87.
In the human KGN granulosa cell line (Huang, Hou and Davis, unpublished) treatment with the
AMPK activator metformin inhibited StAR mRNA expression and progesterone synthesis. In
general, the studies in granulosa cells suggest that the reduction in steroidogenesis was a result of
a reduction in the transcription of genes in the steroidogenic pathway. Other studies showed that
metformin impairs proliferation of bovine granulosa cells and rat theca cells via mechanisms
involving AMPK-mediated inhibition of MTOR signaling and protein synthesis 88–90.
Bowdridge et al. recently reported increases in the expression of AMPK α, β, and γ subunits
during the maturation of the bovine corpus luteum, with the exception of AMPK γ1 and γ2
subunits 91. Other studies from the Flores laboratory provide evidence for increased expression of
genes encoding distinct protein kinase C isoforms and genes participating in Ca2+ homeostasis
during luteal maturation 92. Goravanahally et al. 93 reported that CAMKK2, a downstream target
of Ca2+ and upstream regulator of AMPK is also more highly expressed in mature bovine corpus
luteum than in newly formed luteal tissue. It should be noted that two important physiologic
processes occur during this developmental period; 1) the corpus luteum develops its maximal
capacity for progesterone secretion and 2) the corpus luteum develops the capacity to undergo
luteolysis in response to PGF2α. Based on the high rate of progesterone production during the
mid-luteal phase and pregnancy, it seems likely that any factors that influence metabolic activity
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in steroidogenic cells would increase or decrease AMPK activity and impact steroid secretion.
Hou et al. 94 reported that treatment of primary cultures of bovine luteal cells with AICAR rapidly
increased AMPK activity and significantly reduced LH-stimulated MTOR activity and
progesterone secretion. Additional findings in this report indicated that the inhibition of MTOR
with rapamycin did not contribute to the reduction in LH-stimulated progesterone secretion. More
recently, Bowdridge et al. observed that treatment of bovine luteal tissue slices with either
metformin or AICAR acutely reduced basal progesterone secretion 91. These results indicate that
AMPK activators acutely inhibit luteal progesterone synthesis indicating that the energy status of
luteal cells is an important regulator of steroidogenesis.
1.3. LH inhibits AMPK
The C-terminal domains of AMPK α subunit isoforms in vertebrates contain a
serine/threonine (ST)-rich insert of 50–60 amino acids, the so-called ‘ST loop’ 95.
Phosphorylation of the ST loop serves as a means for negative regulation of AMPK. The amino
acid residues defining the ends of this loop are close to the Thr-172 residue and contain a number
of regulatory phosphorylation sites. The best characterized of these sites is Ser-485 on the AMPK
α1 subunit. The Ser-485 site is phosphorylated by the cyclic AMP-dependent protein kinase, PKA
96

or AKT 97, which subsequently inhibits the phosphorylation of the AMPK α subunit Thr-172

residue by upstream kinases, LKB1 or CaMKK2 95. The AMPK-α2 subunit contains a similar
conserved ST loop and phosphorylation of Ser-491 is likely to exert the same inhibitory effect,
although Ser-491 is a poor substrate for AKT and appears to be also modified by
autophosphorylation 95. Additionally, PKA can phosphorylate the Ser-173 residue (adjacent to
Thr-172 within the activation loop), which can inhibit Thr-172 phosphorylation 98. In a study
using primary cultures of bovine luteal cells, Hou et al. reported that treatment with LH rapidly
inhibited AMPK activity as evidenced by reduced AMPK Thr-172 phosphorylation and reduced

12

phosphorylation of the AMPK substrate ACC 94. Treatment with LH also increased
phosphorylation of AMPK on Ser-485, which is associated with inhibition of AMPK activity 94.
In contrast to granulosa cells, bovine luteal cells contain the required steroidogenic machinery
including HSL, which enables luteal cells to respond to LH or cAMP with rapid increases in
progesterone synthesis. The increases in progesterone occur within 10-30 min 99–101 and precede
the LH-induced increase in StAR expression, which is typically observed 2-4 hours after
treatment 102. These changes are associated with reduced phosphorylation of HSL at the inhibitory
AMPK phosphorylation site Ser-565 and increased phosphorylation of HSL at Ser-563 and 660,
residues that are required for HSL activity (Krause, Talbott, Hou and Davis, unpublished). Thus,
the ability of LH to reduce AMPK activity may allow optimal LH- and PKA-dependent activation
of HSL and provide cholesterol for the already existing steroidogenic machinery. An
experimental model of the proposed interaction among PKA and AMPK regulation of HSL is
shown in Figure 1-4. Physiologic conditions that increase the activity of AMPK require
phosphorylation of the AMPKα subunit on Thr-172 residues 103. This leads to the phosphorylation
of the AMPK substrates: ACC (Ser-79) and HSL (Ser-565), which could reduce the ability of
luteal cells to provide cholesterol substrate in response to a pulse of LH. LH or PKA activators
attenuate AMPK activity through modulation of at least two AMPKα-subunit phosphorylation
sites, Thr-172 (reduced) and Ser-485 (increased). Reduced HSL phosphorylation by AMPK
allows PKA to phosphorylate HSL on Ser-563 and Ser-660 resulting in increased HSL activity
which presumptively provides cholesterol for progesterone synthesis.
1.4. PGF2α activates AMPK
Early studies established that PGF2α binds to and activates its cognate Gq protein-coupled
receptor, the prostaglandin F receptor, PTGFR. This initial event provokes the rapid activation of
phospholipase C, which leads to increases in both cytoplasmic Ca2+ and activation of protein
kinase C. These early events contribute to the activation of additional protein kinase cascades like
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the mitogen-activated protein kinases (ERK1/2, p38, and Jun N-terminal kinase (JNK)) 104 that
contribute to the induction of early responses genes like Finkel-Biskis-Jinkins murine
osteosarcoma viral oncogene homolog (FOS), Jun proto-oncogene (JUN ), early growth response
protein 1 (EGR1), and activating transcription factor 3 (ATF3) 105–108. While these early response
genes have been implicated in the luteolytic response to PGF2α, it is not clear how or whether they
impact metabolic events in luteal cells. The developmental-specific expression of protein kinase
C and CAMKK2 isoforms, proteins involved in Ca2+ homeostasis, and AMPK have been
implicated in the cellular mechanisms of acquisition of luteolytic capacity by bovine corpus
luteum 92,93,109. Based on these observations it seems reasonable to predict that PGF2α could
activate Ca2+/CAMKK2 pathways leading to the activation and phosphorylation of AMPK on
Thr-172.
Bowdridge et al. recently reported that PGF2α rapidly (2 min) and transiently stimulated the
phosphorylation of AMPK on the Ser-485 site in dispersed bovine luteal cells 91. The response
was prevented by treatment with STO-609, a CAMKK2 inhibitor. Treatment with STO-609 also
prevented the modest inhibitory effect of PGF2α on progesterone synthesis in overnight
incubations of dispersed luteal cells91. In recent studies using bovine large luteal cells, we have
observed that PGF2α rapidly stimulates the phosphorylation of AMPK on the stimulatory Thr-172
residue as well as the inhibitory Ser-485 residue (Hou, Zhang, Talbott, and Davis, unpublished
data). The phosphorylation of AMPK was coupled to the phosphorylation of the AMPK target
ACC, indicating that AMPK was activated by PGF2α. The observation that PGF2α can target
multiple sites on AMPK is consistent with findings that PGF2α activates multiple protein kinase
pathways in luteal cells; pathways linked to calcium signaling, protein kinase C, mitogenactivated protein kinases, and MTOR signaling 110. While additional studies are needed to
determine exactly how PGF2α regulates AMPK in luteal cells, it seems clear that activation of
AMPK with pharmacologic tools disrupts luteal progesterone synthesis (Figure 1-5). Studies are
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also needed to determine whether AMPK is activated in vivo during natural and PGF2α -induced
luteolysis. It is conceivable that changes in luteal blood flow, hypoxia, and the presence of
inflammatory mediators all contribute to altering the metabolic status of steroidogenic luteal cells,
resulting in the activation of AMPK and disrupting progesterone synthesis.
1.5. Autophagy
Autophagy plays an important role in cellular and tissue physiology 111–113. The main function
of autophagy is to protect cells against starvation by allowing cells to salvage nutrients by
digesting organelles and macromolecules at times of nutrient scarcity as well as to ensure cell
homeostasis by eliminating damaged organelles and misfolded proteins. Three different types of
autophagy (macroautophagy, microautophagy, and chaperone-mediated autophagy) have been
described, based largely on the processes by which cargo is delivered to lysosomes. In general,
autophagy can be induced by limitations in amino acids, growth factors, energy, and oxygen. The
formation of autophagosomes requires the activation of a number of protein complexes: the
autophagy-related 1 (Atg1)–Unc-51-like kinase complex, which is a key signaling intermediate
that is regulated by MTOR and AMPK; the autophagy-specific class III phosphatidylinositol 3kinase Vps34 complex (consisting of Vps34, Beclin 1, Vsp15 and Atg14L), which produce a pool
of phosphatidylinositol-3-phosphate that is necessary for autophagosome formation; and a
complex of ubiquitin-like proteins: Atg12, Atg5, Atg16 and LC3-I (Atg8) and their conjugation
machinery, which leads to the lipidation of microtubule-associated protein light chain 3 (LC3)
with phosphatidylethanolamine, a process required for autophagosome formation and closure.
The presence of LC3-II, an LC3 cleavage product, inside the mature autophagosome is generally
used as a marker of autophagy.
Autophagy has been shown to occur in oocytes, granulosa cells, and luteal cells and is often
associated with apoptosis. Genetic mouse models demonstrate that Atg7 (-/-) ovaries 114 or germ
cell-specific deletion of Atg7 115 compromised autophagy in the perinatal mouse ovary resulting
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in the early loss of female germ cells. Loss of Beclin 1 (Becn1), which plays a central role in the
regulation of autophagy through activation of the Vps34 complex, also resulted in a significant
loss of germ cells at birth 114. These findings indicate that autophagy may promote survival of
germ cells during ovarian development. Other studies provide evidence for the presence of
autophagosomes in the granulosa cells of atretic follicles of several species 116,117. Studies in the
rat support the idea that activation of the AKT/MTOR signaling pathway suppresses autophagy as
assessed by levels of LC3-II in granulosa cells 116.
The presence of lysosomes and autophagosomes in the corpus luteum was described over 45
years ago 118–121. Recent studies have documented the presence of autophagy-related proteins:
Beclin 1 and LC3 in the luteal tissue of rodents, cows, and humans 122–125. However, in luteal
cells, it remains unclear whether a certain level of autophagy promotes cell survival versus cell
death. In the rat, LC3-II positive autophagosomes were identified during the late luteal phase and
were correlated with luteal cell apoptosis 125,126. Furthermore, treatment of rat luteal cells with
PGF2α under serum-free conditions increased autophagosomes, LC3-II protein, and luteal cell
apoptosis, suggesting that autophagy may be involved in luteal cell death. Choi et al. observed
that although PGF2α increased both ERK1/2 and MTOR activity in rat luteal cells, autophagy
could be prevented by inhibition of ERK1/2 signaling and appeared to be independent of
phosphatidylinositol 3-kinase/AKT/MTOR activity 126. It will be important to understand the
sequence of events in vivo and to determine whether the stimulatory effects of PGF2α on AMPK
activation are linked in some way to autophagy in the corpus luteum.
Gawriluk et al. reported that Becn1 deficiency in the mouse ovary resulted in a reduction of
progesterone production and preterm labor 122. To avoid the loss of germ cells associated the
Becn1 knockout animal, this group targeted Becn1 deletion to the granulosa cells and as a result,
they were able to follow luteal function throughout pregnancy. Although ovulation, implantation,
and progesterone levels during early pregnancy were not affected by Becn1 ablation, they found
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that Becn1 abrogation resulted in a reduction of circulating progesterone in mid to late pregnancy.
The reduction in progesterone resulted in early parturition, which was reversed by treatment with
exogenous progesterone. Of relevance to luteal metabolism were the findings that the numbers of
LDs were reduced and the mitochondria were smaller in the Becn1 deficient ovaries compared to
controls. These changes were not accompanied by changes in the expression of genes important
for the synthesis of progesterone. Exactly how the reduction in LDs and reduced autophagy
contributed to reduced progesterone synthesis remains to be firmly established, but could be a
consequence of impaired lipid transport mechanisms and reduced expression of key receptors
(hormone and cholesterol-uptake) on the luteal cells 122. Studies in other systems indicate that
Becn1 expression and activity is controlled via transcriptional regulation, miR-30a, and by posttranslational modifications (reviewed in 127). Recent studies in cardiac tissue showed that the
transcription factor ATF3 binds to the ATF/cAMP response element of the Becn1 promoter and
that ATF3 is capable of reducing autophagy via suppression of the Becn1-dependent autophagy
pathway 128. Since PGF2α rapidly increases activation of mitogen-activated protein kinases
(ERK1/2, p38, and JNK) and ATF3 expression in bovine and rat luteal cells in vivo and in vitro
104,107

, it is important to determine whether PGF2α inhibits autophagy through changes in Becn1

expression or activity during luteal regression.
It should also be appreciated that Becn1 directly interacts with B-cell lymphoma 2 (Bcl2)
family proteins (Bcl2 and Bcl2/XL) in a manner that negatively regulates autophagy. To
complicate matters, a variety of ligands that regulate intracellular protein kinases, including
Dapk, Rock1, Mst1, and Mapk8, (death-associated protein kinase 1, rho-associated coiled-coil
containing protein kinase 1, macrophage stimulating 1, mitogen-activating protein kinase 8,
respectively), can positively or negatively regulate Becn1/Bcl2 effects on autophagy 127. Beclin 1
can also secondarily affect apoptosis through regulation of anti-apoptotic and pro-apoptotic BH3
domain-containing proteins. In addition to the Bcl2 family, the VDAC (voltage-dependent anion
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channel) family is also involved in ovarian apoptosis and autophagy regulation 129. Vdac2 directly
interacts with Bcl2-antagonist/killer 1 (Bak1) to inhibit its oligomerization, thus suppressing cell
apoptosis. Yuan et al. recently reported that Vdac2 inhibits autophagy in the developing ovary by
interacting with Becn1 and Bcl2L1 to stabilize the Becn1 and Bcl2L1 complex 129. Recent work
by several groups has found a close relationship between autophagy and LDs 130–132. In particular,
LC3 131, ATG2 133, ATG7 130 and several VDAC 56,57 proteins are often associated with LDs and
appear to play important roles in LD formation and function. This suggests that events associated
with autophagy may also impact the formation and function of ovarian LDs. Further work is
needed to understand how LDs and autophagosome components influence both autophagy and
apoptosis and thereby affect luteal function and lifespan.
1.6. Summary
Metabolic processes in the corpus luteum are tightly controlled by luteotropic and luteolytic
factors. Signaling cascades involving LD homeostasis, PKA, AMPK, and autophagy are clearly
important in the control of steroidogenesis. It remains to be determined how these cellular events
are integrated into a physiologic context over the lifespan of the corpus luteum. Understanding
the complex interplay of metabolic and hormonal clues underpinning steroidogenesis is essential
to understanding and developing new therapies for infertility, particularly in the setting of
increasing prevalence of obesity and metabolic diseases such as diabetes and polycystic ovary
syndrome.

18

Figure 1-1 – Lipid droplets in bovine large and small luteal
cells
Large and small bovine luteal cells express lipid droplet (LD)
coat proteins and have unique LDs. Panel A: Expression of the
PLIN family of LD coat proteins in bovine white adipose tissue,
corpus luteum, and centrifugal elutriation-enriched large and
small luteal cells (LC). Reverse transcriptase-polymerase chain
reaction (RT-PCR) analysis of mRNA isolated from bovine fat
and luteal tissue. Panel B: Electron microscopy of LDs and
mitochondria (Mt) in a bovine luteal cell. Panels C and D: Small
and large luteal cells were stained with Bodipy 493/503
(Molecular Probes, 10 μg/ml) to detect neutral lipids (green).
Nuclei: DAPI (blue). Cells in Panel D were stained with adipose
triglyceride lipase (red) showing colocalization with the LDs and
the difference in LD morphology between small and large luteal
cells. Previously published in 161.
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Figure 1-2 – Potential role of hormone-sensitive lipase
in luteal cells
Hormone-sensitive lipase (HSL) stimulates the hydrolysis
of cholesteryl esters (CE) stored in lipid droplets to
liberate cholesterol and fatty acids. The cholesterol is
converted to pregnenolone by the cytochrome p450 sidechain cleavage enzyme (CYP11A1) in the mitochondria
and subsequently converted by the enzyme 3β-hydroxysteroid dehydrogenase (HSD3B) to progesterone. The
released fatty acids (FA) are re-esterified and stored in the
lipid droplets or used for energy production by
mitochondrial β-oxidation. Previously published in 161.
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Figure 1-3 – Roles of luteinizing hormone and AMP-activated kinase in progesterone
secretion
Luteinizing hormone (LH) stimulates cAMP and protein kinase A (PKA) to activate proteins
that will supply cholesterol for progesterone synthesis. The master metabolic regulator AMPactivated protein kinase (AMPK) is a highly conserved metabolic fuel gauge and can influence
progesterone secretion by luteal cells. Elevations in AMP to ATP ratios stimulate AMPK to
restore energy homeostasis by activating alternate catabolic processes generating ATP while
inhibiting energy-consuming processes, i.e., protein, carbohydrate and lipid biosynthesis, as well
as cell growth and proliferation. Activation of AMPK can disrupt steroidogenesis by
phosphorylating and inhibiting hormone sensitive lipase (HSL) and blocking HMGCR (3hydroxy-3-methyl-glutaryl-coenzyme A reductase), the rate-controlling enzyme of the pathway
that produces cholesterol. AMPK can be activated by the tumor suppressor kinase liver kinase
B1 (LKB1) and the Ca2+/calmodulin activated protein kinase CaMKK2, which is activated when
intracellular Ca2+ is increased by hormones like PGF2α. Previously published in 161.
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Figure 1-4 – Potential mechanisms of activation and
inhibition of hormone sensitive lipase in luteal cells
Luteinizing hormone (LH) stimulates protein kinase A
(PKA)-dependent phosphorylation on Ser-563 and Ser660 resulting in activation of hormone sensitive lipase
(HSL), which hydrolyzes cholesteryl esters (CE) stored
in lipid droplets (LD) to release cholesterol and fatty
acids (FA). AMP-activated protein kinase (AMPK)
suppresses the activation of HSL by phosphorylation of
HSL on Ser-565. LH also inactivates AMPK by
increasing AMPK phosphorylation on Ser-485 and
reducing phosphorylation on Thr-172. The ability of LH
to suppress AMPK and activate HSL ensures adequate
cholesterol availability for progesterone synthesis.
Previously published in 161.
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Figure 1-5 – Counteracting mechanisms of luteinizing
hormone and prostaglandin F2α in luteal cell
steroidogenesis
LH and PGF2α have opposite effects on AMP-activated
protein kinase (AMPK). LH-dependent activation of
protein kinase A (PKA) activates of hormone sensitive
lipase (HSL). In contrast, activation of AMPK blocks
activation of HSL. LH-dependent stimulation of cellular
metabolism regulates the use of glucose and fatty acids
(FA) for optimal progesterone synthesis. Conditions that
activate AMPK (hormones, cytokines, reduced nutrients,
reduced blood flow, hypoxia, drugs, and environmental
insults) reduce the ability of LH to provide cholesterol for
progesterone synthesis. Previously published in 161.
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CHAPTER 2: COMPOSITION OF THE LIPID DROPLETS OF THE BOVINE
CORPUS LUTEUM †
Abstract
Establishment and maintenance of pregnancy are dependent on the ability of the ovarian
corpus luteum (CL) to synthesize progesterone. The ovulatory surge of luteinizing hormone (LH)
prompts development of the CL and differentiation of the follicular cells. During differentiation,
there is an increase in expression of steroidogenic enzymes, proteins that transport cholesterol,
and lipid droplet (LD)-associated proteins important for storing cholesteryl esters (CE). Our
purpose was to identify the composition of LDs in ovarian steroidogenic cells. We hypothesized
that LDs are a common feature of steroidogenic luteal cells and could store CE. Bovine ovaries
with functional CLs at days 3 and 10 after ovulation were used for whole tissue analysis. Further
analyses were performed on isolated granulosa, theca, small, and large luteal cells. LDs were
isolated by a step-wise sucrose gradient for subsequent lipid and protein analyses. Luteal LDassociated proteins were determined by Western blot and included classic LD-associated proteins:
PLIN2, PLIN3, PLIN5, vimentin, and adipose triglyceride lipase (ATGL). The neutral core of
luteal LDs was composed primarily of triglyceride (TAG) (168 pmol/μg protein), diglyceride
(5.62 pmol/μg protein) and CE (2.78 pmol/μg protein). Compared to adipocyte LDs, bovine luteal
LDs were enriched in CE, and nearly all CE present in the CL tissue were present in the LD
fraction. The results indicate that bovine luteal LDs are not similar to LDs isolated from adipose
tissue and contain deposits of CE, although TAGs are still the predominant lipid species.

The material presented in this chapter is in preparation to be as submitted as a manuscript: Talbott et al.
Composition of the Lipid Droplets of the Bovine Corpus Luteum.
†
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2.1. Introduction
2.1.1.

Formation and function of the CL

Multiple fertile cycles in mammals depend on the formation of a transient endocrine structure
in the ovary termed the corpus luteum (CL) 134. The CL forms at the beginning of each estrus
cycle and synthesizes progesterone, a hormone critical for early embryonic survival during
pregnancy 135–137. The CL has a tremendous ability to synthesize progesterone, 40 mg/day in
humans 138,139, and the bovine CL can produce ~10-fold more progesterone than in humans 140.
Steroids in the bovine CL are derived primarily through high-density lipoprotein (HDL)-derived
cholesteryl esters 141–143, with smaller amounts from low-density lipoproteins, and minor
contributions from de novo cholesterol synthesis 144. These cholesteryl esters can serves as
precursors for steroid synthesis after removal of the fatty acid. The CL provides an ideal tissue for
studying the mechanisms of steroidogenesis, due to its high steroidogenic output; therefore,
changes in steroid synthesis are easier to detect that may be masked in other tissues. As well,
progesterone is a necessary precursor of androgens, estrogens, glucocorticoids and
mineralocorticoids.
2.1.2.

Luteal LDs

For over 40 years, luteal cells have been noted as containing LDs 145,146. One report
determined that LDs made up 1.6-9.2% of identifiable subcellular components (mitochondria,
granules, etc.) during the functional life span of the CL 147. Armstrong et al. demonstrated that in
rats and rabbits these LDs were primarily composed of cholesteryl esters and that treatment with
LH reduced the total amount of cholesteryl esters present 148. As well, several research groups
showed cholesterol and cholesteryl ester storage using the cholesterol sensing Schultz reagent 149–
154

. Reports by Armstrong, Claesson, Gurarya, and others indicated that luteal LDs in various

species could be altered by treatment with LH and prostaglandin F2 α, which is important in the
involution of the CL 148,155–157. Additionally, they determined that the small luteal cells contained
~400 LDs/cell and large luteal cells had upwards of 1250 LDs/cell indicating a likely role for this
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common luteal cell structure 158. Luteal LDs are postulated to store cholesteryl esters that could
be used for steroidogenesis 159.
2.1.3.

Functional role of LDs

Lipid droplets are unique organelles that store neutral lipids within a phospholipid monolayer,
as opposed to the bilayer surrounding most other organelles 4,160–162. LD-associated proteins coat
the LD, often through unique domains that allow for interaction with a monolayer 17,29,163,164.
These proteins can protect the LD-contained lipids from hydrolysis, as well as protect the cell
from toxic lipid accumulations 16. As well, the LD coat proteins can interact with proteins that
insert new lipids into the LD core, export and/or modify the neutral lipids for use in the cell.
Finally, the coat proteins allow the trafficking and association of LDs with other cellular
structures 165–168. LDs have been most extensively studied in adipose cells, where they form large
unilocular droplets 31,169, though, LDs have been observed in nearly every tissue, as well as
organisms from all domains of life 3–5. However, in many of these conditions, other than adipose
tissue, LD formation is related to pathological conditions, usually due to an oversupply of fats,
including the foamy macrophage in atherosclerotic lesions, and fatty liver disease due to liver
damage 4,162,170,171.
2.2. Materials and Methods
2.2.1.

Animals

Post-pubertal multiparous female cattle (n = 15) of composite breeding (½ Red Angus,
Pinzgauer, Red Poll, Hereford and ½ Red Angus and Gelbvieh) were synchronized using two
intramuscular injections of PGF2α (25mg; Lutalyse®, Zoetis Inc., Kalamazoo Michigan, MI) 11
days apart. At day 3 or day 10 after ovulation, 3-5 cows were subjected to a bilateral ovariectomy
through a right flank approach under local anesthesia 277,278. The CL was removed from the ovary,
weighed and < 5 mm3 sections were snap-frozen in liquid N2 for subsequent protein and RNA
analysis. All animal procedures were completed under an IACUC-approved protocol and
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performed at the University of Nebraska—Lincoln, Animal Sciences Department. Statistical
differences in animal characteristics were determined using one-way analysis of variance in
GraphPad Prism (La Jolla, CA).
2.2.2.

Lipid droplet staining in luteal tissue

Tissue sections were frozen in optimal cutting temperature (O.C.T.) compound (Tissue-Tek)
transported back to the lab on dry ice. Frozen samples were kept at -80 C until sectioning using a
Leica CM3050S instrument and attached to silane-coated slides before fixation in 10%
phosphate-buffered formalin for 1 h. Fixed slides were stained with oil red O and counterstained
with Harris’ hemotoxin using an automated slide staining setup at the University of Nebraska
Medical Center Tissue Sciences Facility. Slides were scanned at 40x using Ventana’s Coreo Au
Slide Scanner. Images were analyzed by Definiens Tissue Studio (Munich, Germany) to count
nuclei and area occupied by oil red O.
2.2.3.

Transmission electron microscopy

Coronal sections (through the stomata) of luteal tissue were fixed in 3% (w/v)
paraformaldehyde and 0.2% glutaraldehyde in phosphate-buffered saline (PBS), pH 7.4, postfixed in 2 % OsO4, resin-embedded, and ultra-thin sectioned for electron microscopy.
Transmission electron microscopy (TEM) images were captured using a Hitachi H7500 at the
University of Nebraska-Lincoln Center for Biotechnology. Three images (magnification: 8,000x)
from each CL were used for quantification of LD number and area using ImageJ 172.
2.2.4.

Isolation of large and small luteal cells

For luteal cell preparations, bovine ovaries were collected during early pregnancy (fetal
crown-rump length < 12 cm) from a local abattoir (JBS USA, Omaha, NE) and transported to the
laboratory on a cold pack. The luteal tissue was dissociated with collagenase as described
previously 173. The cell viability was determined by the trypan blue exclusion test, and luteal cell
preparations with more than 90% viability were used. Small and large luteal cells (SLC, LLC
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respectively) were isolated essentially as previously described 104. Briefly, the mixed luteal cells
were resuspended in elutriation medium (calcium-free Dulbecco’s modified eagle medium
(DMEM) [US Biological D9800-10], supplemented with 25 mM HEPES, 3.89 g/L sodium
bicarbonate, and 3 mg/mL glucose). Resuspended cells were subjected to centrifugal elutriation
with continuous flow using a Beckman Coulter Avanti J-20 XP centrifuge equipped with a
Beckman JE-5.0 elutriator rotor. The fractions containing SLC and LLC were pelleted and
resuspended in basal M199 (0.1% BSA, 100 U/ml penicillin-G-sodium, 100 μg/ml streptomycin
sulfate, and 10 μg/ml gentamicin sulfate). The average purity of SLC was 90% and LLC in were
75%.
2.2.5.

Isolation of granulosa and theca cells

Follicular granulosa and theca cells were prepared from bovine ovaries collected from a local
abattoir (JBS USA, Omaha, NE). Large follicles (> 0.8 cm) were punctured with a 20-gauge
needle and follicular fluid was removed, the needle was reinserted and the granulosa cells were
resuspended in an equal volume of elutriation medium containing 20 µg/mL DNase
(Worthington). After the granulosa cells were removed, the follicle was opened and the theca was
removed from the surrounding stroma and stored in elutriation medium. Small antral follicles (<
0.8 cm) were opened with a scalpel and the granulosa cells were gently scraped from the follicle
wall using the blunt side of the scalpel and resuspended in elutriation medium. Theca were
removed from surrounding stroma and placed in Elutration Medium. Granulosa cells were
washed by centrifugation three times at 150 rcf for 5-10 min and filtration through a 70 μm mesh.
Theca cells were resuspended in 0.2 mg/mL Collagenase 2 (Atlanta Biologicals) in elutriation
medium and dispersed using constant agitation at 37 °C for 1 h. Dispersed theca were removed
from the undigested tissue by filtration through a 70 μm mesh then washed by centrifugation
three times at 150 rcf for 5-10 min. Red blood cells were removed by resuspending theca cells in
dH2O and immediate addition of 2x PBS.
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2.2.6.

Lipid droplet staining in freshly isolated cells.

Cells in suspension were affixed to glass slides using Cytofuge (6.5 g, 5 min) and
immediately fixed in 10% phosphate-buffered formalin. Slides were washed well with PBS, then
stained with oil red O (ORO) in isopropanol for 15 min, rinsed with dH2O and then the nuclei
were briefly counterstained using filtered Harris’ hematoxylin. Coverslips were affixed using
fluromount G.
2.2.7.

Progesterone assay

Jugular blood samples were collected into heparinized tubes and plasma samples were frozen
at -80 C until analysis could be performed. Progesterone concentration in plasma was determined
using a commercial radioimmunoassay (Progesterone CT 07-270102, MP Biomedicals, LLC,
Solon, OH). The intra-assay coefficient of variation of 9.13% and inter-assay coefficient of
variation of 7.99%.
2.2.8.

Lipid droplet isolation from tissue

Tissue (~2.5 g) was washed thoroughly in TE buffer (10 mM Tris, 1 mM EDTA, pH 7.4).
Minced tissue was resuspended in 10 mL tissue homogenate buffer (60% sucrose w/v in TE
buffer containing protease and phosphatase inhibitor cocktail) and homogenized with a Teflon
Dounce homogenizer in a glass vessel. The post-nuclear supernatant (PNS) fraction was obtained
after centrifugation at 2000 rcf for 10min. The supernatant was loaded into a 30 mL
ultracentrifuge tube and overlaid sequentially with 40%, 25%, 10%, and 0% sucrose w/v in TE
buffer containing protease and phosphatase inhibitor cocktails. Samples were centrifuged at
110,000 x g (ravg) for 30 min at 4 °C with no brake in a Beckman Coulter Avanti J-20 XP
ultracentrifuge using an SW 32 Ti rotor. The LDs concentrated in a yellow/white band at the top
of the gradient were harvested and concentrated by centrifugation at 2000 rcf for 10 min at 4 °C
protocol was modified from 174,175.
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2.2.9.

Western blots

Tissue samples were weighed and homogenized (~100 mg/mL) in cell lysis buffer (20mM
Tris [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton x-100, protease and
phosphatase inhibitor cocktails) using OMNI Tissue homogenizer then sonicated for 3 s. Lysates
were centrifuged at 18,350 x g for 15 min at 4 C and the supernatant was collected for SDSPAGE analysis. Protein concentration was determined by Bradford reaction (Bio-Rad 500-0006).
Aliquots of samples (10-30 µg protein) were suspended in protein loading buffer (50 mM Tris pH
6.8, 300 mM glycerol, 25 mM SDS, 45 mM DTT, 260 mM 2-mercaptoethanol, bromophenol)
separated on 10% SDS-PAGE gel and transferred to nitrocellulose membranes. Membranes were
blocked in TBST (10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween 20; pH 7.5) with 5% fat-free
milk for 1 h at room temperature. Membranes were incubated either overnight at 4 C or for 2 h at
room temperature with primary antibody diluted in TBST with 1% non-fat milk or 5% BSA.
After washing, membranes were incubated for 1 h at room temperature with 1:20,000 anti-rabbit
or anti-mouse HRP-conjugated IgG diluted in TBST with 1% non-fat milk. After washing,
protein bands were detected with SuperSignal West Femto (Thermo).
2.2.10. Lipidomics
Lipids from CL tissue LDs were extracted using a standard Bligh and Dyer extraction
protocol 176 and then dried and sent to Avanti Polar Lipids for lipidomics analysis. Extracts were
received as dried residues in glass vials and were immediately stored at -80 °C until analysis. The
samples were provided for lipidomic profiling of free sterols, cholesteryl esters, triacyl- and
diacyl-glycerols, phospholipids, and sphingolipids. The molecular species within each class were
identified, quantified and summed to report the average lipid profile of bovine luteal LDs. To
provide resolution and quantitative ability beyond the mass resolution of the tandem quadrupole
mass spectrometers employed, molecular species were resolved by reversed-phase liquid
chromatography in the presence of class and sub-class specific internal standard compounds
added to each sample. The compounds were detected by tandem mass spectrometry (MS/MS) for
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mass specific fragment ions according to lipid class and molecular weight of the compound,
known as multiple reaction monitoring (MRM). Selectivity was further enhanced by scheduling
the detection of each compound according to its elution from the high-performance liquid
chromatography (HPLC) column, known as scheduled MRM (sMRM). The semi-quantization
was calculated using the integrated area of each analytes MRM peak, divided by the appropriate
internal standard peak area, multiplied by its known concentration. Quantization of cholesterol
and cholesteryl esters were directly calculated with standards and internal standards from
calibration response curves. Lipid concentrations were normalized to the corresponding protein
concentration of each sample.
2.2.11. High-performance thin layer chromatography (HPTLC)
For lipid analyses, 0.25 mL of cell homogenate was extracted overnight with 2.5 mL of
chloroform-methanol (1:1). After removing insoluble material by centrifugation, lipid extracts
were washed according to Folch, Lees, and Sloane Stanley 177 before analysis. The cholesteryl
esters and triglycerides were separated by HPTLC on 10 cm plates using a single solvent system
described by Mangold and Malins 1960 178. The plates were prewashed by development with
chloroform-methanol-water (60:35:8) followed by chloroform-methanol-acetic acid-formic acidwater (35:15:6:2:1). Lipids were dissolved in chloroform-methanol (1:1), and 10 uL was spotted
in a 0.6 cm line at the origin (1 cm above the bottom of the plate). The plate was developed using
petroleum ether (b.p. 60-70 °C)-ethyl ether-acetic acid (45:5:0.5). The plate was sprayed with
10% CuSO4 in phosphoric acid, and lipids were visualized by heating at 180 °C for 5 minutes.
The plates were scanned (instrument) and the images were analyzed using UVP Vision Works LS
software by calculating the area under the curve after lane specific straight line background
correction. A mixture of the following standard lipids was co-chromatographed:
phosphatidylcholine, cholesterol, triglyceride, cholesterol palmitate, oleic acid. Preliminary
analyses were completed to establish the linearity of detection for each lipid class to ensure that
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lipids did not exceed the linear range for quantitation. For every plate of cellular lipids, five lanes
of varying amounts of lipid standards were simultaneously run to generate standard curves for
quantitation. The amount of each cellular lipid was expressed as µg lipid/mg cell protein.
Adapted from 179.
2.2.12. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Target transcript expression was evaluated by isolating RNA from target tissue, reverse
transcription of 1 μg RNA using SuperScript II Reverse Transcriptase (Invitrogen, Grand Island,
NY) followed by RT-PCR using gene-specific primers.
2.3. Results
2.3.1.

Animals

Synchronized multiparous cows were subjected to a bilateral ovariectomy at either day 3 or
day 10 after ovulation. Day 10 CLs weighed significantly more than day 3 CLs (4.7 ± 0.46, 2.8 ±
0.65 g, respectively). Serum progesterone concentrations were also elevated in day 10 (13.05 ±
4.14 ng/mL, P = 0.2) compared to day 3 (4.85 ± 1.47 ng/mL) (Figure 2-1).
2.3.2.

Luteal LDs

Lipid droplets were a prominent feature in both day 3 and day 10 in vivo CLs, oil red O
staining of frozen section of luteal tissue demonstrated that oil red O occupied an area of 26-36
µm2 per nucleus regardless of luteal age (Figure 2-2, A- C). Analysis of TEM images did not
demonstrate a difference in the number of LDs in day 3 and day 10 CLs. As well, TEM images
demonstrated that LDs are abundant within luteal tissue, but characterization of the size of
individual LDs indicated no differences between in LD size between day 3 and day 10 CL (0.41 ±
0.04, 0.41 ± 0.03 µm2/LD, respectively) (Figure 2-2 D, E, & F). Finally, there are no clear
differences in the luteal tissue architecture (Figure 2-2 G, & H) though the total size of the CL is
increased and progesterone secretion is increased in day 10 compared to day 3 CLs (Figure 2-1).
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Discontinuous sucrose gradients were used to separate LDs from whole tissue and created a
distinct yellow band at the top of the sucrose gradient (Figure 2-2 I).
2.3.3.

Lipid droplets in ovarian cells

Granulosa and theca cells are precursors to the steroidogenic cells of the CL. Lipid droplet
content of these follicular precursors was compared to the steroidogenic SLC and LLC. Confocal
images of isolated cell types demonstrated that granulosa and theca cells have fewer and smaller
LDs than the luteal counterparts (Figure 2-3 A & B). As well, SLC appeared to have fewer, but
larger LDs than LLC which contained many small LDs.
2.3.4.

Expression of LD-associated proteins in the CL

Western blot and RT-PCR analysis of proteins known to associate with LDs from bovine fat,
liver, heart and CL tissue demonstrated that the bovine PLIN1 expression is greatest in bovine
adipose tissue. Whereas PLIN2 is greatest in the heart and CL. Both PLIN3 and PLIN5 were
found in all the tissues examined. Adipose triglyceride lipase (ATGL) expression was greatest in
adipose and heart tissue where as abhydrolase domain-containing protein 5 (ABHD5), a
coactivator of ATGL was found in all tissues examined. The cholesteryl ester synthesizer, sterol
O-acyltransferase1 (SOAT1) protein was highest in bovine liver. Finally, HSL, a cholesteryl
esterase, was high in luteal tissue and extremely abundant in adipose tissue (Figure 2-4).
2.3.5.

Lipid composition of LDs

Lipids from CL tissue LDs were extracted and assessed for their relative lipid content.
Triacylglycerides were the predominant lipid species in luteal LDs (168 pmol/µg protein ± 41.9).
Other neutral lipids included diacylglycerol (5.62 ± 2.1 pmol/µg protein) and cholesteryl esters
(2.78 ± 0.70 pmol/µg protein). Sterols were undetectable in all but one LD sample. Polar lipids
were primarily composed of phosphatidylcholine (5.73 ± 1.49 pmol/µg protein), sphingomyelin
(2.68 ± 0.28 pmol/µg protein), phosphatidylinositol (1.69 ± 0.61 pmol/µg protein), and
phosphatidylethanolamine (1.39 ± 0.38 pmol/µg protein) (Figure 2-5 A). The fatty acids of
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cholesteryl esters were composed primarily of oleic acid (18:1, 15% of total), pentadecanoic acid
(15:0, 13%), adrenic acid (22:4, 12%), and erucic acid (22:1, 10%) and smaller amount of other
fatty acids (Figure 2-5 B).
Analysis of whole tissue lipid content was performed on both bovine CL and adipose tissues
by HPTLC. Luteal tissue had 7.4-fold more cholesterol over adipose tissue and 8.2-fold more
cholesteryl esters (Figure 2-5 C). The follicular granulosa and theca cells both had low levels of
lipids and SLC and LLC had significantly more free fatty acids, cholesterol, cholesteryl esters and
triacylglycerides than their follicular counterparts. However, there were no differences in major
lipid classes between granulosa and theca cells or LLC and SLC (Figure 2-5 D).
Purified LDs were compared to the lipid content of whole tissue, post-nuclear supernatent,
and post-nuclear supernatant after removal of LDs. Cholesteryl esters and triglycerides were
found predominately within luteal LDs, and not in other tissue components. Whereas, cholesterol
was not found in the LDs but elsewhere in the tissue, consistent with the lipidomics data. Free
fatty acids were stored equally in LDs and other cellular components (Figure 2-6).
2.4. Discussion
2.4.1.

Overview of study

Within the bovine CL, LDs are a prominent feature which are established by day 3 postovulation and maintained at mid-cycle (day 10). These LDs are enriched in several proteins
including classic LD-associated proteins as well as steroidogenic enzymes. Although the major
constituent of bovine LDs is triglyceride, cholesteryl esters constitute 2.78 ± 0.70 pmol/µg
protein. Bovine luteal cells are enriched in cholesterol and cholesteryl esters compared to bovine
visceral adipose tissue, likely for use in steroidogenesis. In contrast, the granulosa and theca cells
of the follicle have few LDs and have reduced lipid content (of all major classes) compared to the
steroidogenic luteal cells. Although, there does not appear to be a difference in lipid composition
of granulosa and theca cells or of the luteal LLC and SLC.
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2.4.2.

Lipid droplets in luteal tissue

Lipid droplets are a large component of both early (day 3) and mid-cycle CL (day 10)
comprising approximately 26 - 36 µm2/nuclei, which would be approximately 5-16% of luteal
cell area based on other group’s luteal cell area measurements (SLC: 201-216 µm2, LLC 566-581
µm2) in agreement with other studies examining LD /luteal cell area or volume 156,158,180. Lipid
droplets occupied ~2% of the luteal cell volume in a recent study examining ovine luteal cell LDs
158

. Since LDs are rarely seen in luteal endothelial cells, the percentage of the luteal cells occupied

by LDs could be even higher. Individual luteal LDs have a mean area of 0.41 µm2 which does not
differ between day 3 and day 10 CLs. Together this indicates that luteal LDs are an established
feature of luteal tissue by day 3 and does not differ between day 3 and day 10 CLs. Thus, luteal
LDs must form prior to day 3 post-ovulation. This is in keeping with studies by Guraya et al. who
described that granulosa cells in humans developed fine “lipid granules” and “heterogeneous lipid
bodies” within newly ruptured follicles, and that the theca interna cells of newly ruptured follicles
are filled with sudanophilic lipids, including cholesterol and its esters 181. As well, LDs are
increased in granulosa cells of 1 day old CL in rabbits 182. Similarly, treatment of rhesus
macaques with LH or hCG can induce LD-associated proteins in granulosa cells within 12
hours 23. Additionally, transcripts of PLIN2 increase significantly in LH treated bovine granulosa
and theca cells 183 and unpublished data.
2.4.3.

Lipid composition of LDs

Luteal LDs are composed primarily of triglycerides but have a smaller but likely significant
amounts of cholesteryl esters which are greater than other bovine tissues, including adipose,
granulosa, and theca. The cholesteryl esters and triglycerides of luteal cells are stored within the
LDs and not elsewhere in the cells, unlike cholesterol, which is not located in LDs. Cholesteryl
esters are likely substrates for steroidogenesis in bovine luteal cells. The function of the
triglycerides within luteal LDs is uncertain at this time, but may be substrates for β-oxidation
derived energy production to fuel the steroidogenic output of the CL 184,185.
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Several groups in the 1960s provided a histochemical evaluation of lipid composition
throughout the estrous cycle of humans 181, rats 152, and rabbit 182. Despite the few studies of LD
presence and amount in the bovine CL 147,180,186–189, we know of no studies examining the luteal
LD lipid or protein composition. Luteal LDs are also known to be regulated by diet 180, LH
(depletion) 148,190,191 and PGF2α (increase) 61,62,156,192.
In this study, only two time-points in the estrous cycle were evaluated for presence and
composition of LDs. Further research examining the onset of the inclusion of LDs in luteal cells,
as well as examining the presence and composition of the few LDs present in theca and granulosa
cells could provide novel data on the origin and regulation of LDs within the ovary. Additional
experiments examining the changes in LD size, number, and composition after luteotropic and
luteolytic stimulation would benefit the field. Finally, the impact of obesity, undernutrition, and
polycystic ovarian syndrome on luteal LDs may provide insights into mechanisms of infertility.
We believe that luteal LDs play a critical role in progesterone production by storing cholesteryl
esters in bovine luteal cells as a reservoir of substrate in preparation for progesterone synthesis.
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Figure 2-1 – Luteal performance measures of day 3 and day 10 bovine corpus lutea
Cows at day 3 (red, n = 4) and day 10 (orange, n = 3) post-ovulation. A) Corpus luteum
weight in grams B) Serum progesterone concentration. Means ± S.E.M, * P ≤ 0.05.
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Figure 2-2 – Lipid droplets analysis of in vivo tissue
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Figure 2-2 – Lipid droplets analysis of in vivo tissue
(A & B) Representative images of oil red O (ORO) staining of LDs in frozen tissue sections of
the CL from Day 3 (A, red, n = 4) and Day 10 (B, yellow, n = 3) post-ovulation. The images
were acquired using Ventana’s Coreo Au Slide Scanner at 40x, scale bar for both images
appears in (B). C) Quantification of the IHC area (in µm2)/nuclei performed using Definiens
Tissue Studio, bars represent mean ± SEM. P = 0.65, non-significant. D & E) Representative
images of transmission electron micrographs (TEM) of Day 3 (D, red, n = 3) and Day 10 (E,
yellow, n = 3) bovine CL demonstrating LD presence using a magnification of 8,000x, scale
bar for both images appears in (E). F) Each point demonstrates the area (µm2) occupied by
individual lipid droplets in three randomly chosen images from at n = 3 for each condition,
mean ± SEM is overlayed in black. P = 0.84, non-significant. G & H) Representative images
of hematoxylin and eosin (H&E) stained Day 3 (G) and Day 10 (H) paraffin embedded
sections. Large luteal cells, small luteal cells, and endothelial cells of blood vessels are
readily apparent at both stages and no morphological differences are apparent. I)
Representative image of a discontinuous sucrose gradient (steps are labeld with % sucross)
used to isolate luteal LDs, the LDs form a distinct yellow band at the top of the gradient.
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Figure 2-3 – Lipid droplets of isolated cells
A) Confocal fluorescent image showing LD staining in freshly isolated bovine granulosa
(GC), theca (TC) and the steroidogenic luteal cell types: large (LLC) and small luteal cells
(SLC). LDs were stained with the neutral lipid dye BODIPY 493/503 (green), and cells were
immuno-labeled using an aromatase antibody to specifically label granulosa cells (red), and
the nuclei are counter-stained with DAPI (blue). All images are equal magnification. B)
Light microscope image showing LD staining in freshly isolated GC, TC, LLC, and SLC.
LDs were labeled with the neutral lipid dye oil red O (ORO) and nuclei are counter-stained
with Harris’ hemalytoxin. All images are equal magnification and a scale bar is provided.
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Figure 2-4 – Lipid droplet-associated proteins in bovine tissue including the CL
(A) Transmission electron microscopy image of bovine luteal tissue demonstrating the
presence of LD and the close association with multiple mitochondria (Mt). Scale bar is
provided. (B) Analysis of perilipin (PLIN) family members mRNA and protein presence in
various bovine tissues. (C) Analysis of neutral lipid hydrolysis (ATGL, ABHD5, HSL) and
forming (SOAT1) mRNA and protein expression in various bovine tissues.
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Figure 2-5 – Lipid composition of luteal LDs
(A) Analysis of purified LDs from bovine CL of early pregnancy by ultra-performance liquid
chromatography system coupled with tandem quadrupole mass spectrometry. n = 3. TAGtriacylglycerol; DAG-diacylglycerol; CE-cholesteryl esters; ST-sterols; PCphosphatidylcholine; SM-sphingomyelins; PI-phosphatidylinositol; PEphosphatidylethanolamine. (B) Lipidomics determined fatty acid composition of cholesteryl
esters, X:X - number of carbons in the fatty acid: number of double bounds in the fatty acid.
High performance thin layer chromatography (HPTLC) analysis of whole bovine CL versus
adipose tissue FA, free fatty acids. (C) HPTLC analysis of freshly-isolated LLC, SLC, GC,
and TH cells. Bars represent means ± SEM
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Figure 2-6 – Lipid composition of subcellular compartments of luteal tissue
Lipid analysis by HPTLC of whole tissue lysate, post-nuclear supernatant (PNS), lipid droplet
fraction (LD), and post-nuclear supernatant minus LD fraction (PNS –LD). Lipid content of
each fraction was normalized to protein content. Bars indicate means ± S.E.M, n = 2.
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CHAPTER 3: LIPID DROPLETS ARE DYNAMICALLY REGULATED BY
LUTEINIZING HORMONE SIGNALING IN THE BOVINE CORPUS
LUTEUM ‡
Abstract
Growth and maturation of the corpus luteum is accompanied by accumulation of cytoplasmic
lipid droplets (LDs). These LDs are proposed to store cholesteryl esters for progesterone
synthesis. LDs in other tissue can be dynamically regulated, but it is unclear how luteal cells
regulate LDs. Hormone-sensitive lipase (HSL) and other LD-associated proteins including
perilipin2 (PLIN2) were assessed during in vivo and in vitro differentiation of luteal cells from
follicular cell types. In luteal cell cultures, the activation and localization of HSL after hormone
stimulation and the impact of an HSL inhibitor on progesterone secretion were assessed. Finally,
the luteal LD proteome was assessed by both proteomics and Western blot. HSL and PLIN2
increased during in vivo and in vitro differentiation to luteal cell phenotypes. Dose-dependent
inhibition of HSL activity inhibits luteinizing hormone (LH)- and HDL-stimulated progesterone
secretion. Stimulation with LH, forskolin, and 8-br-cAMP phosphorylated HSL at the PKAsensitive Ser563, which is selectively associated with luteal LDs. Proteomics analysis revealed
469 bovine-specific proteins which included steroidogenic enzymes StAR, P450scc, and 3BHSD, which was confirmed by Western blot analysis of in vivo luteal tissue. The surface of LDs
may serve as a novel platform for steroidogenesis through the intimate association and potential
tethering of steroidogenic enzymes present in the mitochondria and endoplasmic reticulum to the
coat proteins of the LDs to facilitate the handoff of steroid precursors at each step to efficiently
produce steroids, such as progesterone.

The material presented in this chapter is in preparation to be as submitted as a manuscript: Talbott et al.
Lipid Droplets are dynamically regulated by luteinizing hormone signaling in the bovine corpus luteum .
‡
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3.1. Introduction
Understanding the regulation of luteal function will allow for the development of advanced
treatment techniques for improving female fertility. We have demonstrated that the corpus luteum
(CL) has numerous lipid droplets (LDs) within the steroidogenic cells (manuscript in preparation,
Chapter 2), which are thought to store the steroid precursor cholesterol as cholesteryl esters. The
formation and breakdown of LDs is known in fat and liver tissue to be regulated by LDassociated proteins which include perilipins (PLINs) and hormone-sensitive lipase (HSL) 10,160,193.
PLIN proteins are embedded within the LD surface and stabilize the organelle and facilitate
interactions with transient LD proteins. Whereas, HSL is an enzyme that can liberate cholesterol
from cholesteryl esters after protein kinase A (PKA) stimulation.
3.1.1.

Regulation of CL formation

The CL is responsible for synthesizing the progesterone that supports early pregnancy in most
mammals 134 and progesterone deficits are associated with early embryonic loss in women 194–196
and female livestock 197–199. Early embryonic loss of pregnancies is commonly associated with
luteal insufficiency, which is characterized by deficiencies in progesterone secretion, either in
amount or duration 200. Luteal insufficiency results in a failure to develop a mature secretory
endometrium, preventing embryo implantation, and has been found in 3-10% of infertile women
and up to 35% of women with recurrent abortion 201,202. In cattle, early embryonic loss accounts
for 30% of infertility cases 197–199, of which, many are believed to be due to a deficiency in
progesterone secretion 200. Improvement of the understanding of CL function and the biosynthesis
of the critical steroid hormone, progesterone, could lead to infertility management strategies for
successful intervention in human and livestock fertility outcomes.
CL formation begins with the luteinizing hormone (LH) surge, which causes ovulation and
initiates the differentiation of follicular granulosa and theca cells into progesterone-secreting
luteal cells. Secretion of progesterone by luteal cells requires direct action of three proteins, 1)
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steroidogenic acute regulatory protein (StAR), which facilitates transport of cholesterol to the
mitochondrial matrix, 2) P450 side-chain cleavage (P450scc) which removes the side-chain from
cholesterol to form pregnenolone, and 3) 3-β hydroxysteroid dehydrogenase (3βHSD) which
dehydrogenates pregnenolone to form progesterone. Key features of CL development include the
development of an extensive vascular bed 203,204, recruitment of neutrophils, 205–207 and monocytes
208,209

. Additionally, CL development and function are metabolically regulated both systemically

210,211

, and intracellularly by key regulators such as insulin 212,213, insulin-like growth factors212,214,

leptin 210,215,216, and adenosine monophosphate-activated protein kinase (AMPK) 88,91,94. In
addition to overall metabolic status, both dietary lipids 158,180,211,217,218 and tissue lipid contents
73,219

can impact ovarian function.

3.1.2.

Lipid droplets in the CL

For over 40 years, luteal cells have been noted as containing LDs 145,146. One report
determined that LDs made up 1.6-9.2% of identifiable subcellular components (mitochondria,
granules, etc.) during the functional life span of the CL 147. LDs have been postulated to store
cholesteryl esters that could be used for steroidogenesis 159. Armstrong et al. demonstrated that in
rats and rabbits these LDs were primarily composed of cholesteryl esters and that treatment with
LH reduced the total amount of cholesteryl esters present 148. As well, several research groups
showed cholesterol and cholesteryl ester storage using the cholesterol sensing Schultz reagent 149–
154

. Reports by Armstrong, Claesson, Gurarya, and others indicated that luteal LDs in various

species could be altered by treatment with LH and prostaglandin F2 α, which is important in the
involution of the CL 148,155–157.
Guraya et al. who described that granulosa cells in humans developed fine “lipid granules”
and “heterogeneous lipid bodies” within newly ruptured follicles, and that the theca interna cells
of newly ruptured follicles are filled with sudanophilic lipids, including cholesterol and its esters
181

. Additionally LDs are increased in granulosa cells of 1 day old CL in rabbits 182. Similarly,
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treatment of primates with LH or hCG can induce LD-associated proteins in granulosa cells
within 12 hours 23. Transcripts of PLIN2 increase significantly in LH treated bovine granulosa
and theca cells 183 and unpublished data.
3.1.3.

Regulation of LDs

Neutral lipids, such as triglycerides and cholesteryl esters, can be stored intracellularly in
specialized LD organelles. These unique organelles store neutral lipids (including cholesteryl
esters) within a phospholipid monolayer, as opposed to the bilayer surrounding most other
organelles. Embedded and associated with the monolayer are LD-associated proteins. The major
LD-associated proteins are the PLIN family which includes, PLIN1 (perilipin), PLIN2
(adipophilin/ADRP/ADFP), and PLIN3 (previously Tip47/M6PRBP1). The PLIN family of
proteins can stabilize the lipid droplet surface and can serve as a platform for recruitment or
sequestration of proteins that insert new lipids into the LD core, as well as exporting and
modifying the neutral lipids for use in the cell. Additional proteins associated with the LD surface
regulate the trafficking of LDs throughout the cell (e.g. Rab) and facilitate LD interaction with
other organelles (PLIN5, vimentin). The LD proteome has been characterized to varying degrees
in steroidogenic tissues and cell lines including, mouse testes 57, the MLTC1 Leydig cell line 56,
and rat granulosa cells 55. Studies in the ovary have indicated that LD-associated PLIN coat
proteins 38,220,221 and HSL, a key enzyme for hormonally-stimulated lipolysis 39,220,221, are
expressed.
3.1.4.

Hormone-sensitive lipase

Lipolysis of LD-stored triglycerides and cholesteryl esters can be stimulated by
catecholamines in adipocytes through the action of HSL, which upon activation, translocates to
the LD surface 26–28. The proposed mechanism of HSL translocation to the LD involves PKAdependent phosphorylation of PLIN1 and HSL, which allows the proteins to interact on the LD
surface 31. The phosphorylation of HSL facilitates its association with PLIN1 on the LD and the
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stored lipid substrates 32, permitting lipid hydrolysis to proceed. Stimulation of HSL catalytic
activity and translocation to LDs occurs by phosphorylation at both Ser‐563 and Ser‐660 by PKA
33–36

. Negative regulation of HSL activity is accomplished by AMPK dependent phosphorylation

of HSL at Ser-565 37. In adipose tissue, HSL contributes to energy homeostasis through lipolysis
of LD-stored substrates after hormonal stimulation of PKA. HSL-null mice have aberrant steroid
production in both the testes and adrenal glands 40,41. Together, these findings suggest that the
intracellular processing and availability of cholesterol for steroidogenesis may include an HSLdependent step. Therefore, we hypothesized that LDs are dynamically regulated in luteal cells,
particularly by activation of PKA downstream of LH signaling.
3.2. Materials and Methods
3.2.1.

Isolation and culture of human granulosa cells

Human granulosa cells were isolated from follicular aspirates of reproductive-age patients
undergoing oocyte retrieval for in vitro fertilization. This study was approved by the Ethics
Review Board of the University of Nebraska Medical Center. Tissue was collected through the
obstetrical and gynecological tissue and fluid bank under an approved Institutional Review
Board. Signed consent forms were obtained from each patient for use of discarded granulosa
cells. Tissue was subsequently acquired from the tissue bank under an exemption from IRB
Review. Ovarian stimulation was induced by treatment with recombinant human follicle
stimulating hormone (FSH), followed by administration of hCG. Oocyte retrieval was performed
35 h after hCG administration by aspirating follicular fluid under ultrasound guidance. After
removal of the oocyte-cumulus complex, all of the follicular aspirates donated from a single
patient were pooled and centrifuged at 400 g for 10 min. Cells were resuspended in M199,
layered onto 40% Percoll, and centrifuged at 200 × g for 20 min. Granulosa cells were collected
from the interphase of the Percoll gradient, washed with M199, and seeded into 24-well plates at
a density of 100,000/well in M199 containing 10% fetal bovine serum (FBS) for overnight
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plating. After overnight plating, cells were washed and then cultured and luteinized in M199
containing PenStrep, 0.1% BSA, 1 μg/mL insulin, 2% FBS, and 10 μM forskolin or 1 IU/mL
hCG. Culture media were changed every 2 d.
3.2.2.

Isolation of large and small luteal cells

For luteal cell preparations, bovine ovaries were collected during early pregnancy (fetal
crown-rump length < 12 cm) from a local abattoir (JBS USA, Omaha, NE) and transported to the
laboratory on a cold pack. The luteal tissue was dissociated with collagenase as described
previously 173. The cell viability was determined by the trypan blue exclusion test, and luteal cell
preparations with more than 90% viability were used. Small luteal cells (SLC) and large luteal
cells (LLC) were separated, essentially as previously described 104. Briefly, the mixed luteal cells
were resuspended in elutriation medium (calcium-free Dulbecco’s modified eagle medium
(DMEM) [US Biological D9800-10], supplemented with 25 mM HEPES, 3.89 g/L sodium
bicarbonate, and 3 mg/mL glucose). Resuspended cells were subjected to centrifugal elutriation
with continuous flow using a Beckman Coulter Avanti J-20 XP centrifuge equipped with a
Beckman JE-5.0 elutriator rotor. The fractions containing SLC and LLC were pelleted and
resuspended in basal M199 (0.1% BSA, 100 U/ml penicillin-G-sodium, 100 μg/ml streptomycin
sulfate, and 10 μg/ml gentamicin sulfate). The average purity of SLC was 90% and LLC in F4
were >50%.
3.2.3.

Isolation of granulosa and theca cells

Follicular granulosa and theca cells were prepared from bovine ovaries collected from a local
abattoir (JBS USA, Omaha, NE). Large follicles (> 0.8 cm) were punctured with a 20-gauge
needle and follicular fluid was removed, the needle was reinserted and the granulosa cells were
resuspended in an equal volume of elutriation medium containing 20 µg/mL DNase
(Worthington). After the granulosa cells were removed, the follicle was opened and the theca was
removed from the surrounding stroma and stored in elutriation medium. Small antral follicles (<
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0.8 cm) were opened with a scalpel and the granulosa cells were gently scraped from the follicle
wall using the blunt side of the scalpel and resuspended in elutriation medium. Theca were
removed from surrounding stroma and placed in Elutration Medium. Granulosa cells were
washed by centrifugation three times at 150 rcf for 5-10 min and filtration through a 70 μm mesh.
Theca cells were resuspended in 0.2 mg/mL Collagenase 2 (Atlanta Biologicals) in elutriation
medium and dispersed using constant agitation at 37 °C for 1 h. Dispersed theca were removed
from the undigested tissue by filtration through a 70 μm mesh then washed by centrifugation
three times at 150 rcf for 5-10 min. Red blood cells were removed by resuspending theca cells in
dH2O and immediate addition of 2x phosphate-buffered saline (PBS). Granulosa and theca cell
viability and concentration were determined by trypan blue exclusion test.
3.2.4.

Luteal cell culture

Bovine SLC and LLC were plated (SLC: 1 × 105, LLC: 4 x 104 cells/cm2) in basal M199 with
5% FBS for 18 h at 37 °C in a humidified atmosphere of 5% CO2. Cells were washed with PBS
and the medium was replaced with serum-free M199 2 h prior to the experiment (treatment
specifics are described in corresponding figure legends).
3.2.5.

Differentiation of granulosa and theca cells to luteal cell types

Bovine granulosa and theca cells were plated (2 x 105 and 4 x 104 cells/cm2, respectively) in
basal DMEM:Ham’s F-12 (F12) (1:1) [100 U/mL penicillin, 100 μg/mL streptomycin, 10 μg/mL
gentamycin, and 0.1% BSA] containing 10% FBS for 36 h at 37 °C in a humidified chamber with
5% CO2. Cells were washed with PBS and medium was replaced with basal DMEM : F12
containing 1% FBS. Cells were treated with either 1% insulin-transferrin-selenium (ITS) or 1%
ITS + 10 µM forskolin to induce differentiation, controls were unstimulated or treated with 5
ng/mL FSH, as described in the figure legends. All wells received equal amounts of dimethyl
sulfoxide (DMSO) and the medium was changed every two days.
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3.2.6.

Western blots

Tissue samples were weighed and homogenized (~100 mg/mL) in cell lysis buffer (20mM
Tris [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton x-100, protease and
phosphatase inhibitor cocktails) using OMNI Tissue homogenizer then sonicated for 3 s. Lysates
were centrifuged at 18,350 x g for 15 min at 4 °C and the supernatant was collected for SDSPAGE analysis. Protein concentration was determined by Bradford reaction (Bio-Rad 500-0006).
Aliquots of samples (10-30 µg protein) were suspended in protein loading buffer (50 mM Tris pH
6.8, 300 mM glycerol, 25 mM SDS, 45 mM DTT, 260 mM 2-mercaptoethanol, bromophenol)
separated on 10% SDS-PAGE gel and transferred to nitrocellulose membranes. Membranes were
blocked in 0.1% Tween 20 in Tris-buffered saline (TBST) (10 mM Tris-HCl, 150 mM NaCl,
0.1% Tween 20; pH 7.5) with 5% fat-free milk for 1 h at room temperature. Membranes were
incubated either overnight at 4 °C or for 2 h at room temperature with primary antibody diluted in
TBST with 1% non-fat milk or 5% BSA. After washing, membranes were incubated for 1 h at
room temperature with 1:20,000 anti-rabbit or anti-mouse HRP-conjugated IgG diluted in TBST
with 1% non-fat milk. After washing, protein bands were detected with SuperSignal West Femto
(Thermo 34095).
3.2.7.

Progesterone assay

Media from luteal cells was diluted in water (1:150) and assayed for progesterone
concentration using either RIA (Siemens TKPG1) or ELISA kit (DRG EIA-1561) following
manufacturers’ instructions and using a 4-parameter regression to interpolate unknowns from the
standard curve.
3.2.8.

Lipid droplet isolation from cells

Cells from 6-100 mm2 dishes were washed twice with PBS and then scraped into PBS
combined and centrifuged for 10 min at 1000 x g, 4 °C. Cells were resuspended in hypotonic lysis
medium (20 mM Tris [pH 7.4], 1 mM EDTA, 10 mM NaF) and homogenized using a Parr cell
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disruption bomb at 300 psi for 12 minutes. The post-nuclear supernatant was obtained by
centrifuging the cell lysate for 10 min at 1,000 x g at 4 °C. The supernatant was mixed with an
equal volume of hypotonic lysis medium containing 60% sucrose and loaded into a 30 mL
polypropylene thick-walled ultracentrifuge tube, overlaid sequentially with 5% and 0% sucrose in
HLM buffer. Samples were centrifuged at 110,000 x g (ravg) for 30 min at 4 °C with no brake in
Beckman Coulter Avanti J-20 XP.and SW 32 Ti rotor. The LDs concentrated in a yellow/white
band at the top of the gradient were harvested and concentrated by centrifugation at 2000 rcf for
10 min at 4 °C with no brake. The protocol was derived from 175.
3.2.9.

Proteomics

Acetone-precipitated LD proteins were suspended in 2x protein loading buffer (100 mM Tris
pH 6.8, 600 mM glycerol, 50 mM SDS, 90 mM DTT, 525 mM 2-mercaptoethanol, and
bromophenol blue) and boiled for 5 min at 100 °C. A 10% SDS-PAGE gel was used to separate
LD proteins. Coomassie blue-stained gel pieces were manually cut into two pieces using a

sterile scalpel and kept in sterile microcentrifuge tubes. Gel pieces were washed with
HPLC water and shrunk by removing all liquid using 100% acetonitrile (ACN). Proteins
were reduced using 2 mM tris(2-carboxyethyl)phosphine (TCEP) in 50 mM ammonium
bicarbonate (AmBic) for 1 h at 37 °C. After incubation, ACN was added to TCEP to
destain gel pieces. After gel pieces were dried by adding additional portion of ACN, thiol
groups of proteins were alkylated with 55 mM iodoacetamide (IAA) in 50 mM AmBic
for 20 min in dark. Samples were dried again with ACN and 10 nM MS-grade trypsin
(Thermo Scientific, Rockford, IL, USA) was added for protein digestion. Samples were
incubated with trypsin for 30 min on ice. After the excess of trypsin was removed from
tubes, 25 mM AmBic was added to the gel pieces. Tryptic digestion continued overnight
at 37 °C. Digested peptides were then extracted from gel with 50% ACN/0.1%
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trifluoroacetic acid solution. Samples were dried in a Speedvac, dissolved in 15 µL of
0.1% formic acid (FA) and submitted for LC-MS/MS analysis.
In-gel digested peptide samples were analyzed using high-resolution mass
spectrometry LC-MS/MS system (LTQ Orbitrap Elite Velos Pro, Thermo Scientific,
West Palm Beach, FL, USA), coupled with an Eksigent NanoLC-Ultra 1D plus
(Eksigent, Dublin, CA, US) and nanoFlex cHiPLC system (Eksigent), equipped with two
alternating peptide traps. 10 µL of each sample were loaded onto the peptide trap using
0.1% FA solvent. The samples were eluted using a 1 hour linear gradient of 0–60% of
ACN in 0.1% FA. The nanospray needle voltage was set to 2400 V in HPLC MS mode
and linear ion trap scan mode was used for MS/MS. Resolution of the full scan in the
Orbitrap was set to 120,000 m/z with a range from 300 to 2000 Da. The collision energy
was set to 35 kV.
The MS/MS spectra from the peptides were analyzed by assigning the fragments to
the candidate sequence using MASCOT search engine (Matrix Science, London, UK,
version 2.5.1) with a Swissprot database (Taxonomy: Mammalia). Parameters on
MASCOT were set as follows: Enzyme: trypsin, Max missed cleavage: 2, Peptide charge:
1+, 2+ and 3+, Peptide tolerance: ± 0.8 Da, Fixed modifications: carbamidomethyl (C),
Variable modifications: oxidation (M), phospho (ST) and phospho (Y), MS/MS
tolerance: ± 0.6 Da, Instrument: ESI-TRAP. MASCOT results for different gel cuts of the
same sample were combined and analyzed using Scaffold (Proteome Software, Inc.,
Portland, OR, version 4.4.5), which allows multiple search results to be condensed into a
single result file. Peptide identifications were accepted if they were established at greater
than 95.0% probability by the Peptide Prophet algorithm 222 Scaffold delta-mass
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correction. Protein identifications were accepted if they were established at greater than
95.0% Protein probabilities were assigned by the Protein Prophet algorithm 223. Proteins
that contained similar peptides and could not be differentiated based on MS/MS analysis
alone were grouped to satisfy the principles of parsimony. Proteins sharing significant
peptide evidence were grouped into clusters.
3.2.10. Animals
Post-pubertal multiparous female cattle (n = 15) of composite breeding (½ Red Angus,
Pinzgauer, Red Poll, Hereford and ½ Red Angus and Gelbvieh) were synchronized using two
intramuscular injections of PGF2α (25mg; Lutalyse®, Zoetis Inc., Kalamazoo Michigan, MI) 11
days apart. A bilateral ovariectomy, between 3 and 10 days post-ovulation, was performed
through a right flank approach under local anesthesia 277,278. The CL was removed from the ovary,
weighed and 2.5 g was used for LD isolation (Section 3.2.11). All animal procedures were
completed under an IACUC-approved protocol and performed at the University of Nebraska—
Lincoln, Animal Sciences Department (Lincoln, NE). Statistical differences in animal
characteristics were determined using one-way analysis of variance in GraphPad Prism (La Jolla,
CA).
3.2.11. Lipid droplet isolation from tissue
Tissue (~2.5 g) was washed thoroughly in TE buffer (10 mM Tris, 1 mM EDTA, pH 7.4).
Minced tissue was resuspended in 10 mL tissue homogenate buffer (60% sucrose w/v in TE
buffer containing protease and phosphatase inhibitor cocktail) and homogenized with a Teflon
Dounce homogenizer in a glass vessel. The post-nuclear supernatant fraction was obtained after
centrifugation at 2000 rcf for 10min. The supernatant was loaded into a 30 mL ultracentrifuge
tube and overlaid sequentially with 40%, 25%, 10%, and 0% sucrose (w/v) in TE buffer
containing protease and phosphatase inhibitor cocktails. Samples were centrifuged at 111,000 x g
(ravg) for 30 min at 4 °C with no brake in a Beckman Coulter Avanti J-20 XP ultracentrifuge using
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an SW 32 Ti rotor. The LDs concentrated in a yellow/white band at the top of the gradient were
harvested and concentrated by centrifugation at 2000 rcf for 10 min at 4 °C, the protocol was
modified from 174,175.
3.2.12. Western blots of LDs
Acetone-precipitated LD proteins were suspended in 2x protein loading buffer (100 mM Tris
pH 6.8, 600 mM glycerol, 50 mM SDS, 90 mM DTT, 525 mM 2-mercaptoethanol, and
bromophenol blue) and boiled for 5 min at 100 °C, separated on a 10% SDS-PAGE gel, and
transferred to nitrocellulose membranes. Membranes were blocked in TBST (10 mM Tris-HCl,
150 mM NaCl, 0.1% Tween 20; pH 7.5) with 5% fat-free milk for 1 h at room temperature.
Membranes were incubated either overnight at 4 °C or for 2 h at room temperature with primary
antibody diluted in TBST with 1% non-fat milk or 5% BSA. After washing, membranes were
incubated for 1 h at room temperature with 1:20,000 anti-rabbit or anti-mouse HRP-conjugated
IgG diluted in TBST with 1% non-fat milk. After washing, protein bands were detected with
SuperSignal West Femto (Thermo 34095).
3.3. Results
3.3.1.

Formation of LDs during differentiation

Previously we identified LD-associated protein transcripts for PLIN2, PLIN3, and LIPE (the
gene encoding HSL) were increased in both steroidogenic luteal cell types over their follicular
counterparts, as assessed by microarray (GSE83524) (Figure 3-1 A) 220. The protein abundance of
PLIN2 and HSL was increased in luteal tissue as assessed by Western blot (Figure 3-1 B). In vitro
differentiation of granulosa cells with 1% ITS + 10 µM forskolin, increased the amounts of HSL,
PLIN2, StAR, P450scc, and 3βHSD that were intermediate to levels seen in luteal cells (Figure
3-2 A). As well, progesterone secretion gradually increased over 7 days in culture with treatment
of ITS + 10 µM forskolin, whereas control treated cells maintained a low level of progesterone
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secretion ( B). The differentiation protocol of 1% ITS + 10 µM forskolin increased LD formation
in both bovine and human granulosa cells ( C & D).
3.3.2.

Phosphorylation of HSL at Ser563 by LH and LH signaling intermediates

Luteal cells were treated with LH, forskolin (an adenylate cyclase activator), and 8-bromo
cyclic AMP (a protein kinase A activator) to determine whether LH and LH signaling pathways
phosphorylated HSL at its activation site Ser563. Treatment of mixed luteal cells with LH,
forskolin or 8-Br cAMP increased phosphorylation of the PKA-sensitive site Ser563 on HSL
within 5 minutes and was sustained for 4 h (Figure 3-3).
3.3.3.

Regulation of LDs

Luteal cells were pretreated with an HSL inhibitor, CAY10499, before stimulation with LH
and/or high-density lipoprotein (HDL) as an exogenous cholesterol source. CAY10499 inhibited
LH-induced progesterone secretion by bovine luteal cells with pretreatment of 10 and 20 µM
CAY10499 (Figure 3-4 A). Treatment with LH stimulated progesterone synthesis (SLC: 6-fold,
LLC: 3.6-fold) which was increased with co-incubation with HDL (SLC: 11.3-fold, LLC: 5-fold).
CAY10499 pretreatment prevented both the LH- and HDL + LH-induced progesterone secretion
but had no effect on basal progesterone secretion in either SLC or LLC (Figure 3-4 C & D). The
influence of off-target effects of CAY10499 was excluded because inclusion of hydroxylated
cholesterols could still increase luteal progesterone secretion [Appendix A-2]
3.3.4.

PKA stimulation promotes alterations in the luteal LD proteome

Stimulation of luteal tissue punches with the PKA activator 8-br-cAMP resulted in
phosphorylation of HSL at Ser563 and an increased HSL localization on luteal LDs (Figure 3-5).
The LDs isolated from untreated and 8-Br cAMP-treated luteal cells were acetone-precipitated
and the protein content was analyzed by proteomics. LC-MS/MS analysis determined 469
bovine-specific proteins were present in bovine LDs isolated from cultured mixed luteal cells; of
these, 85 proteins were increased in 8-Br cAMP-treated samples, and 48 were decreased. The top
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ten most abundant proteins in both treated and untreated LDs included 3βHSD, PLIN2, vimentin,
and P450scc. Proteins with increased abundance on luteal lipid droplets following 8-bromo
cAMP treatment included LD coat protein PLIN2, trafficking (Rab8A, Rab14), and
steroidogenesis (StAR, 3βHSD) [Appendix A-3].
3.3.5.

Luteal LDs are associated with steroidogenic enzymes

Confirmation of proteomics results was achieved by Western blot analysis of purified LDs
from functional bovine CLs obtained by ovariectomy. PLIN3, vimentin, P450scc, and 3βHSD
were all significantly enriched in luteal LDs compared to whole luteal tissue. However,
mitochondrial marker COX IV and endoplasmic reticulum marker HSP47 were nearly absent
from luteal LDs (Figure 3-6). Quantification of immunodetection by Western blot is available in
[Appendix A-5].
3.4. Discussion
Lipid droplets and LD-associated proteins are under regulation by LH signaling in the bovine
CL. As granulosa cells differentiate to form luteal cells, increases in both LDs and LD-associated
proteins, HSL and PLIN2 are seen which correlate with luteal differentiation markers and
progesterone secretion. Signaling by LH causes phosphorylation of HSL at Ser563 and
translocation of HSL to the LD surface (these changes active HSL). Furthermore, chemical
inhibition of HSL by CAY10499 prevents LH-induced progesterone secretion even in the
presence of HDL-supplied cholesterol indicating that cholesteryl esters originating either in LDs
or delivered by HDL are processed by an HSL-dependent step. Finally, luteal LDs have a high
content of steroidogenic enzymes including, 3βHSD and P450scc. Furthermore, LD-associated
StAR can increase by 14-fold after treatment with 8-br cAMP. These data lead us to hypothesize
that the surface of LDs may serve as a novel platform for steroidogenesis through the intimate
association and potential tethering of steroidogenic enzymes to the coat proteins of the LD
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facilitating the handoff of steroid precursors at each step to produce steroids, like progesterone
(Figure 3-7).
Differentiation of granulosa cells occurs after ovulation and is accompanied by increases in
steroidogenic enzymes 3βHSD, P450scc, and StAR, which promote an increase in progesterone
secretion. As bovine granulosa cells differentiate, LDs form and LD-associated proteins increase
in correspondence with standard differentiation markers. This is confirmed by the previous work
of Meidan et al. which examined the in vitro differentiation of theca and granulosa cells into
luteal-like cells 189. This indicates that LD accumulation may be a natural consequence of
granulosa to luteal cell differentiation.
HSL is a key regulator of lipolysis in adipose tissue. In fat tissue, HSL is phosphorylated by
PKA on Ser563 that is correlated with translocation of HSL to LDs and activation of its lipase
activities. Activated HSL results in the release of cholesterol and free fatty acids from neutral
lipid stores within LDs for cellular use. We have shown that HSL can be phosphorylated at S563
after treatment with LH, forskolin, or 8-bromo cAMP. Pretreatment of luteal cell cultures with a
chemical inhibitor of HSL activity, CAY10499, could prevent LH- and LH+HDL-stimulated
progesterone secretion. LH may regulate the phosphorylation of PLINs and HSL via a
cAMP/PKA signaling pathway allowing for hydrolysis of cholesteryl esters stored in luteal LDs
to produce substrate for progesterone synthesis. This indicates that stimulated but not basal
progesterone is processed through an HSL-dependent and likely LD-dependent step.
Isolated luteal LDs were examined using both a non-targeted and targeted approaches. It was
determined that the steroidogenic enzymes StAR, P450scc, and 3βHSD were found in the LDs
fraction in addition to known LD markers such as PLIN2, PLIN3, vimentin, and HSL. However,
other mitochondrial and endoplasmic reticulum markers were not abundant, indicating a selective
association with steroidogenic enzymes. Taken together, these data indicate that the surface of
LDs may serve as a novel platform for steroidogenesis by an intimate association with
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steroidogenic enzymes, allowing for the handoff of steroid precursors from the LD to the
mitochondria and endoplasmic reticulum for steroidogenic modifications of cholesterol. Possible
interactions between LDs, mitochondria, and the endoplasmic reticulum could involve physical
tethering of the membranes similar to mitochondrial associated membranes, whereby the
mitochondria and endoplasmic reticulum have microdomains of highly associated membranes to
facilitate lipid transfer 224.
We found evidence for enrichment of known LD-associated proteins on luteal LDs including
HSL, PLIN3, and vimentin. Additionally the steroidogenic enzymes P450scc and 3βHSD were
enriched in the LD fraction. This is similar for the LD proteome determined for other
steroidogenic cells including the MLTC-1 Leydig cell line (analogous to the granulosa cells of the
female reproductive tract), 56 LDs purified from mouse testes, 57 and lipid-loaded rat granulosa
cells55. The finding of steroidogenic enzymes within the LD proteome by four separate groups
indicate this is an important feature of LDs within steroidogenic cells and is not simply a matter
of contamination. Ultrastructural studies have often noted the close proximity of mitochondria
with LDs 225, and the emerging field of mitochondrial associated membranes offers the possibility
that there are regionalized areas of contact between mitochondria and LDs 226.
Khor et al. compared the proteome of LDs from rat granulosa cells treated in vitro with either
HDLs or fatty acids to enrich cytoplasmic LDs with cholesteryl esters or triacylglycerides,
respectively 55. When comparing the LD proteomes, a large number of proteins (278) were
common to the LDs prepared from either treatment. These proteins included PLIN2 and were
similar to other studies on LD proteomes. They also identified 61 proteins unique to the
cholesteryl ester-rich LDs and 40 proteins unique to triacylglycerol-rich LDs. Notably, they
identified 3βHSD, vimentin, and voltage-dependent anion channel proteins enriched in the
cholesteryl ester-rich LDs. Recent reports on the proteomic analysis of LD isolated from the
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mouse Leydig tumor cell line MLTC-1 56, and mouse testes 57 also revealed the presence of PLIN
family proteins and enzymes involved in the synthesis of steroid hormones.
Previous studies that have examined the LD proteome in steroidogenic tissues have also
found steroidogenic enzymes 55,57. Reports in the monkey 23 and mouse 24 indicate that the ovary
expresses PLIN2, a LD coat protein associated with cholesteryl ester storage 25. Manna et al.
recently reported that activation of the PKA pathway in MA-10 mouse Leydig cells enhanced
expression of HSL and its phosphorylation at Ser-563 and Ser-660. Additionally, inhibition of
HSL activity suppressed cAMP-induced progesterone synthesis and resulted in increased
cholesteryl ester levels in MA-10 cells 42. The data presented herein complements these
observations and provides mechanisms for regulation of LD-associated proteins in luteal cells.
Also of interest is a report 43 demonstrating an interaction between StAR and HSL in the rat
adrenal following treatment with adrenocorticotropic hormone. Furthermore, the co-expression of
StAR and HSL resulted in elevated HSL activity and mitochondrial cholesterol content 43. These
observations, suggest that the proteins involved in production and transport of cholesterol may
co-localize in LDs and mitochondria. We have observed that mitochondria are closely associated
with cytoplasmic LDs in bovine luteal cells (Figure 1-1 B) 161. These observations, in
combination with this study, indicate that luteal LDs and mitochondria may interact to facilitate
steroidogenesis.
These data improve our understanding of the biochemistry of steroidogenesis. As we learn
more about how cholesterol is stored and utilized, particularly during steroidogenesis we can gain
insight into how to manipulate steroidogenesis to either increase or decrease steroid production.
Our study has focused on non-pathological conditions to gain a clear insight into the role of LDs
in highly steroidogenic tissues. Future studies into how LDs and flux of cholesterol through cells
is altered in obesity and polycystic ovarian syndrome could indicate mechanisms by which those
conditions impair fertility, specifically if steroid production or LD formation is altered.
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Additionally, further analysis of the additional cholesteryl esterases and activity will clarify how
the pathways of steroidogenesis within the luteal tissue are regulated. Furthermore, a direct
investigation into the presence of mitochondrial and endoplasmic reticulum tethering to the LD
surface is ongoing.
Formation of LDs during granulosa to luteal cell differentiation appears to be a normal, and
potentially necessary accumulation. Stimulated, but not basal, progesterone is processed through
an HSL-dependent, and likely LD-dependent step. The surface of LDs may serve as a novel
platform for steroidogenesis by an intimate association with steroidogenic enzymes. The close
proximity of mitochondria and the endoplasmic reticulum may facilitate the handoff of steroid
precursors at each step to efficiently produce steroids such as progesterone. We postulate that
progesterone synthesis in enhanced by physical tethering of mitochondria and the endoplasmic
reticulum to the LD surface using a similar mechanism to mitochondrial associated membranes,
which tether microdomains of the endoplasmic reticulum to mitochondria to facilitate lipid
transfer 224. Our results support a growing body of research indicating that LDs play a critical role
in steroid production and may provide novel biomarkers of infertility and therapeutic targets for
altering fertility status of humans and other mammals.
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Figure 3-1 – Lipid droplet-associated proteins were expressed at greater amounts in luteal
cells at both transcriptional and protein levels
(A) Microarray-determined relative transcription expression levels of key LD-associated coat
proteins perilipins 2 and 3 (PLIN2 and PLIN3, respectively), hormone sensitive lipase (HSL,
gene name LIPE), and luteal differentiation marker steroidogenic acute regulatory protein (StAR)
fold changes from precursor follicular cells to luteal cell types is written above brackets. Gene
expression data was generated in a previous study and is publically available (GSE83524) 220.
(B) Western blot analysis of freshly-isolated granulosa, theca, or luteal tissue for expression of
PLIN2, HSL with GAPDH and β-actin as loading controls. ** P ≤ 0.01
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Figure 3-2 – Lipid droplets and LD-associated proteins HSL and PLIN2 increase during
differentiation of granulosa cells to luteal cells
Isolated granulosa cells were differentiated using 1% insulin-transferrin-selenium (ITS) with
10 uM forskolin for up to 7 days. (A) Western blot of bovine granulosa cells, differentiating
granulosa cells, and luteal cells, n = 2 (B) Progesterone concentrations in medium of control
versus differentiating bovine granulosa cells, mean ± S.E.M, n =3. (C) Oil red O staining of
lipid droplets in control versus differentiating bovine granulosa cells after 6 days in culture.
(D) BODIPY 493/503 staining of LDs in control versus differentiating human granulosa cells
after 4 days in culture.
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Figure 3-3 – Phosphorylation of HSL at Ser-563
is increased by LH and protein kinase A
activating compounds
Western blot analysis of time-dependent HSL
phosphorylation at Ser-563 by LH (top), forskolin
(middle), and 8-bromo cAMP (8-br cAMP) from 5
minutes to 2 h post treatment. Appropriate vehicle
treated controls for each treatment are shown as 0
min post-treatment (left-most column).
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Figure 3-4 – Hormone-stimulated progesterone production can be inhibited when HSL
activity is blocked
(A) Quantification of dose-dependent inhibition of LH-induced progesterone secretion of
cultured bovine luteal cells by pretreatment of CAY10499. Mean ± S.E.M. relative to control,
n = 4 (B) Diagram demonstrating the known target of CAY10499 action. FFAs, free fatty
acids. (C) Quantification of progesterone secretion by cultured bovine small luteal cells with
(red) and without (white) 10µM CAY10499 pretreatment and stimulation with high density
lipoprotein (HDL) supplied cholesterol, LH, or LH + HDL combination. Mean ± S.E.M., n =
2 (D) Quantification of progesterone secretion by cultured bovine large luteal cells with and
without 10µM CAY10499 pretreatment and stimulation with high density lipoprotein (HDL)
supplied cholesterol, LH, or LH + HDL combination. Mean ± S.E.M., n = 2. * P ≤ 0.05, ** P
≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001
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Figure 3-5 – Phosphorylation of HSL results in its
translocation to LDs in bovine luteal tissue
Western blot analysis of total cellular lysate and
corresponding LD-associated proteins from bovine
luteal tissue biopsies treated with 8-br cAMP, a PKA
activator.
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Figure 3-6 – Western blot analysis of LD associated
proteins from functional bovine CL confirms
proteomic identification of LD-associated
steroidogenic enzymes
Western blot analysis of total cellular lysate and
corresponding LD-associated proteins from fully
functional bovine luteal tissue. Each panel is labeled
with the examined protein and the apparent molecular
weight of the band based on simultaneously run markers
follows each protein in parentheses (kDa).
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Figure 3-7 – Proposed organization of luteal LDs, mitochondria,
and endoplasmic reticulum to facilitate steroidogenesis
Scheme depicting potential organization of LDs, mitochondria, and
the endoplasmic reticulum. Also depicted is the action of LH,
through PKA, inducing activation of HSL which supplies newly
released cholesterol to StAR in the mitochondria for processing into
the steroid precursor pregnenolone, which is converted to
progesterone in the endoplasmic reticulum by 3 beta hydroxysteroid
dehydrogenase (3βHSD).
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CHAPTER 4: EARLY TRANSCRIPTOME RESPONSES OF THE BOVINE MIDCYCLE CORPUS LUTEUM TO PROSTAGLANDIN F2 ALPHA
INCLUDES CYTOKINE SIGNALING §
Abstract
In ruminants, prostaglandin F2alpha (PGF2α)-mediated luteolysis is essential for initiation of
the estrous cycle and is a target for improving fertility. To deduce early PGF2α-provoked changes
in the corpus luteum a short time-course (0.5–4 h) was performed on cows at mid-cycle. A
microarray-determined transcriptome was established and examined by bioinformatic pathway
analysis. Classic PGF2α effects were evident by changes in early response genes (FOS, JUN) and
prediction of active pathways (PKC, MAPK). Several cytokine transcripts were elevated and
NF-κB and STAT activation were predicted by pathway analysis. Self-organizing map analysis
(SOMs) grouped differentially expressed transcripts into ten mRNA expression patterns
indicative of temporal signaling cascades. Comparison with two analogous datasets revealed a
conserved group of 124 transcripts similarly altered by PGF2α treatment, which both, directly and
indirectly, indicated cytokine activation. Elevated levels of cytokine transcripts after PGF2α and
predicted activation of cytokine pathways implicate inflammatory reactions early in PGF2αmediated luteolysis.

The material presented in this chapter was submitted as a manuscript: Talbott et al. Early transcriptome
responses of the bovine mid-cycle corpus luteum to prostaglandin F2α includes cytokine signaling.
Molecular and Cellular Endocrinology 2017 221.
§
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4.1. Introduction
In mammals, multiple fertile cycles depend on the formation and regression of a transient
endocrine structure in the ovary termed the corpus luteum (CL) 134,227. The CL forms at the
beginning of each estrous cycle and synthesizes progesterone, a hormone critical for early
embryonic survival during pregnancy 135–137,228. However, before the next follicle can develop, the
steroidogenic luteal cells of the CL must cease the production of progesterone—contingent on the
absence of a pregnancy—and ultimately undergo apoptosis 123,229. Prostaglandin F2alpha (PGF2α)
is a recognized lipid mediator that triggers CL regression after an unsuccessful reproductive cycle
or at parturition in mammals 65,134,230. Thus, PGF2α-mediated luteolysis is a key checkpoint in the
reproductive cycle and is a useful target for controlling the estrous cycle and fertility.
Signaling by PGF2α has been studied extensively in vitro, and the classic signaling pathway
involves the binding of PGF2α to its G-protein-coupled receptor and activating Gαq/11 231–233. The
early intracellular signaling events initiated by PGF2α in luteal cells include the activation of
phospholipase C 234,235, phospholipase A2 236,237, an increase in intracellular Ca2+ 235, activation of
protein kinase C (PKC) 105 and activation of mitogen-activated protein kinase (MAPK) signaling
cascades including extracellular signal-regulated kinase (ERK) 105,238–241. These signaling
cascades are responsible for the transcriptional and translational induction of several early
response genes including transcription factors such as, Finkel-Biskis-Jinkins murine
osteosarcoma viral oncogene homolog (FOS) 105, Jun proto-oncogene (JUN) 105, early growth
response 1 (EGR1) 106, and activating transcription factor 3 (ATF3) 104. The transcription factors
induced by PGF2α control the abundance of target messenger RNAs (mRNAs) which, when
translated, alter the luteal proteome enabling luteolysis to proceed. For example, sustained ATF3
expression can inhibit luteinizing hormone-induced progesterone production by bovine luteal
cells 104. As well, EGR1 expression stimulates the synthesis of transforming growth factor beta
(TGFβ) 106, which coordinates the activities of a number of cell types during luteal regression.
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Specifically, TGFβ inhibits luteal progesterone secretion 106,242,243, acts on luteal endothelial cells
to disrupt the microvasculature 244, and stimulates the profibrotic activity of luteal fibroblasts 245.
The luteolytic process is a well-coordinated series of events similar to an acute inflammatory
response consisting of a sequential time-dependent infiltration of neutrophils 205,207,246,247,
macrophages 205,209,248–250, and T lymphocytes 205,209,248,251. Accordingly, there is likely timedependent secretion of cytokines to recruit and activate the various leukocytes 203,252–254. Several
cytokine transcripts are induced by PGF2α in the mid- to late-stage CL including tumor necrosis
factor alpha (TNF) 255,256, interleukin 1 beta (IL1B) 108,255,257, interferon gamma 255, TGFB1
106,256,257

, and the chemokines; C-C motif chemokine ligand 2 (CCL2, previously known as

MCP1) 257–259 and C-X-C motif 8 (CXCL8, previously known as CXCL8) 108,207,246,256,257,260. These
cytokines have pleiotropic effects on luteal cells, including inhibition of progesterone secretion
261–266

, stimulation of PGF2α secretion 263–267, and stimulation of apoptosis of multiple luteal cell

types 262,263,268–272. The production of luteolytic factors, decrease in progesterone secretion,
recruitment of immune cells, the release of pro-inflammatory cytokines, reduction in blood
supply, and the creation of a hypoxic environment 273,274 likely act in concert within the CL to
cause the functional and structural regression of the CL.
The purpose of this study was to understand the early PGF2α-elicited changes in the CL
based on temporal patterns of early transcript expression following in vivo treatment with PGF2α.
While many studies have examined luteolytic alterations both in vivo and in vitro, most studies
have focused on changes 3-24 hours after PGF2α administration 256,257 or used targeted rather than
global approaches 108,275,276. Therefore, little is known about the very early temporal changes in
global mRNA expression elicited in response to PGF2α treatment in vivo. Examination of the
early transcriptional responses to PGF2α will provide a context for understanding the events
responsible for orchestrating the cascade of events required for functional and eventual structural
regression of the CL. In the present study, a systems biology approach using Affymetrix Bovine
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Arrays was employed to evaluate gene expression at 0.5 - 4 hours post-PGF2; followed by
bioinformatics analysis of PGF2α-mediated signals. We hypothesized that the sequence of events
after in vivo PGF2α administration would include early changes of classical targets of PGF2α
signaling pathways followed by fluctuations in targets of cytokine signaling at later time-points.
4.2. Materials and Methods
4.2.1.

Animals

Post-pubertal multiparous female cattle (n = 15) of composite breeding (½ Red Angus,
Pinzgauer, Red Poll, Hereford and ½ Red Angus and Gelbvieh) were synchronized using two
intramuscular injections of PGF2α (25mg; Lutalyse®, Zoetis Inc., Kalamazoo Michigan, MI) 11
days apart. At mid-cycle (days 9-10), cows were treated with an intramuscular injection of saline
(n = 3) or PGF2α (n = 12). At each of four time-points post-injection (0.5, 1, 2, and 4 h) three
cows per treatment were subjected to a bilateral ovariectomy through a right flank approach under
local anesthesia 277,278. The CL was removed from each ovary, weighed and < 5 mm3 sections
were snap-frozen in liquid N2 for subsequent protein and ribonucleic acid (RNA) analysis. Plasma
progesterone concentrations were determined using the ImmuChem Progesterone Coated Tube
radioimmunoassay kit (MP Biomedicals, Santa Ana, CA) with an intra-assay coefficient of
variation of 9.13% and inter-assay coefficient of variation of 7.99%. The University of NebraskaLincoln Institutional Animal Care and Use Committee approved all procedures and facilities used
in this animal experiment and animal procedures were performed at the University of Nebraska—
Lincoln, Animal Science Department. Statistical differences in animal characteristics were
determined using Kruskal-Wallis test followed by Dunn’s post-test or one-way analysis of
variance followed by Bonferroni's multiple comparison test as appropriate (GraphPad Prism, La
Jolla, CA).
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4.2.2.

Steroidogenic luteal cell culture

Bovine ovaries were collected during mid-cycle or early pregnancy from a local
slaughterhouse (JBS® USA, Omaha, NE). Steroidogenic cells were prepared from luteal slices by
enzymatic digestion with type II collagenase (103 IU/mL) as described previously 106. Enriched
fractions of small luteal cells (SLC) and large luteal cells (LLC) were prepared from CLs of early
pregnancy using centrifugal elutriation similar to a previous study 104. The unseparated luteal cells
were resuspended in elutriation medium (calcium-free Dulbecco’s modified eagle medium
(DMEM) [D9800-10 US Biological, Salem, MA], supplemented with 25 mM 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3.89 g/L sodium bicarbonate, and 3
mg/mL glucose). Resuspended cells were subjected to centrifugal elutriation with continuous
flow using a Beckman Coulter Avanti J-20 XP centrifuge equipped with a Beckman JE-5.0
elutriator rotor. The first 100 mL fraction containing primarily erythrocytes and endothelial cells
was collected using 1800 rpm and 16 mL/min flow rate, the next 100 mL were discarded. The
second 100 mL fraction contained endothelial and SLC (1400 rpm and 16 mL/min). The third 100
mL fraction contained primarily SLC (1200 rpm, 24 mL/min), and the next 100 mL were
discarded. The fourth fraction contained primarily LLC (680 rpm and 30 mL/min). The fractions
containing SLC and LLC were pelleted and resuspended in basal M199 (0.1% bovine serum
albumin (BSA), 100 U/ml penicillin, 100 μg/ml streptomycin, and 10 μg/ml gentamycin). The
average purity of SLC was ~90% and LLC was > 50%.
Cells were seeded at a density of 1 × 105 cells/cm2 for mid-cycle mixed luteal cells, 1 × 105
cells/cm2 for SLC and a density of 4 × 104 cells/cm2 for LLC. Cells were allowed to attach in a
5% CO2 incubator at 37 °C in basal M199 medium containing 5% fetal bovine serum. The next
day, the medium was removed and cells washed with phosphate-buffered saline. The cells were
incubated in serum-free medium for 3 hours before applying treatments as described in the
legends to the figures [PGF2α (in ethanol, #16010, Cayman Chemical, Ann Arbor, MI), TNFα
(210-TA, R&D, Minneapolis, MN), IL-1β (RP0106B), IL-6 (RP0014B), IL-17A (RP0056B,
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Kingfisher Biotech, Saint Paul, MN)]. Luteal cell cultures were harvested into lysis buffer (20
mM Tris [pH 7.5], 150 mM NaCl, 1 mM EDTA (ethylenediaminetetraacetic acid), 0.2 mM
EGTA, 1% Triton X-100, protease and phosphatase inhibitor cocktails) and lysed by sonication.
Lysates were centrifuged at 18,000 g for 15 minutes at 4 °C and the supernatant collected for
suspension in sodium dodecyl sulfate (SDS) loading buffer (50 mM Tris [pH 6.8], 300 mM
glycerol, 25 mM SDS, 45 mM dithiothreitol, 260 mM 2-mercaptoethanol, bromophenol blue).
Proteins were separated by electrophoresis using 10% SDS-polyacrylamide gels and transferred
to nitrocellulose membranes. Membranes were blocked with 5% non-fat milk in 0.1% Tween 20
in Tris-buffered saline (TBST) then incubated overnight with the primary antibody diluted in 1%
non-fat milk or BSA in TBST at 4 °C. After three, 5-minute washes with TBST, membranes were
incubated for 1 hour at room temperature with anti-rabbit or mouse (1:20,000) horseradish
peroxidase-conjugated IgG diluted in TBST with 1% non-fat milk. After three 5-minute washes,
protein bands were detected with ECL reagent (SuperSignal West Femto Thermo Science,
Miami, OK, or PerkinElmer, Waltham, MA). Signals were visualized on FluorChem M
(ProteinSimple, San Jose, CA) or UVP (UVP, LLC, Upland, CA) systems. Phosphorylated
nuclear factor kappa B (NF-κB) subunit P65 (phospho-P65, 3031 AB_330559) and
phosphorylated ERK1/2 P44/P42 (phospho-P44/P42, 9101, AB_331646) antibodies were from
Cell Signaling Technology (Danvers, MA); β-actin (A5441, AB_476744) and β-tubulin (T4026,
AB_477577) antibodies were from Sigma (St. Louis, MO); and anti-mouse (115-035-205,
AB_2338513) and anti-rabbit (111-035-003, AB_2313567) HRP-conjugated IgG from Jackson
(West Grove, PA). Protein band density was analyzed using UVP software (Version 6.7.4), using
area density of equally sized rectangles encompassing the bands at the appropriate molecular
weight, normalized to the corresponding β-actin density and compared to control treatment by
fold change.
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4.2.3.

Affymetrix bovine gene chip microarray

Each CL from the in vivo experiment described in Section 2.1 was homogenized and RNA
was extracted using a Stratagene RNA Isolation Kit (Santa Clara, CA) following manufacturer’s
instructions. Transcriptional changes were analyzed by hybridization of 500 ng biotinylated
cDNA using Affymetrix (Santa Clara, CA) bovine whole-transcript microarray (Bovine Gene v1
Array [BovGene-1_0-v1]; GPL17645) at the University of Nebraska Medical Center Microarray
Core Facility. Validation of target transcripts was performed after reverse transcription of 1 μg
RNA using SuperScript II Reverse Transcriptase (Invitrogen, Grand Island, NY) followed by
quantitative real-time PCR (qPCR) using gene-specific primers (Appendix B-1) on a CFX96
TouchTM Real-Time PCR Cycler (Bio-Rad, Hercules, CA) with SsoFastTM EvaGreen® Supermix
(Bio-Rad, Hercules, CA). Comprehensive microarray methods and data are available in the Gene
Expression Omnibus (GEO) database under accession GSE94069 and are described in the
accompanying Data in Brief article 279.
4.2.4.

Microarray statistics

The microarray data were preprocessed using the robust multi-array average (RMA) method
from Affymetrix expression console software (Affymetrix Inc., Santa Clara, CA) to normalize
data at the exon level. The mean intensities of multiple probe sets of the same gene were
calculated under each array to obtain the corresponding gene expression intensities. The data was
filtered to keep the genes with a raw expression value after preprocessing to be 10 or more for at
least three of the 15 samples. Linear Models for Microarray Analysis 280 in the Bioconductor suite
281

under the statistical program R 282 was applied to compare the log ratio between each of the

PGF2α time-points and the saline control after adjusting for the box effect. R code used to
process the data is available in 279. Transcripts with a fold change of at least 1.5 and a BenjaminiHochberg adjusted P-value of less than 0.05 for each treatment condition versus control were
identified as differentially expressed genes.
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4.2.5.

Self-organizing maps and statistics

Microarray data was filtered to keep genes with a raw expression value after preprocessing to
be 30 or more for at least three of the 15 samples. The log ratio between each of the time-points
and the saline control were compared using Linear Models of Microarray Analysis in the
Bioconductor suite in R. The self-organizing map (SOM) clustering algorithm GeneCluster 2.0 283
was applied to differentially expressed genes that had a greater than 1.5-fold change in expression
and P-value ≤ 0.05 between PGF2α-treated samples and the saline control. The mean normalized
log2 intensity values from each of the five examined biological conditions were used as transcript
expression profiles in the clustering analysis. The number of iterations in SOM clustering was set
to 500,000 to generate SOMs and hierarchical clustering (correlation-based distance, average
link).
4.2.6.

Dataset comparisons

Two previously published microarray datasets, GSE23348 257 and GSE27961 256 examined
the effect of in vivo PGF2α or analog treatment on the bovine luteal transcriptome using
Affymetrix Bovine Whole Genome Gene Chips (GPL 2112). These datasets were chosen for
comparison to the transcriptome dataset presented herein based on similarities in the experimental
protocol comparing mid-cycle control CL expression profiles to CL profiles after treatment with
PGF2α or analog for 4 hours (GSE23348) or 6 hours (GSE27961). Original.CEL and.CHP files
were downloaded from the GEO database and processed as described in Section 4.2.4 Microarray
statistics. The differentially expressed mRNAs at 4 or 6 hours were compared between the three
microarray datasets to determine the similarities among the datasets.
4.2.7.

Pathway analysis

Pathway analysis was evaluated using Ingenuity Pathway Analysis (IPA) [Application: Build:
430520M Copyright 2017 QIAGEN (Redwood City, CA)]. Transcripts found to be differentially
expressed compared to saline-injected controls with ≥ 1.5-fold change and P ≤ 0.05 were input
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into IPA for core analysis using Entrez gene IDs for evaluations of the time-course and
comparison datasets. Unmapped genes ranged from 6.5-20.7% per individual time-points or
datasets. Datasets were assessed for prediction of upstream regulators and signaling pathways.
Additional pathway analysis was completed using DAVID (Version 6.8, released: Oct 2016)
284,285

, PANTHER Database (Version 11.1, released: Oct 2016) 286–288, and STRING Database

(Version 10.0, released: Apr 16, 2016) 289 to validate IPA findings and provide unique
perspectives based on each tool’s functionality. Functional categorization of genes common to all
three datasets examined was done by manual annotation of a single major functional category for
each gene based on National Center for Biotechnology Information and GeneCardsSuite
descriptions and gene ontology annotations of genes.
4.3. Results
4.3.1.

Bovine microarray

The analysis of the Affymetrix gene arrays revealed 1654 gene transcripts that were
differentially expressed. The number of differentially expressed genes increased throughout the
time-course (Figure 4-1 A). Up-regulated transcripts predominated at early time-points in
response to PGF2α (89.6% and 97.1% up-regulated, 0.5 and 1 h, respectively). Similar numbers
of up-regulated and down-regulated transcripts were observed at 2 hours post-PGF2α (53.4% upregulated genes). Conversely, at 4 hours post-PGF2α, 58.2% of differentially regulated transcripts
were down-regulated. The overlap of altered transcripts among time-points is shown in a Venn
diagram in Figure 4-1 B. Of note, 14 of the 29 differentially expressed mRNAs detected at 0.5
hours post-PGF2α were differentially expressed at all 4 time-points. Additionally, at 4 hours postPGF2α, there were 1,507 differentially expressed transcripts unique to that time-point.
Comprehensive microarray data is found in the GEO database under accession GSE94069. A full
list of differentially expressed genes, fold changes and P-values is provided in Appendix B-2.
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The top 10 up-regulated and down-regulated transcripts (by fold-change) at each time-point
along with their fold change and P-values are listed in Table 4-1 & Table 4-2, respectively.
Transcription factors were particularly prominent early in the time-course response to PGF2α and
although the number of transcription factors continued to increase, they made up a lower
proportion of differentially expressed genes as the time-course proceeded. One-half hour after
PGF2α treatment, 34.5% of the mapped differentially expressed genes had a transcription factor
classification using DAVID molecular function analysis and at 4 hours post-PGF2α, only 1.9% of
the differentially expressed genes were classified as transcription factors [Appendix B-4].
Transcription factors that were up-regulated at all time-points investigated included ATF3, BTG2,
FOS, FOSB, EGR3, JUNB, NR4A1, NR4A2, NR4A3, and ZFP36. Verification of microarray
results was completed using qPCR to verify the stimulation of several immediate-early response
genes (ATF3, FOS, JUN, JUNB) which peaked between 1-2 hours (Figure 4-1 C).
Several cytokine and cytokine-related transcripts were up-regulated in response to PGF2α. At
2 hours post-PGF2α, up-regulated cytokine transcripts included CCL8, IL1A, IL1B, and IL33.
Lastly, at 4 hours, 25 cytokine-related transcripts were up-regulated including all of the upregulated cytokines at 2 hours and additionally including, CCL2, CCL3, CCL4, CXCL2, CXCL5
CXCL8, CXCL13, and IL18. Validation of selected cytokine transcripts was performed by qPCR
(Figure 4-1 D) and described by 260. Suppressor of cytokine signaling 3 (SOCS3), which encodes
a protein important in preventing over-activation of inflammatory conditions, was the first
inflammation/cytokine-related transcript significantly up-regulated at 1 hour. At the 2- and 4-hour
time-points, both SOCS3 and SOCS1 were up-regulated [Appendix B-2].
Down-regulated genes included NF5A2 (also known as LRH1); however, many of the downregulated genes have no known role in CL function or luteolysis. Analysis by IPA of downregulated genes indicated activation of ‘decreased size of body’ (z-scores; -4.029 and -8.795 at 2
and 4 hours, respectively). Upstream regulators included activation of NUPR1 (z-scores; 2.53,
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4.01 at 2 and 4 hours, respectively) and inhibition of vascular endothelial growth factor (VEGF),
upstream transcription factor 1 (USF1), and endothelin 1 (EDN1) (z-scores at 4 hours; -4.55, 2.58, -2.43, respectively). Functional analysis by DAVID of down-regulated genes at 4 hours
indicated an enrichment in insulin signaling and cyclic adenosine monophosphate signaling and
metabolic processes.
4.3.2.

Functional luteolysis

Serum progesterone was significantly decreased by PGF2α treatment at 2 and 4 hours (51%
and 54%, respectively) compared to saline-treated mid-cycle cows (Figure 4-2 A). Cows from
different treatment groups were not different in age, weight or number of calves produced. There
were no significant differences among groups in CL weight, ovary dimensions, and antral follicle
counts [Appendix B-5].
Despite the decrease in progesterone secretion by 2 hours post-PGF2α, there were no changes
within our time-course in the transcripts that directly control progesterone synthesis (Figure 4-2
B). The proteins encoded by StAR, CYP11A1, and HSD3B1 (steroidogenic acute regulatory
protein, cytochrome P450 family 11 subfamily A member 1, and hydroxyl-δ-5-steroid
dehydrogenase, 3 β and steroid δ-isomerase 1, respectively) are directly responsible for the
modification of cholesterol to progesterone, but the abundance of the transcripts were not
changed following PGF2α treatment. Additionally, no changes were observed in the luteinizing
hormone/chorionic gonadotropin receptor (LHCGR) or lipoprotein receptors: SCARB1, and LDLR
(scavenger receptor class B member 1, and low-density lipoprotein receptor).
Conversely, several transcripts associated with cholesterol availability were differentially
regulated. Transcript abundance of lipase E, hormone-sensitive type (LIPE), was decreased at 2
and 4 hours; LIPE encodes the cholesteryl esterase hormone-sensitive lipase (HSL). As well, the
LDLR adaptor protein (LDLRAP1) transcript abundance decreased beginning at 2 hours. Other
genes that have products influencing cholesterol availability that increased during the time-course
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included insulin induced gene 1 (INSIG1) and cholesterol 25-hydroxylase (CH25H) transcripts.
Genes encoding members of the lipid droplet coat protein family, perilipin (PLINs), were also
altered after PGF2α treatment including a 2.6 fold increase in PLIN2 transcript levels, and -1.9
fold decrease in PLIN3. Finally, there were no changes observed in transcript abundance of genes
for reverse cholesterol transport proteins (ABCA1, ABCG1, NR1H2, NF1H3, APOA1, and APOE)
except ABCA1, which was reduced at 4 hours.
4.3.3.

Pathway analysis of short time-course

Ingenuity Pathway Analysis identified known PGF2α mediators including PGF2α itself
(identified in IPA as the synthetic PGF2α, dinoprost), PKC group 105, ERK/MAPK 105,238–241, and
Ca2+ 290. All of these known PGF2α signaling intermediates were predicted as activated by IPA
and the activation z-scores for each of these mediators are graphically represented in Figure
4-3 A. Most of these upstream regulators were predicted to have the greatest effect at 2 hours.
Upstream regulator analysis predicted TNFα, IL-1β, IL-6 and IL-17A as active upstream
regulators during the short time-course. Figure 4-3 B displays the activation z-scores of several
inflammatory cytokines during the 4-hour time-course demonstrating that activation scores for
these inflammatory cytokines increased throughout the study. Inflammatory cytokine signaling
often involves activation of NF-κB and signal transducer and activator of transcription (STAT)
291,292

and both NF-κB and STAT3 were predicted to be activated during PGF2α–induced luteal

regression. Additionally, inhibitors of cytokine signaling, SOCS1 and SOCS3 were predicted to
be inhibited (Figure 4-3 C).
To test whether PGF2α or the predicted cytokines were capable of activating NF-κB,
dispersed luteal cells from mid-cycle CL or enriched preparations of SLCs and LLCs were treated
with PGF2α or select cytokines and acute activation of NF-κB and ERK pathways were
examined. Figure 4-3 D & E shows that PGF2α rapidly stimulated ERK phosphorylation but did
not alter phosphorylation of the NF-κB subunit P65 in a 5-120 minute timecourse. Figure 4-3 D
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illustrates that TNFα, IL-1β, and IL-17A consistently stimulated the phosphorylation of NF-κB
P65 in dispersed mid-cycle luteal cells. The cytokines, TNFα, IL-1β, and IL-17A stimulated
phosphorylation of P65 in both SLC and LLC, and PGF2α selectively stimulated ERK
phosphorylation in LLC but had no effect on P65 (Figure 4-3 F). Interleukin-6 did not stimulate
phosphorylation of ERK or P65 NF-κB as it is known to activate the JAK/STAT signaling
pathway 293.
Ingenuity Pathway Analysis highlighted canonical pathways predicted to be activated or
inhibited within this dataset based on the downstream targets’ differential expression (P-value)
and direction of change (z-score). The top five canonical pathways identified from each timepoint are listed in Table 4-3. At 0.5 hours post-PGF2α, no pathways had a z-score ≥ |2|, likely due
to the small number of differentially expressed genes. However, several pathways had P-values ≤
0.05, including ‘NRF2-mediated Oxidative Stress Response’. A total of seven pathways were
predicted as activated at the 1-hour time-point. At 2 hours post-PGF2α, five pathways were
predicted as activated and at 4 hours post-PGF2α, 20 pathways were identified (5 activated and
15 inhibited). Two canonical pathways were predicted to be activated in 2 of the 4 time-points
examined, ‘cholecystokinin/gastrin-mediated signaling’, and ‘Toll-like receptor signaling’.
Several additional canonical pathways including, ‘Acute Phase Response Signaling’, ‘ILK
Signaling’, and ‘TGF-β Signaling’ were identified that had z-scores ≥ |1| in at least two timepoints.
4.3.4.

PGF2α activates well-organized transcriptional cascades

Ten SOMs were generated based on transcripts that had similar changes in their expression
profiles relative to control throughout all four time-points. The differentially expressed transcripts
included in each SOM are found in Appendix B-6. Of these, two SOMs reflected the expression
patterns of early response genes (Figure 4-4 A & F) and reached peak levels in 1-2 hours and then
returned toward baseline. Four SOMs corresponded to early and delayed-early responsive
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transcripts with changes in mRNA abundance early in the time-course (but less rapid than the
immediate-early response genes) which either plateaued (Figure 4-4 B & G) or continued to
change throughout the examined time frame (Figure 4-4 C & H). Finally, there were two SOMs
where changes in transcript abundance did not begin until the 2-hour time-point indicative of lateresponse genes (Figure 4-4 D & I). Two additional SOMs had biphasic transcript profiles, which
changed early (either up- or down-regulated), returned to baseline and then rebounded at later
time-points (Figure 4-4 E & J).
Up-regulated SOMs had several common IPA-predicted upstream regulators such as TNFα,
TGFβ, IL-1β, and NF-κB. Down-regulated SOMs had common inhibition predictions of VEGF,
peroxisome proliferator-activated receptors ligands, and T3 (the thyroid hormone,
triiodothyronine). Functional analysis by IPA of the genes in each SOM predicted activated
‘migration of cells’ and inhibition of organismal death in immediately-early up-regulated genes.
Early and delayed-early up-regulated gene patterns had functional predictions of ‘cell survival’.
Late up-regulated gene patterns were consistent with increases in ‘migration of cells’ and
biphasic up-regulated genes had functional predictions of inhibited ‘organismal death’. Downregulated SOMs had functional predictions of ‘organismal death’ for immediate-early and downregulated gene patterns. Functional annotations predicted activation of ‘organismal death’ in
delayed-early down-regulated SOM, increased ‘morbidity or mortality’ in late down-regulated
genes, and death and increased ‘organismal death’ in biphasic down-regulated genes.
Functional annotations of each SOM revealed that SOMs, which peaked early, had a greater
proportion of genes with a ‘regulation of gene expression’ biological process annotation by
DAVID; including, within the immediate-early categories 47.2% of up- and 18.2% of downregulated genes. In the early responses, ‘regulation of gene expression’ composed of 31.4% of
up-regulated and 22.9% of down-regulated genes. Within the delayed-early SOMs, 19.2% of upand 22.3% of down-regulated genes were also annotated with ‘regulation of gene expression’.
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Whereas, late-response gene patterns had fewer genes classified as ‘regulation of gene
expression’ compared to earlier gene profiles (18.2% up- and 19.6% down-regulated). Instead,
delayed-early and late up-regulated SOMs had 7.1% of genes associated with “inflammatory
reactions” (P-values: 1.50E-05, 9.50E-08, DAVID). Biphasic up-regulated genes had biological
process annotations including immune response-activating signal transduction. Finally, biphasic
down-regulated genes had annotations related to fibrosis. Of the down-regulated SOMs, several
contained components of peroxisome proliferator-activated receptor signaling and VEGF
signaling.
4.3.5.

Dataset comparisons

Two previously published microarray datasets examined the effect of in vivo PGF2α
treatment on mid-cycle bovine CL. The similarities in experimental design allowed direct
comparison of the microarray data at 4 hours post-PGF2α to the previously published microarray
analyses from GSE23348 257 and GSE27961 256. Mondal et al. collected luteal tissue from Angus
crossbred heifers 4 hours after giving an intramuscular injection of 25 mg Lutalyse at day 11 of
the estrous cycle. Shah et al. treated non-lactating Bubalus bubalis (water buffalo) cows with a
500 µg dose of Juramate (equivalent to 25 mg of Lutalyse 294) and collected luteal tissue at 6
hours post-PGF2α. The overlap of differentially expressed transcripts between the three datasets
is visually represented in a Venn diagram in Figure 4-5 A. Comparison of the three datasets
revealed 515 genes found by at least 2 of the 3 studies, and 124 genes that were similarly altered
in all the datasets including 43 up-regulated genes and 81 down-regulated genes. A full list of the
genes common to all three datasets is available in Table 4-4.
Independent bioinformatics analysis of each dataset revealed common regulatory elements.
First, IPA predicted similar upstream regulators in each dataset such as PKC, MAPK/ERK,
TNFα, IL-1α/β, and IL-17. Canonical pathway analysis of each of the three datasets commonly
predicted activation of triggering receptor expressed on myeloid cells 1 (TREM1) signaling, an
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important pathway for activation of macrophages and neutrophils 295. Bioinformatic analysis of
the 124 genes common to all 3 datasets indicated activation of FOS, JUNB, MAPK/ERK, IL-1β,
TNFα, TGFβ, IL-6 (Figure 4-5 B) as well as canonical pathways like IL-6 Signaling, Acute Phase
Response Signaling, and NF-κB Signaling. Pathway analysis of the 124 common genes by IPA,
DAVID, PANTHER, and STRING consistently reported enrichment of TGFβ signaling (4 of 4)
and p53 signaling (3 of 4). Finally, the functional analysis indicated groups of genes involved in
cell-cell interaction (12.9%), cytokine signaling (8.9%), and transcriptional regulation (8.1%) in
Figure 4-5 C. The genes in each functional category are listed in Table 4-4.
4.4. Discussion
4.4.1.

Overview of study

This study uses a systems biology approach to provide a detailed understanding of the early
(0.5 – 4 h) transcriptional effects that occur during PGF2α-induced luteolysis in vivo. Our
analysis predicts activation of cytokines (TNFα, IL-1β, IL-6, IL-17A, & IL-33) and cytokine
signaling intermediates (NF-κB, STAT) early in the time-course. However, changes in cytokine
transcripts are not apparent until 2 - 4 hours post-PGF2α. The effects of PGF2α in vivo may
require the activation of secondary mediators, such as cytokines, which activate NF-κB and
STAT signaling because PGF2α is unable to stimulatephosphorylation of NF-κB P65 in isolated
luteal cells. The rapid influx of various immune cells in response to the initiation of luteolysis
207,209,246

and the release of pre-formed cytokines could explain the prediction of cytokine

signaling effects very early in the PGF2α response. As well, the activation of NF-κB signaling
could contribute to later responses seen after PGF2α administration.
Analysis of gene expression changes also confirms changes in the transcriptome that are
consistent with PGF2α signaling. Evidence of classical PGF2α signaling activation is seen
directly in the rapid induction of immediate-early response genes (ATF3, EGR1, FOS, JUN, and
NR4A2), consistent with changes in genes documented to be direct targets of PGF2α signaling
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92,104,105,108,296,297

. Bioinformatics analysis also identifies upstream regulators consistent with

known PGF2α signaling mediators such as dinoprost (PGF2α), PKC, Ca2+, and ERK. The
bioinformatics findings indicating activation of classical PGF2α signaling pathways after in vivo
treatment are an important validation of the predictive power of the bioinformatics tools used in
this study. Comparison with similar datasets 256,257 yields comparable results, predicting both
PGF2α signaling and cytokine signaling in the CL after PGF2α treatment.
4.4.2.

Induction of functional luteolysis

In this study, in vivo administration of PGF2α decreases serum progesterone within 2 hours
of treatment. However, serum progesterone concentrations are not under 1 ng/mL, a cutoff that
indicates irreversible functional regression, which typically occurs 18-24 hours after the onset of
luteolysis 298–301. Additionally, there are no changes in CL weight, indicating that structural
regression of the CL has not yet begun. The reduction in serum progesterone concentrations is not
accompanied by reductions in the expression of the steroidogenic enzymes: StAR, CYP11A1, and
HSD3B1. Furthermore, transcripts for key receptors (LHCGR, SCARB1, or LDLR) intimately
involved in progesterone synthesis are also unchanged. These findings showing a marked
reduction in serum progesterone prior to changes in steroidogenic gene transcript abundance are
similar to other studies 108,255–257. However, it is possible that changes in abundance or function of
specific proteins may occur prior to down-regulation of the corresponding mRNA 256,302.
These observations suggest that alternate pathways could contribute to the early reduction in
luteal progesterone synthesis. Based on our findings, it seems possible that the decrease in LIPE
could contribute to the decrease in progesterone production because its protein product, HSL,
interacts directly with lipid droplets to hydrolyze cholesteryl esters to liberate cholesterol for
steroidogenesis 8,40,42,43. The reduction in LIPE expression together with alterations in LDLRAP1,
INSIG1, and CH25H transcript abundance could have a combined negative effect on intracellular
cholesterol availability. Decreases in LDLRAP1 could inhibit progesterone production by
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reducing the cholesterol available for use in the cell since endocytosis of low-density lipoprotein
particles requires the LDLRAP1 cofactor 303,304. An increase in INSIG1 concentrations could
affect steroidogenesis through suppressing transcription of de novo cholesterol synthesis and
uptake proteins, 305,306; however, de novo synthesis is not a primary source of cholesterol for
steroidogenesis in the CL 143,307,308. Finally, increases in CH25H could catalyze the hydroxylation
of cholesterol to 25-hydroxycholesterol which is a potent inhibitor of de novo cholesterol
synthesis 309. However, 25-hydroxycholesterol can also act as a substrate for steroidogenesis 310
although it is unclear how physiological concentrations of this oxysterol would act on bovine
luteal cells or neighboring cells.
Activation of reverse cholesterol transport could also effectively reduce intracellular
cholesterol availability for progesterone synthesis. Other studies have reported an increase in
reverse cholesterol transport transcripts such as ABCA1, ABCG1, NR1H2, NF1H3, APOA1, and
APOE during luteolysis 311–313. However, in this dataset, only a single transcript of the reverse
cholesterol transport process, ABCA1, changes compared to control, and it decreases. Thus,
changes in transcript abundance that contribute to increases in reverse cholesterol transport do not
appear to contribute to the early reductions in circulating progesterone.
4.4.3.

Cytokine signaling

The present study implicates IL-33 and IL-17 cytokines as potential regulators of luteal
regression, although neither have previously been proposed to have a role in luteolysis.
Nevertheless, transcripts abundance of IL33 increase 17-fold over controls and up-regulated in
all three datasets. Two recent reports indicate that IL-33 may play a role in follicular atresia 314,315
and we propose that IL-33 may play a similar role in luteal regression. Preliminary data in our
laboratory indicates that IL-33 does not have a direct effect on in vitro primary luteal cell
cultures, presumably because luteal cells lack or have a low representation of components of the
IL-33 receptor complex 220,279. In the regressing CL, IL-33 could play a role in macrophage
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recruitment 314,315, mast cell activation 316, and is likely derived from the endothelial cells rather
than the steroidogenic cells of the CL 315,316.
Another novel cytokine highlighted in this dataset is IL-17A, which is identified as an
activated upstream regulator in three of the time-points examined. There are no reports of a role
for IL-17 in the CL, however, a recent study by Ozkan et al. demonstrated that elevated serum IL17 concentrations predicted infertility and poor responsiveness to in vitro fertilization 317.
Analysis of this dataset using a more robust method of calling differentially expressed transcripts
increased z-score predicted activation of IL-17 signaling 318, and our data indicate that IL-17 can
directly activate NF-κB and ERK1/2 signaling in luteal cell cultures. How IL-33 and IL-17
contribute to luteal regression is a subject of future investigations.
Cytokine signaling intermediates such as NF-κB and STAT3 are predicted by IPA to be
activated in response to PGF2α throughout the time-course. Activation of NF-κB or prediction of
NF-κB activation is consistently reported after PGF2α treatment in vivo 256,257,319,320. However, in
vitro PGF2α does not phosphorylate NF-κB in luteal cells (present study) or endometrial
adenocarcinoma cells 321. Thus, in vivo PGF2α may use secondary mediators, such as cytokines,
which would activate NF-κB and STAT signaling. This prediction is supported by significant
increases in expression of SOCS3 transcripts within 1 hour (4-fold) and SOCS1 at 4 hours (1.7fold), findings consistent with a well-controlled tissue-specific inflammatory response. However,
IPA predicts the inhibition of SOCS1 and SOCS3 during the PGF2α time-course, which could b.
This expands on work by ourselves and others that previously proposed a role for cytokines and
immune cells in PGF2α-induced luteolysis at 3 or more hours after PGF2α treatment
106,207,244,246,256,257,260,322

.

We found both direct and indirect evidence for increases in expression of pro-inflammatory
cytokines and signaling during the early responses to PGF2α. Changes in cytokine-related
transcripts do not occur until 2-4 hours post-PGF2α treatment; although, IPA predicts upstream
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cytokine activation and signaling at all 4 time-points. Secretion of cytokines (TNFα, TGFβ, and
CXCL8) can be stimulated by PGF2α treatment in the ovary 106,207,323, and other tissues 321,324. For
example, PGF2α treatment in vivo and in vitro induces CXCL8 108,207,246,260,325, a cytokine which
potentially serves to recruit neutrophils and macrophages to the CL 207,260,326,327. The recruitment
and activation of immune cells along with the actions of pre-formed cytokines could be
responsible for the very early gene expression changes that are indicative of cytokine signaling.
Both neutrophils and mast cells can store and release large amounts of cytokines and other
bioactive proteins immediately after activation without the need for de novo synthesis of proteins
328–330

. This would allow for immediate responses without requiring transcription or translation;

therefore, these genes would not be identified in transcriptome-based studies.
4.4.4.

PGF2α activates well-organized signaling cascades

Analysis of SOMs demonstrates that a coordinated cascade of transcription occurs after
PGF2α administration and includes immediate-early, early, delayed-early, late, and biphasic
transcriptional responses. This suggests that a carefully orchestrated succession of gene
expression changes occurs during PGF2α-induced luteolysis. Our analysis clarifies the early
temporal responses required for PGF2α-induced luteolysis. As expected, the immediate-early upregulated and early down-regulated responses are composed primarily of transcription factors.
Later signaling waves contain a greater proportion of genes that are non-transcription factors
suggesting that genes with an immediate-early expression profile could trigger transcription of
early, and delayed-early type genes which could then alter transcription of late-type genes in a
transcriptional cascade 331.
Up-regulated gene patterns are consistent with inflammatory response and activation of
immune cells. The common upstream regulators TNFα, TGFβ, IL-1β, and NF-κB support this
prediction. Down-regulated SOMs correspond with the activation of death pathways and
inhibition of cellular proliferation. Interestingly, up-regulated SOMs had functional annotations
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such as decreased organismal death whereas down-regulated SOMs noted increased organismal
death, which highlights that during a complex event such as luteolysis, there are populations of
cells, which are activated and proliferating (potentially immune cells), and other cell types that
will be inhibited and primed for apoptosis such as endothelial and steroidogenic luteal cells.
Notably, the common upstream regulators EDN1 and VEGF support the idea that CL regression
involves early changes in the vasculature, which has been previously suggested 332–334. Moreover,
several studies indicate that biphasic transcriptional responses are correlated with fluctuations in
activation of NF-κB in response to cytokines like TNFα 335–337. These biphasic, oscillatory
responses that can activate both acute and chronic changes within the target tissues are
characteristic of cytokine and NF-κB signaling 335–339. In accordance, the cytokines IL-1β, and
TNFα are predicted as upstream regulators of the up-regulated biphasic response SOM.
Additionally, Mondal et al. proposed that sustained activation of NF-κB signaling only occurred
in PGF2α-sensitive luteal tissues, and the biphasic patterns of gene expression could reflect both
acute activation and the beginning of a chronic activation of target genes. Together these SOMS
indicate a cascade of events, whereby immediate-early response genes, composed mostly of
transcription factors alters early and delayed-early gene expressions, which contribute to changes
in the expression of late-response genes.
4.4.5.

Dataset comparison and relationship to previous studies

Comparison of our dataset to two other studies, GSE23348 257 and GSE27961 256 that used
microarray analysis to determine the bovine luteal transcriptome after PGF2α treatment. Our
dataset comparison reveals 124 differentially expressed transcripts common to all three datasets,
including BCL6, BMP2, FOSL1, IL33, INHBA, and NR5A2. Bioinformatics analysis of the
common transcripts predicts activation of cytokine signaling and includes the upstream regulators
IL-1β, TNFα, and TGFβ. This comparison provides several high confidence transcriptome
changes that occur in the bovine CL after PGF2α treatment, which vary minimally across study
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sites and investigation groups, providing an important resource for future studies. Importantly,
our analysis of the differentially expressed genes common to all three datasets as well as each
independent dataset are consistent with the activation of both PGF2α and cytokine signaling.
Additionally, functional annotations of common genes indicate a large proportion of gene
products function in cytokine signaling and cell-cell interaction, which both play critical roles in
luteolysis. These findings validate the predictions based on the short time-course and support a
growing body of literature that suggests that immune cells and cytokines play a key role in CL
regression.
4.4.6.

Conclusions from the study

Shortly after PGF2α administration, phospholipase C, PKC, Ca2+, and ERK trigger a variety
of signaling cascades to begin the luteolytic process. Our data suggests that in vivo, PGF2α
administration stimulates a series of transcriptional waves likely as a result of classical PGF2α
and cytokine signaling events, as early as 30 minutes post-PGF2α treatment. This is the beginning
of a cascade of events that will initiate decreases in progesterone secretion (2-12 hours postPGF2α) and result in the structural regression of the CL 12-18 hours post-PGF2α 240,340. The
earliest decreases in progesterone secretion during luteolysis may be due to changes in protein
function and in LIPE/HSL expression and other transcripts which regulate cholesterol
availability rather than changes in the expression of mRNA encoding the primary steroidogenic
enzymes. We propose that during the early stages of functional regression in combination with
PGF2α, the reduction in progesterone, and increase in inflammatory cytokines (potentially
including IL-33 and IL-17) contribute to luteal regression. As the intra-luteal concentrations of
PGF2α and inflammatory cytokines increase they may act within an auto-amplification loop
eventually reaching a critical point from which there is no rescue from the luteolytic cascade
67,341–344

. Future studies to identify the specific transcriptional changes occurring in steroidogenic
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cells, endothelial cells, immune cells, and fibroblasts is needed to better understand the dynamic
network of changes that enable functional and structural luteal regression.
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Figure 4-1 - Time-course of the transcriptomic response to PGF2α
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Figure 4-1 – Time-course of the transcriptomic response to PGF2α
Mid-cycle cows (n = 3/time-point) were treated with 25 mg PGF2α for 0.5, 1, 2, and 4 hours
and control saline injections (n = 3). Samples were analyzed by Affymetrix bovine whole
transcript microarray (Bovine Gene v1 Array [BovGene-1_0-v1]; GPL17645) and
differentially expressed transcripts were identified based on fold change ≥ |1.5| and BenjaminiHochberg adjusted P-value ≤ 0.05 compared to saline controls (n = 3). (A) Number of
upregulated and downregulated differentially expressed transcripts at each time-point graphed
on a log scale, upregulated transcripts appear in red above the central axis, and downregulated
transcripts appear in green below the axis. (B) Venn diagram of the number of differentially
expressed genes that overlapped between the four time-points examined. Each oval is labeled
with the time-point and the total number of differentially expressed genes in the time-point.
Overlapping parts of the ovals are labeled with the number of transcripts that were
differentially expressed at the corresponding time-points. (C & D). Quantitative PCR
(qPCR) analysis of target genes normalized to ACTB and GAPDH expression and compared to
saline controls using fold-change are displayed using bar graphs to represent mean ± SEM and
plotted on the left Y-axis. Microarray determined fold-change of the target genes compared to
control are overlayed using filled circles • to represent the mean (n = 3) and plotted on the
right Y-axis. (C) Selected transcription factor genes (ATF3, FOS, JUN, and JUNB) were
significantly different from control values (P < 0.0001) as determined by qPCR and
determined as differentially expressed in the microarray (except JUN at 4 h). (D). Target
cytokine transcripts (CCL2, CCL8, CXCL2, and CXCL8) were all upregulated at 4 h (P <
0.01). Additionally, CXCL8 was significantly upregulated at 1 and 2 hours (P < 0.0001, P <
0.05, respectively) as determined by qPCR. Determination of differentially expressed
transcripts by microarray indicated significant upregulation of CXCL2 and CXCL8 at 4 hours
and CCL8 at both 2 and 4 hours. Submitted for publication as part of 221.
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Figure 4-2 – PGF2α induced
reductions in progesterone are
correlated with reductions in the
expression of genes controlling
intracellular cholesterol availability
(A) Serum progesterone concentrations
of cows 0.5 - 4 hour post-PGF2α
treatment (n = 3/time-point). * P ≤
0.05, ** P ≤ 0.01 compared to salinetreated animals. (B) Heat map of genes
that regulate cholesterol availability,
progesterone synthesis, and reverse
cholesterol transport. Green indicates
decreased and red indicates increased
transcripts over control. Yellow boxes
indicate time-points that were
significantly altered from saline
controls and fold changes from saline
controls are indicated in the respective
boxes. Submitted for publication as
part of 221.
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Figure 4-3 – In vivo treatment with PGF2α predicts classical PGF2α and cytokine signaling
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Figure 4-3 – In vivo treatment with PGF2α predicts classical PGF2α and cytokine
signaling
(A, B & C) The activation z-score of specific upstream regulators, determined by IPA,
graphed against time. (A) Classic mediators of PGF2α signaling including, PGF2α itself
(dinoprost, black), protein kinase C (PKC group, blue), ERK (red), and Ca2+ (green). (B)
Cytokine activation scores including, TNFα (black), IL-1β (blue), IL-6 (red), and IL-17
(green). (C) Cytokine signaling molecules: NF-κB (black), STAT3 (blue), and suppressors
of cytokine signaling, SOCS1 (red) and SOCS3 (green). (D) Phospho-P65 quantification
(mean ± SEM) of non-pregnant mid-cycle luteal cells (n = 3) treated with TNFα, IL-1β, IL17A and PGF2α for 30 minutes followed by Western blot analysis, normalized to β-actin and
compared to untreated controls, representative immunoblots are shown below the bar graph. *
P ≤ 0.05 compared to control. (E) Western blot of non-pregnant mid-cycle luteal cells treated
with PGF2α for the indicated times immunoblotted for phospho-P65, phospho-ERK1/2, βtubulin, and β-actin. (F) Western blot of small luteal cells (SLC) and large luteal cells (LLC)
treated with TNFα, IL-1β, IL-6, IL-17A (10 ng/mL each) and PGF2α (100 nM) for 30 minutes
and immunoblotted for phospho-P65, phospho-ERK1/2, β-tubulin, and β-actin. Submitted for
publication as part of 221.
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Figure 4-4 – Temporal response waves to PGF2α
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Figure 4-4 – Temporal response waves to PGF2α
Self-organizing maps (SOMs) graphs were generated as detailed in Methods. Each graph
shows the average log2 transcript expression intensity ± SEM of the transcripts grouped into
each SOM. Red dashed lines demonstrate the average transcript expression intensity at
baseline. Numbers in the upper right of the individual graphs represent the number of
transcripts within each SOM. Groups of transcripts that were upregulated during the PGF2α
time-course are shown on the left (A, B, C, D, & E) and downregulated transcripts on the
right (F, G, H, I, & J). (A & F) SOMs showed responses typical of immediate-early
response genes, peaked between 1-2 hour and returned to baseline. (B & G) SOMs
demonstrated early response genes, peaked at 2 hours and maintained through the 4-hour
time-point. (C & H) SOMs demonstrated delayed-early response genes, which gradually
moved away from baseline throughout the time-course. (D & I) SOMs showed late-response
genes, which stayed near the baseline and then began changing at 2-4 hour. (E & J) Biphasic
SOMs, which had an early change in transcript expression, returned to baseline and then had a
second change in transcription levels. Boxes to the right of the graphs include the top
upstream regulators predicted to be involved using IPA at the peak of change from controls,
along with their corresponding IPA determined activation z-score. Data points in each SOM
are labeled to indicate the percentage of transcripts that are differentially expressed at each
time-point: ***** 99-100%; **** 76-98%; *** 51-75%, ** 26-50%, * 1-25%. Submitted for
publication as part of 221.
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Figure 4-5 – Common gene alterations in response to PGF2α
(A) Venn diagrams demonstrate the number of differentially expressed genes that overlapped
between the three examined datasets GSE94069 (blue, Talbott et al., 2017), GSE23348 (red,
Mondal et al., 2011), and GSE27961 (green, Shah et al., 2014). The legend indicates the
numbers of total differentially expressed genes in parentheses for each dataset. Overlapping
parts of the circles are labeled with the corresponding number of transcripts that are
differentially expressed in that situation. (B) The top 15 IPA-predicted upstream regulators
based on the 124 common genes with corresponding IPA molecule type designations and zscores. (C) Functional categorization of the 124 common genes common to all three datasets,
sections are labeled with both the category and the number of genes in each category.
Submitted for publication as part of 221.
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Table 4-1 – Top ten up-regulated genes at each time-point

0.5 h

1h

2h

4h

Gene
Symbol
FOS
NR4A1
NR4A2
NR4A3
FOSB
APOLD1
IER2
EGR1
JUNB
CYR61
NR4A3
FOSB
DUSP2
NR4A1
EGR4
FOS
ATF3
NR4A2
ARC
DUSP5
EGR4
FOSB
SERPINB2
ARC
DUSP5
NR4A3
F3
ATF3
INA
MMP12
MMP12
SERPINB2
SERPINE1
CSRP3

Entrez ID
280795
528390
540245
528877
540819
538827
525380
407125
514246
508941
528877
540819
539140
528390
407155
280795
515266
540245
519403
507061
407155
540819
505184
519403
507061
528877
280686
515266
532236
526981
526981
505184
281375
540407

SERPINA14

286871

IL33
IL1A
TNFSF18
DUSP5
INHBA

507054
281250
768081
507061
281867

Gene Name
Fos proto-oncogene, AP-1 transcription factor subunit
nuclear receptor subfamily 4 group A member 1
nuclear receptor subfamily 4 group A member 2
nuclear receptor subfamily 4 group A member 3
FosB proto-oncogene, AP-1 transcription factor subunit
apolipoprotein L domain containing 1
immediate early response 2
early growth response 1
JunB proto-oncogene, AP-1 transcription factor subunit
cysteine rich angiogenic inducer 61
nuclear receptor subfamily 4 group A member 3
FosB proto-oncogene, AP-1 transcription factor subunit
dual specificity phosphatase 2
nuclear receptor subfamily 4 group A member 1
early growth response 4
Fos proto-oncogene, AP-1 transcription factor subunit
activating transcription factor 3
nuclear receptor subfamily 4 group A member 2
activity regulated cytoskeleton associated protein
dual specificity phosphatase 5
early growth response 4
FosB proto-oncogene, AP-1 transcription factor subunit
serpin peptidase inhibitor, clade B (ovalbumin), member 2
activity regulated cytoskeleton associated protein
dual specificity phosphatase 5
nuclear receptor subfamily 4 group A member 3
coagulation factor III, tissue factor
activating transcription factor 3
internexin neuronal intermediate filament protein alpha
matrix metallopeptidase 12
matrix metallopeptidase 12
serpin peptidase inhibitor, clade B (ovalbumin), member 2
serpin family E member 1
cysteine and glycine rich protein 3
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase,
antitrypsin), member 14
interleukin 33
interleukin 1 alpha
tumor necrosis factor superfamily member 18
dual specificity phosphatase 5
inhibin beta A subunit

Submitted for publication as part of 221.

Fold
Change
14.94
8.56
7.34
7.15
6.74
6.57
6.04
5.57
4.86
4.61
27.85
16.65
13.06
11.36
10.81
10.50
9.00
8.84
7.06
6.55
20.38
15.13
14.42
13.90
12.31
11.77
11.10
11.09
10.41
10.26
41.71
25.49
17.87
17.82

P-value
8.22E-04
1.30E-05
4.94E-06
2.67E-04
2.40E-04
8.33E-04
4.50E-05
2.40E-04
1.79E-06
3.03E-03
7.81E-07
1.38E-06
7.27E-05
1.38E-06
1.26E-04
1.38E-03
1.22E-05
9.30E-07
4.02E-04
9.51E-06
1.44E-05
2.80E-06
1.74E-04
1.79E-05
4.85E-07
1.49E-05
1.89E-02
4.85E-06
2.25E-03
2.11E-03
1.06E-05
1.31E-05
1.01E-06
2.31E-04

17.57

2.58E-04

17.46
16.65
15.38
14.52
13.57

1.76E-07
1.77E-05
1.60E-06
1.23E-07
1.23E-07
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Table 4-2 – Top ten down-regulated genes at each time-point

0.5 h

1h

2h

4h

Gene Symbol
LOC100337120
LOC783362
MIR2450B
GBP4
ARHGAP25
CARD6
GRIA1
LOC783362
CEP295NL
CALB2
LOC510193
LOC100337457
FAM13C
LOC100337120
RUNDC3B
SDPR
LOC783362
APLNR
FOXL2
ARHGAP20
PIEZO2
NPNT
GPAM
LRIG3

Entrez ID
100337120
783362
100313224
100298387
534994
520291
529618
783362
100125412
513947
527460
100337457
540918
100337120
525116
532333
783362
615435
281770
515501
522631
513362
497202
506574

MAMSTR

505540

TNS3

516555

Gene Name
T-cell activation Rho GTPase-activating protein-like
uncharacterized LOC783362
microRNA 2450b
guanylate binding protein 4
Rho GTPase activating protein 25
caspase recruitment domain family member 6
glutamate ionotropic receptor AMPA type subunit 1
uncharacterized LOC783362
CEP295 N-terminal like
calbindin 2
apolipoprotein L3
solute carrier family 23 member 2
family with sequence similarity 13 member C
T-cell activation Rho GTPase-activating protein-like
RUN domain containing 3B
serum deprivation response
uncharacterized LOC783362
apelin receptor
forkhead box L2
Rho GTPase activating protein 20
piezo type mechanosensitive ion channel component 2
nephronectin
glycerol-3-phosphate acyltransferase, mitochondrial
leucine rich repeats and immunoglobulin like domains 3
MEF2 activating motif and SAP domain containing
transcriptional regulator
tensin 3

Submitted for publication as part of
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.

Fold
Change
-3.81
-3.81
-3.46
-2.56
-2.06
-1.75
-4.57
-4.24
-3.95
-3.57
-3.41
-3.23
-3.20
-3.04
-2.82
-2.78
-4.77
-4.20
-4.16
-4.05
-3.80
-3.69
-3.55
-3.50

P-value
4.47E-03
3.25E-03
8.13E-03
3.74E-02
8.59E-03
3.74E-02
3.26E-02
7.48E-04
3.30E-02
1.63E-02
4.43E-02
3.33E-02
2.88E-03
6.89E-03
7.69E-03
7.24E-03
1.44E-04
5.10E-04
3.35E-06
3.06E-04
2.39E-04
8.59E-04
7.42E-03
5.31E-04

-3.38

9.54E-04

-3.31

8.60E-05
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Table 4-3 – Top five canonical pathways predictions during each timepoint during the early
response to PGF2α treatment

0.5 h

1h

Ingenuity Canonical Pathways
NRF2-mediated Oxidative Stress Response
Corticotropin Releasing Hormone Signaling
IGF-1 Signaling
IL-17A Signaling in Gastric Cells
PI3K Signaling in B Lymphocytes
ILK Signaling
Cholecystokinin/Gastrin-mediated Signaling
HMGB1 Signaling
Endothelin-1 Signaling
IL-8 Signaling
Cholecystokinin/Gastrin-mediated Signaling
Acute Phase Response Signaling

2h

Toll-like Receptor Signaling
TGF-β Signaling
LPS/IL-1 Mediated Inhibition
Function

of

RXR

z-score

2.449
2
2
2
2
2.646
2.121

P-value
1.41E-02
1.41E-02
1.41E-02
1.41E-02
1.41E-02
2.34E-02
3.89E-02
2.45E-02
8.71E-02
1.08E-01
2.99E-01
4.81E-01

2
2
2

2.99E-01
5.45E-01
7.43E-01

-2.714

3.23E-01

-2.683

4.69E-01

-2.496

1.64E-01

-2.449

1.78E-01

2.449

3.44E-01

Death Receptor Signaling

Integrin Signaling
4h
UVA-Induced MAPK Signaling

Retinoic acid Mediated Apoptosis Signaling
MIF Regulation of Innate Immunity

Submitted for publication as part of 221.

Molecules
FOS, JUN, DNAJB1, JUNB
FOS, JUN, NR4A1
FOS, JUN, CYR61
FOS, JUN
FOS, JUN, ATF3
FOS, JUN, SNAI1, MYC, SNAI2, RND3
FOS, JUN, SRF, RND3
FOS, JUN, SERPINE1, PLAT, RND3
FOS, JUN, MYC, EDNRB
FOS, JUN, ANGPT2, RND3
FOS, JUN, SRF, IL1B, IL1A, RND3, IL33
FOS, JUN, IL1B, JAK2, SOCS3, IL1A,
SERPINE1, IL33
FOS, JUN, IL1B, IL1A, TRAF1, IL33
FOS, JUN, INHBA, SERPINE1
JUN, IL1B, PPARGC1B, IL1A, NR5A2, IL33
IKBKG, TANK, CFLAR, NFKB1, PARP1,
PARP4, CASP9, NFKBIA, ACIN1, TNKS,
BIRC3, SPTAN1
ASAP1, TLN1, RRAS2, ITGAV, ITGA2,
CAPN1, TSPAN4, PXN, PIK3C2B, MYL9,
PIK3R1, GAB1, ITGA9, SOS1, PIK3CG,
RHOG, PIK3CA, ARHGEF7, MAP2K2,
TSPAN5, PPP1CB, PLCG1, ACTN4
SMPD2, MTOR, PARP4, RRAS2, CASP9,
PIK3C2B, PIK3R1, GAB1, TP53, TNKS,
PIK3CG, FOS, RPS6KA5, PARP1, PIK3CA,
PLCG1
CFLAR, PARP1, PARP4, CASP9, RXRB,
CRABP2, RARG, TNKS
FOS, LY96, NFKB1, CD14, NFKBIA, TP53
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Table 4-4 – Common transcripts differentially expressed in response to PGF2α treatment
Fold Change
Entrez
Gene
Gene ID
Cell-cell interaction
SERPINB2
505184
SERPINE1
281375
AMIGO2
514273
PLAUR
281983
SDC4
508133
HS3ST5
540355
MMP1
281308
THBS1
281530
CLDN1
414922
CD44
281057
CLDND1
515537
ITGAV
281875
EMCN
616367
CLIC5
281696
TMEM204
615464
NPNT
513362
Cytokine signaling
IL33
507054
INHBA
281867
SPP1
281499
MT2A
404070
BAMBI
530147
NRG1
281361
IL18
281249
BMP2
615037
STAMBP
532672
CD14
281048
PDGFC
613787
Transcriptional Regulation
ELL2
782605
HMGA1
618849
AGO2
404130
RPF2
511294
EIF4A1
504958
CPEB2
538880
POLR1E
511587
DCP1B
514548
HEXIM1
539696
ZMYM3
522721
Metabolism
ARG2
518752
GCNT4
782825
HK2
788926
LDHA
281274
PDP1
280891
RPIA
613376
METRNL
534297
PGM5
785045
MPPED2
540914

GSE94069

GSE23348

GSE27961

25.49
17.87
8.27
6.83
6.59
4.77
4.11
2.89
2.65
2.49
2.45
1.75
-2.05
-2.41
-2.83
-3.69

5.27
28.96
8.65
5.92
8.44
7.73
12.26
2.02
3.52
3.44
1.55
1.93
-1.55
-1.69
-1.72
-2.33

5.10
31.00
8.09
7.39
19.13
9.33
6.44
3.90
3.23
8.22
1.79
2.79
-2.74
-2.19
-1.89
-2.51

17.46
13.57
5.73
3.56
3.41
3.14
3.08
3.02
1.82
1.81
1.70

6.92
19.69
7.55
4.65
1.57
2.15
2.53
5.47
1.98
2.48
1.77

2.96
27.25
4.65
3.99
2.99
8.78
2.50
3.92
3.19
3.68
1.78

2.30
1.86
1.75
1.59
1.56
-1.63
-1.65
-1.71
-2.88
-3.11

2.15
4.11
2.03
1.62
1.53
-1.95
-1.90
-1.54
-2.24
-2.18

4.06
3.71
2.41
1.50
1.71
-1.67
-2.53
-1.95
-2.37
-2.62

5.95
4.47
3.50
1.77
1.64
1.52
1.52
-1.68
-2.35

2.56
2.84
3.61
1.54
1.50
1.68
1.89
-1.73
-1.60

3.95
3.18
4.24
2.32
2.02
2.04
2.11
-2.02
-2.33
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Table 4-4 – Common transcripts differentially expressed in response to PGF2α treatment
(continued)
Fold Change
Entrez
Gene
Gene ID
Transcription factor
FOSL1
531389
BCL6
539020
SRF
533039
TGIF1
510050
BZW2
326579
NR5A2
541305
ZNF22
768051
ZNF827
104974573
Signaling
PDE8A
506787
PDE4B
100124505
PPP4R4
537521
TMEM64
536822
PIK3CA
282306
EVC2
280834
DACT1
538778
TMEM88
507172
Lipid metabolism
OLR1
281368
SRD5A1
614612
SPHK1
618605
PITPNC1
782067
ABCD4
515848
OXSM
513530
MID1IP1
615572
GPAM
497202
Cell cycle/apoptosis
CDKN1A
513497
TNFRSF12A 617439
BTG1
281032
CCNG2
512960
STK17A
513665
BTG3
541054
CCNYL1
538167
IFT122
536731
Small G-protein regulation
RASA2
533491
TIAM1
536517
RHOBTB1
540513
WIPF3
786606
AGFG2
510361
RGL1
522344
ARHGAP19
526945
Neuron function
GAL
280799
CA8
515918
STK38L
514787
SLITRK2
540117
PNMA1
538718
SEMA6D
518458
PTHLH
286767

GSE94069

GSE23348

GSE27961

2.85
2.69
2.58
2.29
2.11
-1.79
-2.29
-2.30

2.80
3.49
2.42
2.50
1.85
-2.27
-1.68
-1.53

3.19
2.23
2.75
1.90
2.19
-2.58
-1.73
-1.67

1.97
1.76
1.72
1.62
1.54
-1.70
-2.18
-2.76

2.31
2.22
3.59
1.70
1.57
-1.52
-1.90
-1.78

4.12
3.60
10.10
1.69
1.80
-1.78
-1.75
-2.75

9.18
2.43
2.18
1.53
-1.80
-1.86
-1.90
-3.55

14.54
2.31
2.27
1.57
-1.80
-2.40
-1.89
-2.86

15.84
4.57
2.04
1.55
-1.80
-2.14
-2.68
-2.34

4.16
2.63
2.58
2.18
2.05
1.89
1.70
-1.53

3.67
2.45
1.80
1.59
1.81
1.53
1.69
-1.71

2.55
4.22
2.29
1.90
1.90
2.11
1.97
-1.64

3.21
2.28
-1.85
-1.90
-2.08
-2.23
-2.34

1.74
3.43
-1.57
-1.55
-2.01
-1.58
-2.02

1.70
2.38
-2.49
-2.13
-1.93
-1.73
-2.08

10.15
2.97
2.05
2.01
-1.98
-2.28
-2.49

55.44
3.60
1.54
4.08
-3.18
-2.05
-3.91

11.39
6.36
1.85
6.64
-1.83
-1.95
-4.55
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Table 4-4 – Common transcripts differentially expressed in response to PGF2α treatment
(continued)
Fold Change
Entrez
Gene
GSE94069
Gene ID
Cytoskeleton regulation
Cnn1
534583
5.19
MICAL2
534041
3.39
TPM4
535277
2.63
MARCKSL1
539555
2.19
RAI14
525869
1.89
MYO18A
519634
-1.98
TNS3
516555
-3.31
Post-translational modification
UFM1
530547
2.63
DPH3
511579
2.62
RWDD3
614557
-1.62
KBTBD4
617482
-1.74
TRIM68
538657
-2.30
Membrane transporter
TRPC4
282102
4.33
SLC39A8
508193
2.86
SLC20A2
518905
2.79
SLC2A1
282356
2.44
SLC12A2
286845
1.78
DNA regulation and repair
RBBP8
512977
4.08
H2AFZ
287016
1.61
PAPD7
523016
1.50
ZRANB3
529922
-1.88
MUM1
513471
-2.16
G-protein coupled receptor
F2RL2
512581
2.17
AGTR1
281607
-2.16
APLNR
615435
-4.20
Chaperone
DNAJA1
528862
2.31
HSPA2
281827
-1.96
Unknown
C23H6orf141 100271839 2.45
LHFPL2
616131
2.35
LOC540312
540312
-1.81
CYYR1
768230
-1.98
LOC511229
511229
-2.33

Submitted for publication as part of 221.

GSE23348

GSE27961

6.55
3.45
1.66
2.84
2.24
-1.51
-3.03

5.80
7.05
2.56
1.95
2.24
-1.61
-3.13

1.72
1.84
-2.22
-1.52
-1.64

1.92
1.57
-2.16
-1.59
-1.54

3.33
2.58
1.89
2.43
2.69

3.50
3.73
1.53
4.71
1.57

1.99
1.54
1.86
-1.82
-1.71

3.10
1.55
3.36
-1.53
-1.55

1.82
-2.07
-2.76

3.34
-1.95
-1.83

1.60
-1.65

1.51
-1.57

1.98
3.32
-1.84
-1.51
-2.08

6.27
2.16
-4.54
-2.08
-1.77
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CHAPTER 5: EFFECTS OF CXCL8 AND IMMUNE CELLS ON THE
REGULATION OF LUTEAL PROGESTERONE SECRETION **
Abstract
Recent studies suggest that chemokines may mediate the luteolytic action of prostaglandin
F2α (PGF2α). Our objective was to identify chemokines induced by PGF2α in vivo and to
determine the effects of CXCL8 on specific luteal cell types in vitro. Mid-cycle cows were
injected with saline or PGF2α, ovaries were removed after 0.5 - 4 h and chemokine expression
was analyzed by qPCR. In vitro expression of CXCL8 was analyzed after PGF2α administration
and with cell signaling inhibitors to determine the mechanism of PGF2α-induced chemokine
expression. Purified neutrophils were analyzed for migration and activation in response to
CXCL8 and PGF2α. Purified luteal cell types (steroidogenic, endothelial and fibroblast cells)
were used to identify which cells respond to chemokines. Neutrophils and peripheral blood
mononuclear cells (PBMCs) were co-cultured with steroidogenic cells to determine their effect on
progesterone production. CXCL8, CXCL2, CCL2, and CCL8 transcripts were rapidly increased
following PGF2α treatment in vivo. The stimulatory action of PGF2α on CXCL8 mRNA
expression in vitro was prevented by inhibition of p38 and JNK signaling. CXCL8, but not
PGF2α, TNFα, or TGFβ, stimulated neutrophil migration. CXCL8 had no apparent action in
purified luteal steroidogenic, endothelial, or fibroblast cells, but CXCL8 stimulated extracellular
signal-regulated kinase (ERK) phosphorylation in neutrophils. In co-culture experiments neither
CXCL8 nor activated neutrophils altered basal or luteinizing hormone (LH)-stimulated luteal cell
progesterone synthesis. In contrast, activated PBMCs inhibited LH-stimulated progesterone
synthesis from cultured luteal cells. These data implicate a complex cascade of events during
luteolysis involving chemokine signaling, neutrophil recruitment, and immune cell action within
the corpus luteum.

The material presented in this chapter was previously published: Talbott et al. Effects of IL8 and immune
cells on the regulation of luteal progesterone secretion. Reproduction 2014 260.
**
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5.1. Introduction
The corpus luteum develops after ovulation and secretes progesterone, a steroid hormone
essential for the establishment and maintenance of early pregnancy 134,230. In the absence of
hormonal cues or pregnancy the corpus luteum will regress in a process termed luteolysis. In
many species, luteolysis is mediated by uterine and/or intra-luteal release of prostaglandin F2
alpha (PGF2α) 65,67,343,345. PGF2α has been shown to act indirectly at the vascular level to cause
disruption of luteal capillaries 244 and apoptosis of capillary endothelial cells 346. PGF2α has also
been implicated in the initiation of luteal cell apoptosis in vivo 65,347; however, PGF2α alone
cannot directly reduce the viability of luteal cells in vitro 65,348. Thus, other mechanisms must be
activated for luteolysis to proceed through both the functional (loss of progesterone secretion) and
structural (apoptosis and tissue remodeling) stages of regression.
Immune cells and their effector cytokines participate in various reproductive processes
203,246,349,350

including: ovulation 351,352, endometrial function 353,354, as well as corpus luteum

formation and regression 203,246,349,354–357. CXCL8 (previously known as IL-8) is a known
chemotactic cytokine secreted by a variety of cells in response to inflammatory stimuli. CXCL8
secretion is implicated in the recruitment and activation of neutrophils 358,359, including within the
corpus luteum 207,246,360. In rabbits, neutralization of CXCL8 suppresses neutrophil activation and
ovulation 352. Recent studies also indicate that neutrophils and CXCL8 are involved in
establishment of the corpus luteum following ovulation. CXCL8 and neutrophils are known to
promote angiogenesis 361,362 findings which have been recently extended to the developing corpus
luteum 207,246,363. CXCL8 is also capable of stimulating progesterone secretion by luteinizing
granulosa 326 and theca cells 364.
Our objective was to identify chemokines induced by PGF2α in vivo and to determine the
effect of CXCL8 on specific luteal cell types in vitro. We employed co-cultures to evaluate the
effects of immune cells on luteal progesterone synthesis. The present study demonstrates that
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PGF2α stimulates the transcription of CXCL8, CCL8, CCL2 and CXCL2. While CXCL8 was
effective at recruitment of neutrophils, neither CXCL8 nor activated neutrophils reduced
luteinizing hormone (LH)-stimulated luteal progesterone synthesis. In contrast, activated
polymorphic mononuclear cells (PBMCs) inhibited LH-stimulated progesterone by luteal cells in
vitro. Indicating that the activation of immune cells during luteolysis may be involved in the
regression of the bovine corpus luteum.
5.2. Materials and Methods
5.2.1.

In vivo studies

All animal procedures were conducted under an IACUC-approved protocol and performed at
the University of Nebraska-Lincoln, Animal Sciences Department. Post-pubertal female cattle of
composite breeding age were given an intramuscular injection at mid-cycle (days 9-10) with
saline (n = 3) or 25 mg of the PGF2α analog, Lutalyse (Pharmacia & Upjohn Company, New
York, NY, n = 12). Ovariectomies were performed at 0.5, 1, 2, and 4 h after treatment and RNA
was isolated from the corpora lutea using an Absolutely mRNA Purification Kit (Agilent
Technologies Inc., Santa Clara, CA.) according to the manufacturer’s instructions. RNA yields
were measured using a fluorescence detection kit (RiboGreen; Invitrogen, Carlsbad, CA).
Screening with whole-transcript bovine microarray (Affymetrix, Santa Clara, CA) revealed
several chemokines that were induced following treatment with PGF2α. Quantitative real-time
polymerase chain reaction (qPCR) was used to validate changes in CXCL8, CCL2, CCL8, and
CXCL2 mRNA using the primers provided in Table 5-1. First-strand cDNA was synthesized from
1 μg total RNA using iScriptTM cDNA synthesis kit (Bio-Rad, Hercules, CA) according to the
manufacturers' instructions. qPCR was performed using the CFX96TM Real-Time PCR
Detection System (Bio-Rad, Hercules, CA) with ssoFastTM EvaGreen® Supermix (Bio-Rad,
Hercules, CA) with the following parameters: 95 °C for 30 s followed by 40 cycles of: 95 °C for
5 s, and 55 °C for 5 s. β-actin (ACTB) or glyceraldehyde 3-phosphate dehydrogenase (GADPH)
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were used as internal standards of mRNA expression. The authenticity of the PCR signal was
verified by reactions containing no RNA or reactions omitting reverse transcriptase. Melt curve
analysis was performed to ensure amplification of a single product at the predicted melting
temperature.
5.2.2.

In vitro studies

All cell culture experiments described below were done in tissue culture plastic (Corning
CoStar, Corning, NY) and included penicillin (100 IU/ml, Gibco Life Technologies, Carlesbad,
CA) streptomycin (100 μg/ml, Gibco Life Technologies, Carlesbad, CA), and amphotericin (50
μg/ml, MP Biomedicals, Santa Ana, CA) in cell culture medium to prevent bacterial and fungal
growth.
5.2.3.

Isolation of bovine luteal cells

Bovine ovaries were collected from a local abattoir (JBS, Omaha, NE). The tissue was
obtained from cows during early pregnancy (fetal crown-rump length < 10 cm) to assure luteal
function 365. The luteal tissue was dissected from the ovary and dissociated with 103 IU/mL
collagenase (Atlanta Biologicals, Norcross, GA) as described previously 366. Luteal cell viability
was determined using trypan blue exclusion, and luteal cell preparations with more than 90%
viability were used. Enriched bovine steroidogenic luteal cells (1 × 105 cells/cm2) were plated as
previously described 94. Cells were incubated overnight in medium 199 (M199, Lonza, Basel,
Switzerland) supplemented with 5% fetal bovine serum (FBS, Valley Biomedical, Winchester,
VA). The next day the medium was changed and the incubations were continued for 1 day in
FBS-free media. On the day of the experiment, the medium was replaced with fresh FBS-free
medium for 2-3 h to pre-equilibrate before applying the treatments detailed in the figure legends.
5.2.4.

Isolation of bovine endothelial and fibroblast cells

Endothelial cells were isolated from bovine corpus luteum of early pregnancy and purified as
described before 245. Endothelial cells were positive for vascular endothelial cell cadherin (VE-
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cadherin) and negative for steroidogenic enzymes and prolyl 4-hydroxylase (antibodies are listed
in Table 5-2). Cells were grown to ~80% confluence in Dulbecco’s Modified Eagle Medium
(DMEM, Corning CellGro, Corning, NY) containing 10% FBS and 20 μg/ml endothelial cell
growth supplement (ECGS, Millipore, Bedford, MA). The medium was changed to serum-free
DMEM containing 20 μg/ml ECGS for 2 h prior to treatment as described in the figure legends.
Fibroblasts were isolated from the bovine corpus luteum and characterized as previously
described 245. The fibroblasts were positive for prolyl 4-hydroxylase and collagen 1 and negative
for steroidogenic enzymes and VE-cadherin (antibodies listed in Table 5-2). Luteal fibroblasts
were grown to ~80% confluence and changed to serum-free DMEM for 2 h prior to treatment
with CXCL8 as described in the figure legends.
5.2.5.

Isolation of bovine neutrophils and migration assays

Potassium ethylenediaminetetraacetic acid (Sigma-Aldrich, St. Louis, MO)-anticoagulated
bovine blood samples were collected from a local abattoir (JBS, Omaha, NE), centrifuged, and
subjected to Percoll gradient (Sigma-Aldrich, St. Louis, MO) separation to isolate neutrophils.
The remaining erythrocytes were lysed by rapid treatment with dH2O and the remaining cells
were resuspended in Roswell Park Memorial Institute 1640 medium (RPMI, Thermo Fisher
Scientific HyClone, Waltham, MA). Cell migration was assayed using the Boyden chamber
method. Bovine neutrophils (2.5 x 105) were seeded in transparent polyethylene terephthalate
membrane cell culture inserts with 3 µm pores (B&D Falcon, Franklin Lakes, NJ) placed in 24well plates. The lower chamber was filled with 500 µl RPMI with or without 30 ng/mL CXCL8
(R&D Systems, Minneapolis, MN), 100 nM PGF2α, 10 ng/ml tumor necrosis factor alpha (TNFα,
R&D Systems, Minneapolis, MN) or 1 ng/ml transforming growth factor beta 1 (TGFβ). Cell
migration was carried out for up to 24 h at 37 °C. Migrated cells were counted with a
hemacytometer.
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To determine the signaling pathways used by CXCL8 in bovine neutrophils, we treated
neutrophils with CXCL8 or TNFα (R&D Systems, Minneapolis, MN), a modulator of immune
function and activator of multiple signaling pathways. Western blot analysis was performed to
examine the mitogen-activated protein kinase (ERK1/2, p38 and JNK), AKT and NF-κB
signaling pathways using phospho-specific antibodies. See Table 5-2 for a complete list of
antibodies used.
5.2.6.

Isolation of human neutrophils and degranulation assays

Human neutrophils were isolated from peripheral blood of healthy donors by density gradient
centrifugation under an approved IRB at the University of Nebraska Medical Center, using
polymorphprep (Axis-Shield, Oslo, Norway) in accordance with manufacturer’s instruction.
Purified neutrophils were resuspended in RPMI + 5% FBS. Neutrophils (3 x 105 cells) were
incubated with different concentrations of CXCL8 at 37 °C for 1 h. Neutrophil degranulation was
examined by florescence-activated cell sorting for increased cell surface expression of granule
molecules carcinoembryonic antigen-related cell adhesion molecule 8 (CD66b); and integrin
alpha M (ITGAM, also known as CD11b). Cells were stained with fluorescein isothiocynate
(FITC)-conjugated mouse anti-human CD66b antibody and allophycocyanin (APC)-conjugated
mouse anti-human CD11b antibody on ice for 30 min. After rinsing, cells were fixed with
phosphate-buffered saline plus 2% formaldehyde. Flow cytometry analysis was done using a
Becton Dickinson (Franklin Lakes, NJ) FACSCaliber flow cytometer and was performed at the
University of Nebraska Medical Center Cell and Tissue Analysis Facility.
5.2.7.

Isolation of bovine peripheral blood mononuclear cells (PBMC)

Acid citrate dextrose-anticoagulated blood samples from cows were collected from a local
abattoir (JBS, Omaha, NE). Blood was then diluted 1:2 in cold Hank’s Balance Salt Solution
(HBSS, Corning CellGro, Corning, NY) with 2 mM EDTA (Sigma-Aldrich, St. Louis, MO) and
5% FBS. Diluted blood was underlayed with an equal volume of Histopaque (specific gravity =
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1.083, Sigma-Aldrich, St. Louis, MO) and centrifuged at 900 x g for 30 min. PBMCs were
collected from interface between the plasma and Histopaque. The cells were then washed in
HBSS three times before use.
5.2.8.

Co-culture experiments

Enriched bovine steroidogenic luteal cells were plated (∼1 × 105 cells/cm2) in basal M199
medium containing 5% FBS in 48-well plates overnight as described above.
5.2.9.

Neutrophil-luteal cell co-culture:

Neutrophils were isolated on the same day that luteal cells were prepared. Purified
neutrophils were then cultured in RPMI (10% FBS) with or without 30 ng/ml CXCL8 and 20 nM
phorbol myristate acetate (PMA, EMD Millipore Calbiochem, Billerica, MA) overnight. After 24
h the medium was replaced on the luteal cell cultures. Neutrophils (250,000 cells/ml) were then
added to the luteal cells in M199 and RPMI (1:1) with 10% FBS for 2 h before adding control
media or 10 ng/ml bLH (Tucker Endocrine Research Institute, Atlanta, GA). Medium from each
well was collected 6 hours after LH or control treatments for progesterone analysis.
5.2.10. PBMC-luteal cell co-culture:
Twenty-four hours after plating the luteal cells, the medium was removed from the culture
wells and replaced with fresh M199. Then an equal volume of newly isolated bovine PBMCs in
RPMI (100,000 cells/ml) were added to the luteal cell culture. Co-cultures were incubated for 24
h in M199 and RPMI (1:1 ratio) + 10% FBS, and with or without 10 µg/ml concavalin A (Sigma,
St. Louis, MO) to activate the PBMCs. After 24 h of co-culture, medium was replaced with
M199:RPMI + 10% FBS for 2 h to pre-equilibrate the cells before the addition of control media
or 10 ng/ml LH. Medium was removed from each well after 6 h of control or LH treatment for
progesterone analysis.
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5.2.11. Western blot analysis
Cultures of neutrophils, steroidogenic cells, luteal endothelial cells, and luteal fibroblasts
were harvested with ice cold cell lysis buffer [20 mM Tris-HCl (pH = 7), 150 mM NaCl, 1 mM
Na2EDTA, 1 mM EGTA, 1% Triton X-100 and protease and phosphatase inhibitor cocktails
(Sigma-Aldrich, St. Louis, MO)]. Protein concentration was determined and 40-60 µg protein
was subjected to 10% SDS-PAGE. After transfer to polyvinylidene fluoride (PVDF) membranes,
the membranes were probed with appropriate amounts of primary antibodies and bound
antibodies were detected with a horse radish peroxidase-conjugated secondary antibody and the
Femto Western Blotting Detection Kit (GE Healthcare Amersham, Cleveland, OH). Signals were
visualized using a Digital Sciences Image Station 440 (Kodak, Rochester, NY).
5.2.12. Progesterone analysis
Conditioned media were collected for progesterone determination using Coat-A-Count
progesterone radioimmunoassay kit (Siemens, Deerfield, IL) according to the manufacturer’s
instructions and as previously reported 94.
5.2.13. Statistical analysis
All experiments were performed at least two times using different cell preparations with
qualitatively comparable results. The data are presented as representative experiments or as the
means ± SEM of the averages from multiple experiments. The differences in means were
analyzed by t test or analysis of variance followed by multiple range testing. P ≤ 0.05 was
considered statistically significant.
5.3. Results
5.3.1.

PGF2α stimulates chemokine gene expression in vivo

Treatment with PGF2α in vivo resulted in a 4.3-fold increase in CXCL8 mRNA within 30 min
and a 9-fold increase in CXCL8 mRNA within 1 h of administration (Figure 5-1 A). Treatment
with PGF2α also increased CCL8, CXCL2, and CCL2 mRNA after 1 h (fold increases of 2.5 ±
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0.6; 2.9 ± 0.7 and 3.1 ± 0.6, respectively). After a brief lag the expression of chemokine mRNA
increased dramatically after 4 h of treatment with PGF2α. A 35 ± 4 fold increase in CXCL8
mRNA expression was observed in response to a 4 h treatment with PGF2α. At the 4 h mark
PGF2α also stimulated significant (P ≤ 0.05) increases in CCL8, CCL2 and CXCL2 mRNA
expression (29 ± 3.8, 12 ± 1.5 and 6.4 ± 1 fold, respectively).
5.3.2.

PGF2α stimulates CXCL8 expression in vitro

Treatment of steroidogenic luteal cells with PGF2α for 1 h in vitro also increased CXCL8
mRNA expression (3-fold increase, P ≤ 0.05; (Figure 5-1 B). Luteal steroidogenic cells were
pretreated in the presence or absence of specific inhibitors of the mitogen-activated protein kinase
(MAPK) signaling cascade to determine which intracellular signals contribute to the stimulatory
effect of PGF2α on the induction of CXCL8 gene expression (Figure 5-1 B). Pretreatment with
the ERK1/2 inhibitor U0126 (Enzo Life Sciences, Farmingdale, NY) failed to prevent the
stimulatory effect of PGF2α on CXCL8 mRNA (Figure 5-1 B). In contrast, inhibition of the
stress-activated protein kinase p38 MAPK with SB2037580 resulted in a complete inhibition of
the response to PGF2α. Treatment with the JNK inhibitor SP600125 also resulted in a significant
inhibition (77%, P ≤ 0.05) of the PGF2α-induced increase in CXCL8 mRNA.
5.3.3.

CXCL8 enduces migration of bovine neutrophils

To determine whether CXCL8 would affect the function of bovine neutrophils, we purified
neutrophils from blood collected at slaughter from non-pregnant cows. As shown in Figure 5-2 A
neutrophils stained with hematoxylin and eosin had distinct multi-lobular nuclei, a characteristic
of neutrophils. A Boyden chamber assay (Figure 5-2 A) was used to determine whether CXCL8
or other factors produced during luteolysis could increase migration of bovine neutrophils. We
observed that treatment for 18 h with 30 ng/ml CXCL8 caused a 20-fold (P ≤ 0.05) increase in
neutrophil migration. However, treatment of neutrophils with 100 nM PGF2α under identical
conditions had no effect on neutrophil migration (Figure 5-2 B). Migration assays were also
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performed with other chemokines that have been implicated in luteal regression; namely TNFα
346,367

and TGFβ 244,245. In experiments evaluating neutrophil migration during a 3 h treatment

period, we found that 30 ng/ml CXCL8, but not 100 nM PGF2α, 10 ng/ml TNFα, or 1 ng/ml
TGFβ, was capable of stimulating migration of neutrophils (Figure 5-2 C).
Activation of neutrophils results in the rapid cell surface expression of molecules that allows
for endothelium attachment for extravasation. Treatment of human neutrophils with increasing
concentrations of human CXCL8 (0-100 ng/ml) resulted in the rapid expression of the cell
adhesion molecules ITGAM and as determined by flow cytometry (not shown).
5.3.4.

CXCL8 selectively stimulates signaling in bovine neutrophils

Treatment with CXCL8 for 15 min stimulated an increase (5-fold, P ≤ 0.05) in ERK1/2
phosphorylation (Figure 5-3 A). The response was transient and returned to control levels within
120 min following CXCL8 treatment (Figure 5-3 A & Figure 5-4A). CXCL8 did not stimulate
either the p38 or the JNK MAPK signaling pathways (Figure 5-3). In contrast to CXCL8, TNFα
provoked sustained ERK phosphorylation, as well as p38 and JNK phosphorylation in bovine
neutrophils throughout the 120 min investigated (Figure 5-3). CXCL8 exerted a slight, but
consistent, increase in the phosphorylation of p65-NF-κB and AKT; whereas, TNFα stimulated a
robust increase in p65-NF-κB and AKT phosphorylation in neutrophils. To determine whether
CXCL8 could similarly stimulate other cells of the corpus luteum, we treated bovine luteal
fibroblasts, endothelial cells and steroidogenic cells with CXCL8 under a various treatment times
and concentrations. CXCL8 did not stimulate the phosphorylation of AKT, ERK or NF-κB in any
other cell type examined. As a positive control we observed that TNFα stimulated MAPK and
NF-κB signaling in each cell type examined; whereas PGF2α only stimulated MAPK signaling in
luteal steroidogenic cells (data not shown).
In view of the very prominent effect of CXCL8 on ERK signaling in neutrophils, we tested
whether the CXCL8-induced increase in ERK phosphorylation was associated with the effect of
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CXCL8 on neutrophil migration. Pretreatment with 5 μM of U0126, completely blocked the
induction of ERK phosphorylation (Figure 5-4 A), but did not prevent the stimulatory effect of
CXCL8 on bovine neutrophil migration (Figure 5-4 B).
5.3.5.

Effect of CXCL8 and immune cells on progesterone secretion

Experiments were performed to determine whether CXCL8 altered progesterone secretion.
Pretreatment of steroidogenic luteal cells with increasing amounts of CXCL8 (0-30 ng/ml) did
not alter basal or LH-simulated progesterone production in luteal cells (Figure 5-3 A). Next, we
co-cultured neutrophils with steroidogenic cells and evaluated the ability of LH to stimulate
progesterone secretion. We observed that co-cultures of steroidogenic cells and neutrophils had
no effect on the ability of LH to increase progesterone (Figure 5-3 B). Furthermore, co-cultures of
steroidogenic cells and activated neutrophils had no effect on basal or LH-stimulated
progesterone production.
Co-cultures of steroidogenic cells and PBMCs had no effect on the ability of LH to secrete
progesterone (Figure 5-6). However, LH-stimulated progesterone production was completely
abrogated (P ≤ 0.05) in cultures of activated PBMCs and steroidogenic luteal cells (Figure 5-6).
5.4. Discussion
For over 30 years the immune system has been postulated as essential for fertility 368. The
present study provides additional insight into the expression and function of chemokines during
luteal regression. We observed that induction of luteal regression in cows with a bolus of PGF2α
in vivo resulted in a rapid increase in the expression of CXCL8, CCL8, CCL2, and CXCL2. Our
findings confirm recent findings by Shirasuna et al., 2012 246 that PGF2α treatment of dairy cattle
increased luteal CXCL8 mRNA by approximately 4-fold within 30 min. In that study, the fold
increase in CXCL8 mRNA remained constant over 4-hr of treatment with PGF2α. In the present
study using beef cattle we observed more robust increases in luteal CXCL8 mRNA expression; 9fold increases within 1 h and 35-fold increases after 4 h of PGF2α treatment. At present it is not
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clear whether the differences in the magnitude of the responses are due to differences in the cattle
breeds since there are reported differences in the responses of beef and dairy cattle to
synchronization protocols using PGF2α 369 or other factors. Based on the pronounced increase in
CXCL8 expression, it was selected for further analysis. We found that CXCL8 acted directly on
neutrophils but had little effect on other cell types in the mid-cycle corpus luteum. Furthermore,
co-cultures of luteal cells with activated neutrophils did not alter LH-stimulated progesterone
synthesis; whereas co-cultures with activated PBMCs suppressed LH-stimulated progesterone
synthesis.
Activation of the PGF2α receptor rapidly induces calcium mobilization and activation of
PKC 235. These initial signaling events lead to the activation of ERK1/2 238,239, p38, and JNK
104,240,241

in vivo and in vitro, with subsequent activation of multiple transcription factors. The

MAPK signaling family induces early response genes such as FOS and JUN 105, NR4A1 108,134,
EGR1 106,108, and ATF3 104 in the corpus luteum. To determine which intracellular signals
contribute to the stimulatory effect of PGF2α on CXCL8 gene expression, luteal cells were treated
with specific inhibitors of ERK1/2, p38, and JNK. We observed that the ERK1/2 inhibitor U0126
had no effect on CXCL8 mRNA expression in response to PGF2α, while the p38 MAPK inhibitor
SB2037580 and the JNK inhibitor SP600125 significantly inhibited the PGF2α -mediated
upregulation of CXCL8 mRNA. The results indicate that the stress-activated MAPKs: p38 and
JNK play an important and perhaps overlapping role in the induction of CXCL8 mRNA in
response to PGF2α.
Chemokines like CXCL8 are responsible for the recruitment of immune cells to chemokineproducing tissues. Our findings demonstrate that CXCL8 is chemotactic for bovine neutrophils, in
agreement with previous literature 207,246,358,359. CXCL8 stimulated a 6-fold increase in neutrophil
migration within 3 h and after 24 h CXCL8-treatment increased neutrophil migration nearly 20fold. In contrast, treatment with PGF2α had no effect on neutrophil migration at either time-point.
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These findings are consistent the studies by 246,370 showing that immune cells are unresponsive to
PGF2α because they do not express the PGF2α receptor. In the present study we also report that
TNFα and TGFβ, two cytokines induced rapidly in the bovine corpus luteum in response to
PGF2α and implicated in events associated with luteal regression 106,245,257,346, did not increase the
migration of bovine neutrophils in the Boyden chamber assay. Our observations support the
recent reports 108,246,257,321 showing that PGF2α induces CXCL8 mRNA and that the expression of
CXCL8 is associated with the appearance of neutrophils in the bovine corpus luteum 203,207,246. In
addition, our studies indicate that CXCL8 stimulates the degranulation of human neutrophils
which supports the studies of Shirasuna et al., 2012 246 indicating that the rapid appearance of Eselectin on neutrophils follows treatment with CXCL8. Since other chemokines (CCL8, CCL2,
and CXCL2) are induced concomitantly with CXCL8, it will be important to evaluate the
contributions of each individual chemokine to the recruitment of specific immune cells into the
regressing corpus luteum. Future experiments should also address how combinations of these
chemokines signal the recruitment and activation of immune cells within the corpus luteum 371.
Treatment of neutrophils with CXCL8 stimulated a robust increase in ERK phosphorylation,
a slight increase in AKT and NF-κB phosphorylation, and had no effect on p38 and JNK
signaling. In contrast, TNFα activated all of these pathways simultaneously in neutrophils. Since
ERK signaling was the most prominent pathway activated following CXCL8 treatment of bovine
neutrophils, we determined whether neutrophil migration could be blocked by treatment with the
ERK1/2 inhibitor U0126. Interestingly, we found that inhibition of ERK signaling with U0126
had no inhibitory effect on CXCL8-stimulated neutrophil migration. These results suggest that
another signaling pathway is responsible for CXCL8-stimulated chemotaxis, likely the PI3K and
Rac signaling pathway 372,373. Further studies are required to determine the contributions of other
signaling pathways to neutrophil activation and migration.
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CXCL8 has been shown to induce diverse cellular responses in cells other than neutrophils
358

. Recent studies suggest that CXCL8 may contribute the angiogenesis in the newly forming

corpus luteum 207 and progesterone secretion by granulosa 326 and theca 364 cells. Treatment with
various CXCL8 concentrations and treatment times revealed no changes in cell signaling in
steroidogenic cells, endothelial cells, or fibroblasts isolated from the bovine corpus luteum.
However, CXCL8 stimulated a robust increase in ERK phosphorylation in neutrophils.
Furthermore, CXCL8 did not affect basal or LH-stimulated progesterone secretion from cultured
luteal cells. In contrast to the findings by Shimizu et al., 2012 326, we found no evidence
suggesting that CXCL8 acted directly on bovine luteal cells types that are involved in luteal
regression (e.g., endothelial cells, fibroblasts and steroidogenic cells). Based on these findings it
appears that CXCL8 exerts specific effects on ovarian cell types depending on their stage of
differentiation. Given that the corpus luteum is highly differentiated and undergoes regression in
response to PGF2α, the lack of a stimulatory effect of CXCL8 on angiogenesis and
steroidogenesis may be expected since the vasculature and steroid secretion are disrupted during
regression 65,134,245,374. It is possible that during luteal regression CXCL8-activated neutrophils
contribute to phagocytosis during structural regression of the corpus luteum.
The increase observed in multiple chemokines suggests that immune cells other than
neutrophils could be recruited in to the corpus luteum following administration of PGF2α. In fact,
studies from multiple laboratories have demonstrated an increase in neutrophils, T cells, or
macrophages during the regression of the corpus luteum in rodents 375, rabbits 376, ruminants
209,377

, primates 353, and women 205,249,378,379. A previous report indicated that co-culture of rat

neutrophils with luteal cells resulted in a decrease in progesterone secretion, presumably as a
result of oxidative stress 380. However, under our experimental conditions co-cultures of bovine
neutrophils and steroidogenic luteal cells did not alter basal or LH-stimulated progesterone
synthesis. Treatment of neutrophils with CXCL8 and PMA, alone or in combination, to activate
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neutrophils was not sufficient to reduce progesterone secretion under co-culture conditions. In
addition to neutrophils, monocytes are immune effector cells that are also equipped with
chemokine receptors and adhesion receptors that mediate migration from blood to tissues 381.
Since we observed that PGF2α rapidly induced the expression of other chemokines (CCL8,
CCL2, and CXCL2), which could recruit other types of immune cells, we established a co-culture
system with PBMCs and luteal cells. Although, un-activated PBMCs did not reduce progesterone
secretion, we observed that activated PBMCs effectively reduced LH-driven progesterone
secretion. These observations support our earlier findings 370 that activated immune cells may
contribute a factor (or factors) that impair steroidogenesis in response to LH. It is known that
activated monocytes produce inflammatory cytokines, nitric oxide, and reactive oxygen species
381,382

all of which may contribute individually or in combination to the inhibition of progesterone

synthesis 347,383,384. In the in vivo setting, activated monocytes may also secret matrix
metalloproteinases that contribute to the degradation of the extracellular matrix 381, which could
facilitate the recruitment of additional inflammatory cells to the regressing corpus luteum.
A complex interaction of endocrine and immune cells appears to be required to mediate the
structural and functional regression of the bovine corpus luteum. Since chemokines act
synergistically to activate their target cells 371, additional studies are needed to examine the
actions of chemokines as a complex cocktail rather in isolation as performed in the present study.
The current findings complement a recent review 385 that postulates that immune cells in the
developing and functional corpus luteum play a supportive role, but once corpus luteum
regression is triggered, the immune cells promote apoptosis, debris clearage and tissue
remodeling. Understanding these endocrine and immune events is important for increasing our
ability to control reproductive function to facilitate full-term pregnancies in both humans and
livestock.
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Figure 5-1 – Induction of chemokines following
treatment with PGF in vivo and in vitro
A) Midluteal phase cows were treated with saline or the
PGF analog Lutalyse (25 mg) for up to 4 h. Ovaries
were surgically removed and RNA was isolated from
corpora lutea. Quantitative real- time PCR was carried
out. Results are shown as means ±S.E.M., n=3. (B) To
determine the cellular signaling pathway leading to the
induction of IL8 mRNA, bovine steroidogenic luteal
cells were pretreated for 60 min with vehicle, the
ERK1/2 inhibitor U0126 (20 mM), the p38 MAPK
inhibitor SB207580 (10 mM), or the JNK inhibitor
SP600125 (20 mM). Luteal cells were then treated with
control media (open bars) or PGF (100 nM, solid bars)
for 60 min. Quantitative real-time PCR for IL8 mRNA
was carried out. Results are shown as means S.E.M.,
n=3. *P≤0.05; **P≤0.01; NS, not significant.
Previously published in 260.
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Figure 5-2 – Stimulatory effects of CXCL8 on neutrophils.
(A) Bovine neutrophils were isolated as described in the Materials and Methods. Hematoxylin
and eosin stain of the purified bovine neutrophils used in the chemotaxis assay is shown in the
figure. Neutrophils (105 cells) were placed in the upper chamber of a Boyden apparatus and
control media or CXCL8 (30 ng/ml) was placed in the lower chamber. Cell numbers in the
lower chamber were quantified at various intervals. (B) Control media (Control), CXCL8 (30
ng/ml) or PGF (100 nM) was added to the lower chamber and migration of bovine neutrophils
was determined after 18 h. Result are shown as mean±S.E.M., n=3. *P≤0.05, vs control. (C)
Control media (Control), CXCL8 (30 ng/ml), PGF (100 nM), TNF (10 ng/ml), or TGFB1 (1
ng/ml) was added to the lower chamber and migration of bovine neutrophils was determined
after 3 h. Results are shown as mean±S.E.M., n=4 for CTL, CXCL8, PGF, and n=2 for TNF
and TGFB1. *P≤0.05 vs control. Previously published in 260.
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Figure 5-3 – IL8 stimulates early signaling
responses in bovine neutrophils.
A) Bovine neutrophils were treated without or with IL8
(30 ng/ml) or TNF (10 ng/ml) for 15 or 120 min to
identify early cell signaling responses. Western blot
analysis was performed using phospho-specific
antibodies for ERK, p38 and JNK MAPKs, AKT, and
p65 NFκB. B-actin served as a loading control. B)
Cells were treated as above and quantitative analysis of
phospho-ERK signaling is shown as mean ± SEM, n=4.
Previously published in 260.
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Figure 5-4 – CXCL8 stimulated neutrophil
migration is independent of ERK signaling.
A) Neutrophils were pre-treated for 60 min with
vehicle or the ERK1/2 inhibitor U0126 (5 μM) prior to
treatment for 15 or 60 min with IL8 (30 ng/ml).
Western blot analysis was performed for ERK and
phospho-ERK. β-actin served as a loading control. B)
Neutrophils were placed in a Boydon chamber and pretreated for 60 min with vehicle or U0126 (5 µM) prior
to treatment with IL8 (30 ng/ml). Neutrophil migration
was determined after 24 h. Results are shown as mean
± SEM, n=3. Previously published in 260.
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Figure 5-5 – CXCL8 and neutrophils do not inhibit luteal progesterone
production.
(A) Steroidogenic luteal cells were pretreated with increasing amounts of CXCL8 (0–
30 ng/ml) for 30 min and then treated without (Control) or with LH (10 ng/ml) for 4
h. Progesterone in the media was measured by radioimmunoassay (RIA). Results are
shown as mean ± S.E.M., n=4. (B) Steroidogenic luteal cells were co-cultured with
bovine neutrophils or activated bovine neutrophils as described in the Materials and
Methods. Cells were then treated without (Control) or with LH (10 ng/ml) for 4 h.
Progesterone in the media was measured by RIA. Results are shown as mean ±
S.E.M., n=3. *P≤0.05 vs control; not significant (NS). Previously published in 260.
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Figure 5-6 – Cocultures of luteal cells with
activated peripheral blood mononuclear cells
(PBMCs) inhibit luteal progesterone production.
Steroidogenic luteal cells were cocultured with
bovine PBMCs or activated PBMCs as described in
the Materials and methods. Cells were then treated
without (Control) or with LH (10 ng/ml) for 4 h.
Progesterone in the media was measured by RIA.
Results are shown as mean ± S.E.M., n=4. *P≤0.05;
NS, not significant. Previously published in 260.
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Table 5-1 – Bovine primers for qPCR
Gene Name

Primers for qPCR

CXCL8

F: TGTGAAGCTGCAGTTCTGTCAAG
R: TGCACCCACTTTTCCTTGGGGT

CCL2

F: TGCTCGCTCAGCCAGATGCAAT
R: GGACACTTGCTGCTGGTGACTCT

CCL8

F: TCTCAGGCTGAAGCCCCCGT
R: ACTGAATCTGGCTGAGCGAGCA

CXCL2

F: GCGCCCGTGGTCAACGAACT
R: AGACTGGCTATGACTTCGGTTTGGT

ACTB

F: ACACCGCAACCAGTTCGCCAT
R: AAGACGGCCCGGGGAGCATC

GAPDH

F: AGATGGTGAAGGTCGGAGTG
R: GATCTCGCTCCTGGAAGATG

Previously published in 260.
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Table 5-2 – Antibodies used for cell signaling, Western blots, and flow analysis
Antibody
VE-cadherin
StAR
3β-HSD
P450scc
Prolyl 4-hydroxylase
Collagen 1
Phospho ERK1/2
Phospho p38
Phospho JNK
Phospho AKT
Phospho P65-NF-κB
IκBα
β-Actin
FITC mouse anti-human
CD66b
APC mouse anti-human
CD11b
Previously published in 260.

Vendor
Pierce (Rockford, IL, USA)
Douglas Stocco, Ph.D. (Texas Tech Univ)
Ian Mason, Ph.D. (Dallas, TX, USA)
Millipore (Danvers, MA, USA)
Acris (Brisbane, QLD, Australia)
Rockland Monoclonal (Gilbertsville, PA,
USA)
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Santa Cruz (Santa Cruz, CA, USA)
Cell Signaling (Danvers, MA, USA)
Cell Signaling (Danvers, MA, USA)
Santa Cruz (Santa Cruz, CA, USA)
Sigma-Aldrich (St. Louis, MO, USA)
AbD Serotec (Raleigh, NC, USA)
BD Biosciences (Franklin Lakes, NJ,
USA)
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CHAPTER 6: DISCUSSION
6.1. Overview
This dissertation describes a study of the mechanisms regulating the genesis and involution of
the temporary endocrine structure, the corpus luteum (CL), through use of a bovine model.
During the rise of the CL, the composition and regulation of lipid droplets (LDs) were studied
and it was determined that LDs comprise a substantial proportion of luteal cell structures, and
store cholesteryl esters and triglycerides. As well, the LD-associated proteome was assessed and
established that steroidogenic enzymes are enriched in purified luteal LD fractions.
Demonstrating that luteal LDs may serve as critical mediators of steroidogenesis by storing
substrates for steroidogenesis and a close association with steroidogenic enzymes. At the fall of
the CL alterations in the luteal transcriptome were determined and revealed changes consistent
with early activation of cytokine signaling. One target, C-X-C motif chemokine ligand 8
(previously IL-8), was assessed for its ability to regulate luteal cell function. CXCL8 expression
was determined to be induced via p38 and JNK signaling and could induce bovine neutrophil
migration however, only activated peripheral blood mononuclear cells (PBMC) could inhibit
luteal cell progesterone secretion. Together, these data indicate that LDs and cytokines can play
important roles in CL development, function, and regression.
6.2. Composition of the lipid droplets of the bovine corpus luteum
Within the bovine CL LDs are a prominent feature which are established by day 3 postovulation and maintained at mid-cycle (day 10). Lipid droplets are a large component of both
early (day 3) and mid-cycle CL (day 10) comprising 26 - 36 µm2/nuclei, which amounts to 5-16%
of luteal cell area. These LDs are enriched in several classic LD-associated proteins as assessed
by mRNA and protein abundance. Although the major constituent of bovine LDs is triglyceride,
cholesteryl esters constitute 2.78 ± 0.70 pmol/µg protein. Luteal cells are enriched in cholesterol
and cholesteryl esters compared to adipose tissue, likely for use in steroidogenesis. In contrast,
the granulosa and theca cells of the follicle have few lipid droplets, and have reduced lipid
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content (of all major classes) compared to the steroidogenic luteal cells. There does not appear to
be a difference in lipid composition of granulosa versus theca cells or of the large luteal cells
(LLC) versus small luteal cells (SLC). We propose that luteal LDs play a critical role in
progesterone production by storing cholesteryl esters, and interacting with steroidogenic proteins
to efficiently produce steroids.
6.3. Lipid droplets are dynamically regulated by luteinizing hormone signaling in the bovine
corpus luteum
Lipid droplets and LD-associated proteins are under regulation by luteinizing hormone (LH)
signaling in the bovine corpus luteum. As granulosa cells differentiate to form luteal cells
increases in both LDs and LD-associated proteins, hormone sensitive lipase (HSL) and PLIN2 are
seen which correlate with luteal differentiation markers and progesterone secretion. Signaling by
LH causes phosphorylation at S563 and translocation of HSL, which are associated with an
activated state of HSL. Furthermore, chemical inhibition of HSL prevents LH-induced
progesterone secretion even in the presence of HDL-supplied cholesterol indicating that
cholesteryl esters are processed by an HSL-dependent step. Finally, luteal lipid droplets have a
high content of steroidogenic enzymes, 3βHSD and P450scc, and LD-associated steroidogenic
acute regulatory protein (StAR) can increase by 14-fold after activation of protein kinase A
(PKA). These data lead us to believe that the surface of lipid droplets may serve as a novel
platform for steroidogenesis through the intimate association and potential tethering of
steroidogenic enzymes to the coat proteins of the lipid droplet to facilitate the handoff of steroid
precursors at each step to produce efficiently steroids like progesterone (Figure 3-7).
These data have implications for our understanding of the biochemistry of steroidogenesis.
As we learn more about how cholesterol is stored and utilized, particularly during steroidogenesis
we can gain insight into how to manipulate the system to either increase or decrease steroid
production. Our study has focused on non-pathological conditions to gain a clear insight into the
role of LDs in highly steroidogenic tissues. Future studies into how LDs and flux of cholesterol
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through cells is altered in in obesity, and polycystic ovarian syndrome could indicate mechanisms
by which those conditions impair fertility.
LDs are a natural consequence of granulosa-to-luteal cell differentiation. Stimulated but not
basal progesterone is processed through an HSL-dependent and likely LD-dependent step. The
surface of lipid droplets may serve as a novel platform for steroidogenesis by an intimate
association with steroidogenic enzymes. The close proximity of mitochondria and the
endoplasmic reticulum facilitates the handoff of steroid precursors at each step to efficiently
produce steroids such as progesterone. Potentially this could involve physical tethering of
mitochondria and the endoplasmic reticulum to the LD surface using a similar mechanism to
mitochondrial associated membranes, which tether microdomains of the endoplasmic reticulum to
mitochondria to facilitate lipid transfer 224.
6.4. Early transcriptome responses of the bovine mid-cycle corpus luteum to prostaglandin
F2 alpha includes cytokine signaling
This study uses a systems biology approach to provide a detailed understanding of the early
(0.5 – 4 h) mRNA changes that occur during PGF2α-induced luteolysis in vivo. Our analysis
predicts activation of cytokines (TNFα, IL-1β, IL-6, IL-17A, & IL-33) and cytokine signaling
intermediates (NF-κB, signal transducer and activator of transcription (STAT)) early in the timecourse. However, changes in cytokine transcripts are not apparent until 2 - 4 hours post-PGF2α.
The effects of PGF2α in vivo may require the activation of secondary mediators, such as
cytokines, which activate NF-κB and STAT signaling because PGF2α is unable to stimulate
NF-κB P65 phosphorylation in isolated luteal cells. The rapid influx of various immune cells in
response to the initiation of luteolysis 207,209,246 and the release of pre-formed cytokines could
explain the prediction of cytokine signaling effects very early in the PGF2α response. As well,
the activation of NF-κB signaling could contribute to later responses seen after PGF2α
administration.
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Shortly after PGF2α administration, phospholipase C, PKC, Ca2+, and extracellular signalregulated kinase (ERK) trigger a variety of signaling cascades to begin the luteolytic process.
Our data suggests that in vivo, PGF2α administration stimulates a series of transcriptional waves
likely as a result of classical PGF2α and cytokine signaling events, as early as 30 minutes postPGF2α treatment. This is the beginning of a cascade of events that will initiate decreases in
progesterone secretion (2-12 hours post-PGF2α) and result in the structural regression of the CL
12-18 hours post-PGF2α 240,340. The earliest decreases in progesterone secretion during luteolysis
may be due to changes LIPE/HSL expression and other transcripts which regulate cholesterol
availability rather than changes in the primary steroidogenic enzymes. We propose that during
the early stages of functional regression in combination with PGF2α, the reduction in
progesterone, and increase in inflammatory cytokines (potentially including IL-33 and IL-17)
contribute to luteal regression. As the intra-luteal concentrations of PGF2α and inflammatory
cytokines increase they may act within an auto-amplification loop eventually reaching a critical
point from which there is no rescue from the luteolytic cascade 67,341–344. Future studies to identify
the specific transcriptional changes occurring in steroidogenic cells, endothelial cells, immune
cells, and fibroblasts is needed to better understand the dynamic network of changes that enable
functional and structural luteal regression.
6.5. Effects of CXCL8 and immune cells on the regulation of luteal progesterone secretion
For over thirty years the immune system has been postulated as essential for fertility 368. The
present study provides additional insight into the expression and function of chemokines during
luteal regression. We observed that induction of luteal regression in cows with a bolus of PGF2α
in vivo resulted in a rapid increase in the expression of CXCL8, CCL8, CCL2, and CXCL2. Our
findings confirm recent findings by Shirasuna et al., 2012 246 that PGF2α treatment of dairy cattle
increased luteal CXCL8 mRNA by approximately 4-fold within 30 min. In that study, the fold
increase in CXCL8 mRNA remained constant over 4-hr of treatment with PGF2α. In the present
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study using beef cattle, we observed more robust increases in luteal CXCL8 mRNA expression; a
9-fold increase within 1 h and 35-fold increases after 4 h of PGF2α treatment. At present, it is not
clear whether the differences in the magnitude of the responses are due to differences in the cattle
breeds since there are reported differences in the responses of beef and dairy cattle to
synchronization protocols using PGF2α 369 or other factors. Based on the pronounced increase in
CXCL8 expression, it was selected for further analysis. We found that CXCL8 acted directly on
neutrophils but had little effect on other cell types in the mid-cycle corpus luteum. Furthermore,
co-cultures of luteal cells with activated neutrophils did not alter LH-stimulated progesterone
synthesis; whereas co-cultures with activated PBMCs suppressed LH-stimulated progesterone
synthesis.
A complex interaction of endocrine and immune cells appears to be required to mediate the
structural and functional regression of the bovine corpus luteum. Since chemokines act
synergistically to activate their target cells 371, additional studies are needed to examine the
actions of chemokines as a complex cocktail rather in isolation as performed in the present study.
The current findings complement a recent review 385 that postulates that immune cells in the
developing and functional corpus luteum play a supportive role, but once corpus luteum
regression has been triggered, the immune cells promote apoptosis, clearage of debris and tissue
remodeling. Understanding these endocrine and immune events is important for increasing our
ability to control reproductive function to facilitate full-term pregnancies in both humans and
livestock.
6.6. Conclusions
This dissertation describes a study of the mechanisms regulating the genesis and involution of
the temporary endocrine structure, the corpus luteum, using a bovine model. During the rise of
the CL, the composition and regulation of LDs were studied and it was determined that LDs
comprise a substantial proportion of luteal cell structures, and store cholesteryl esters and
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triglycerides. Finally, the LD-associated proteome was determined and established that
steroidogenic enzymes are enriched in purified LD fractions. This demonstrates that luteal LDs
may serve as critical mediators of steroidogenesis by storing substrate and a close association
with steroidogenic machinery. At the fall of the CL alterations in the luteal transcriptome were
determined and revealed decreased LIPE levels as well as changes consistent with early
activation of cytokine signaling. One target, C-X-C motif chemokine ligand 8 (previously IL-8),
was assessed for its ability to regulate luteal cell function. CXCL8 expression was determined to
be induced via p38 and JNK signaling and could induce bovine neutrophil migration, however,
only activated PBMCs could inhibit luteal cell progesterone secretion. Together, these indicate
that LDs and cytokines can play important roles in CL development, function, and regression.
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SUPPLEMENTAL DATA FOR CHAPTER 3

Appendix A-1 – Verification of CAY10499 on-target effects
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Appendix A-1 – Verification of CAY10499 on-target effects
Hydroxylated cholesterol has increased bioavailability in cells, due to free diffusiblity. If
CAY10499 had effects on steroidogenic modification steps it is anticipated that hydroxylated
cholesterols would not increase progesterone secretion. (A) Luteal cell cultures in the
presence of increasing concentrations of 22-OH cholesterol were treated with LH and/or
CAY10499 (B) Luteal cell cultures in the presence of increasing concentrations of 25-OH
cholesterol were treated with LH and/or CAY10499
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Appendix A-3 – Luteal lipid droplet-associated proteins determined by proteomics
Symbol
3BHS
PLIN2
ACTC
VIME
ATPB
ACTG
CP11A
ATPA
CH60
ERG7
GRP78
ACON
MDHM
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3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase
Perilipin-2
Actin, alpha cardiac muscle 1
Vimentin
ATP synthase subunit beta, mitochondrial
Actin, cytoplasmic 2
cholesterol side-chain cleavage enzyme, mitochondrial
ATP synthase subunit alpha, mitochondrial
60 kDa heat shock protein, mitochondrial
Lanosterol synthase
78 kDa glucose-regulated protein
Aconitate hydratase, mitochondrial
Malate dehydrogenase, mitochondrial
Protein disulfide-isomerase
NADH-cytochrome b5 reductase 3
Branched-chain-amino-acid aminotransferase, mitochondrial
Protein disulfide-isomerase A3
Serum albumin
Sterol-4-alpha-carboxylate 3-dehydrogenase,
decarboxylating
Aldehyde dehydrogenase, mitochondrial
Endoplasmin
Aspartate aminotransferase, mitochondrial
NADPH:adrenodoxin oxidoreductase, mitochondrial
Alpha-actinin-4
Serpin H1
Calreticulin
3-hydroxyacyl-CoA dehydrogenase type-2
Heat shock cognate 71 kDa protein
Cytochrome b-c1 complex subunit 2, mitochondrial
Histone H4
Acetyl-CoA acetyltransferase, mitochondrial
Tropomyosin alpha-1 chain
Voltage-dependent anion-selective channel protein 1
Peptidyl-prolyl cis-trans isomerase B
ADP/ATP translocase 3
Methylmalonate-semialdehyde dehydrogenase [acylating],
mitochondrial
Prostacyclin synthase
Trifunctional enzyme subunit beta, mitochondrial
Alpha-actinin-1
Voltage-dependent anion-selective channel protein 2
Tubulin beta-5 chain
Glyceraldehyde-3-phosphate dehydrogenase
Dihydrolipoyllysine-residue succinyltransferase component
of 2-oxoglutarate dehydrogenase complex, mitochondrial
Tubulin alpha-4A chain
Thioredoxin-dependent peroxide reductase, mitochondrial
3-ketoacyl-CoA thiolase, mitochondrial
Ornithine aminotransferase, mitochondrial
Glycogen phosphorylase, liver form
Elongation factor Tu, mitochondrial
Alpha-aminoadipic semialdehyde dehydrogenase
Succinate dehydrogenase [ubiquinone] flavoprotein subunit,
mitochondrial
ATP synthase subunit O, mitochondrial
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P-value
0.035
0.005
0.00072
0.46
0.0057
< 0.00010
0.017
0.089
< 0.00010
< 0.00010
0.018
0.33
0.23
0.0026
0.51
< 0.00010
0.0018
< 0.00010
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58
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44
58
31
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35
37
24
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31
36
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80
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50
52
44
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0.19
0.051
0.078
0.0065
0.38
0.52
0.085
0.00072
0.00032
0.065
0.047
0.52
< 0.00010
0.21
0.044
0.25
0.029
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35
17
32
29
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41
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0.099
0.17
< 0.00010
0.45
0.089
0.23
0.33
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29
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0.39
0.024
0.49
0.07
< 0.00010
0.0076
0.00035
0.034
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0.012
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ODPB
SODM
ETFA
HS71A
ADT1
RAB1B
ODO1
QCR1
A2MG
ACADV
ODPA
PDIA4
CISY
MPCP
AT1A1
VDAC3
NDUS1
AT5F1
TBB4B
ATP5H
LONM
PHB
CATD
ECHM
ITAV
H2B1N
HSP72
ETFB
PHB2
5NTD
PCCB
TMEDA
ANXA1
TPM2
LETM1
CASA1
RAB5C
EF1A1
HSPB1
3HIDH
SUCB2
SCRB1
TSP1
SCPDL
GNS
FDFT
RPN2
CY1
APOA1
HBB
FINC
CPT2
TRAP1

Pyruvate dehydrogenase E1 component subunit beta,
mitochondrial
Superoxide dismutase [Mn], mitochondrial
Electron transfer flavoprotein subunit alpha, mitochondrial
Heat shock 70 kDa protein 1A
ADP/ATP translocase 1
Ras-related protein Rab-1B
2-oxoglutarate dehydrogenase, mitochondrial
Cytochrome b-c1 complex subunit 1, mitochondrial
Alpha-2-macroglobulin
Very long-chain specific acyl-CoA dehydrogenase,
mitochondrial
Pyruvate dehydrogenase E1 component subunit alpha,
somatic form, mitochondrial
Protein disulfide-isomerase A4
Citrate synthase, mitochondrial
Phosphate carrier protein, mitochondrial
Sodium/potassium-transporting ATPase subunit alpha-1
Voltage-dependent anion-selective channel protein 3
NADH-ubiquinone oxidoreductase 75 kDa subunit,
mitochondrial
ATP synthase F(0) complex subunit B1, mitochondrial
Tubulin beta-4B chain
ATP synthase subunit d, mitochondrial
Lon protease homolog, mitochondrial
Prohibitin
Cathepsin D
Enoyl-CoA hydratase, mitochondrial
Integrin alpha-V
Histone H2B type 1-N
Heat shock-related 70 kDa protein 2
Electron transfer flavoprotein subunit beta
Prohibitin-2
5'-nucleotidase
Propionyl-CoA carboxylase beta chain, mitochondrial
Transmembrane emp24 domain-containing protein 10
Annexin A1
Tropomyosin beta chain
LETM1 and EF-hand domain-containing protein 1,
mitochondrial
Alpha-S1-casein
Ras-related protein Rab-5C
Elongation factor 1-alpha 1
Heat shock protein beta-1
3-hydroxyisobutyrate dehydrogenase, mitochondrial
Succinyl-CoA ligase [GDP-forming] subunit beta,
mitochondrial
Scavenger receptor class B member 1
Thrombospondin-1
Saccharopine dehydrogenase-like oxidoreductase
N-acetylglucosamine-6-sulfatase
Squalene synthase
Dolichyl-diphosphooligosaccharide--protein
glycosyltransferase subunit 2
Cytochrome c1, heme protein, mitochondrial
Apolipoprotein A-I
Hemoglobin subunit beta
Fibronectin
Carnitine O-palmitoyltransferase 2, mitochondrial
Heat shock protein 75 kDa, mitochondrial

22
16
25
31
26
20
16
22
27

38
43
33
27
31
35
39
32
25

0.038
< 0.00010
0.44
0.0032
0.28
0.046
< 0.00010
0.33
0.0093

21

31

0.24

19
22
21
17
25
20

33
28
29
32
23
28

0.059
0.38
0.44
0.021
0.011
0.35

20
19
22
14
21
18
18
12
24
16
20
15
14
15
16
16
17
15

28
28
24
32
25
26
25
31
18
26
21
27
27
24
23
23
21
24

0.41
0.25
0.13
0.0012
0.26
0.33
0.45
0.0004
0.0012
0.13
0.092
0.057
0.027
0.22
0.45
0.34
0.41
0.18

15
29
18
12
14
9

21
8
18
23
22
26

0.45
< 0.00010
0.18
0.05
0.26
0.00033

13
15
14
14
16
14

21
19
20
20
18
20

0.21
0.39
0.45
0.45
0.22
0.33

13
14
6
19
9
14
16

20
19
27
14
23
18
16

0.35
0.46
< 0.00010
0.0023
0.00099
0.53
0.066
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NNTM
IDHP
M2OM
HS90A
DHE3
SFXN1
OST48
TXTP
IDH3A
ACLY
ITB1
COX41
GSTA1
COX2
(+10)
HA1B
SUCA
CATA
KAD2
ENOA
GLU2B
PBIP1
RAB8A
LG3BP
1433Z
PGRC1
ACSS3
ACDSB
RL40
(+35)
ANT3
ACADS
ML12B
MYL6
ATPG
H2AJ
NDUV2
GLCM
CH10
RB11B
ACSM1
NDKB
STAR
NDUA9
NDUA8
EF2
RLA0
ERLN2
GLYM
ABHD6
NDUBA
ANXA5

NAD(P) transhydrogenase, mitochondrial
Isocitrate dehydrogenase [NADP], mitochondrial
Mitochondrial 2-oxoglutarate/malate carrier protein
Heat shock protein HSP 90-alpha
Glutamate dehydrogenase 1, mitochondrial
Sideroflexin-1
Dolichyl-diphosphooligosaccharide--protein
glycosyltransferase 48 kDa subunit
Tricarboxylate transport protein, mitochondrial
Isocitrate dehydrogenase [NAD] subunit alpha,
mitochondrial
ATP-citrate synthase
Integrin beta-1
Cytochrome c oxidase subunit 4 isoform 1, mitochondrial
Glutathione S-transferase A1

21
9
12
18
9
11

11
22
18
12
20
18

< 0.00010
0.0052
0.3
0.00037
0.018
0.24

12
15

17
15

0.48
0.11

7
16
13
13
12

22
12
15
15
16

0.00028
0.0059
0.28
0.32
0.51

Cytochrome c oxidase subunit 2
BOLA class I histocompatibility antigen, alpha chain BL3-7
Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha,
mitochondrial
Catalase
Adenylate kinase 2, mitochondrial
Alpha-enolase
Glucosidase 2 subunit beta
Pre-B-cell leukemia transcription factor-interacting protein 1
Ras-related protein Rab-8A
Galectin-3-binding protein
14-3-3 protein zeta/delta
Membrane-associated progesterone receptor component 1
Acyl-CoA synthetase short-chain family member 3,
mitochondrial
Short/branched chain specific acyl-CoA dehydrogenase,
mitochondrial

7
10

20
16

0.00068
0.22

11
11
10
13
14
12
5
12
9
10

15
15
16
13
12
13
20
13
16
15

0.49
0.45
0.24
0.13
0.034
0.25
< 0.00010
0.22
0.28
0.3

11

13

0.3

6

18

0.0017

Ubiquitin-60S ribosomal protein L40
Antithrombin-III
Short-chain specific acyl-CoA dehydrogenase, mitochondrial
Myosin regulatory light chain 12B
Myosin light polypeptide 6
ATP synthase subunit gamma, mitochondrial
Histone H2A.J
NADH dehydrogenase [ubiquinone] flavoprotein 2,
mitochondrial
Glucosylceramidase
10 kDa heat shock protein, mitochondrial
Ras-related protein Rab-11B
Acyl-coenzyme A synthetase ACSM1, mitochondrial
Nucleoside diphosphate kinase B
steroidogenic acute regulatory protein, mitochondrial
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex
subunit 9, mitochondrial
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex
subunit 8
Elongation factor 2
60S acidic ribosomal protein P0
Erlin-2
Serine hydroxymethyltransferase, mitochondrial
Monoacylglycerol lipase ABHD6
NADH dehydrogenase [ubiquinone] 1 beta subcomplex
subunit 10
Annexin A5

11
8
6
6
4
12
5

13
15
17
17
19
10
17

0.36
0.09
0.0038
0.005
< 0.00010
0.062
0.00069

8
10
10
9
11
6
1

13
10
10
11
9
14
18

0.31
0.16
0.13
0.46
0.067
0.028
< 0.00010

5

14

0.0055

4
7
7
8
8
7

15
11
12
10
11
10

0.00022
0.34
0.17
0.45
0.49
0.48

5
5

12
12

0.05
0.027
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COX5A
EZRI
MYO1C
PYC
NCPR
DHX9
HNRPK
RL7
RL18
RL12
SDHB
CAZA1
PLBL2
H2AZ
PRDX5
TMED9
BGAL
RCN3
RL7A
ERP29
ARPC4
NDUV1
TRXR2
THRB
PGK1
NDUS3
KAD3
02-Mar
ATP5I
PRDX4
SAM50
LACB
PTBP1
DHRS4
EF1G
C1QBP
CYC
GRPE1
CATK
NDUAD
ZADH2
QOR
TGM2
TAGL
ADX
DHCR7
HBA
RAC1
RS9
MTCH2
PRDX1
RAB5A
SUCB1

Cytochrome c oxidase subunit 5A, mitochondrial
Ezrin
Unconventional myosin-Ic
Pyruvate carboxylase, mitochondrial
NADPH--cytochrome P450 reductase
ATP-dependent RNA helicase A
Heterogeneous nuclear ribonucleoprotein K
60S ribosomal protein L7
60S ribosomal protein L18
60S ribosomal protein L12
Succinate dehydrogenase [ubiquinone] iron-sulfur subunit,
mitochondrial
F-actin-capping protein subunit alpha-1
Putative phospholipase B-like 2
Histone H2A.Z
Peroxiredoxin-5, mitochondrial
Transmembrane emp24 domain-containing protein 9
Beta-galactosidase
Reticulocalbin-3
60S ribosomal protein L7a
Endoplasmic reticulum resident protein 29
Actin-related protein 2/3 complex subunit 4
NADH dehydrogenase [ubiquinone] flavoprotein 1,
mitochondrial
Thioredoxin reductase 2, mitochondrial
Prothrombin
Phosphoglycerate kinase 1
NADH dehydrogenase [ubiquinone] iron-sulfur protein 3,
mitochondrial
GTP:AMP phosphotransferase AK3, mitochondrial
Mitochondrial amidoxime reducing component 2
ATP synthase subunit e, mitochondrial
Peroxiredoxin-4
Sorting and assembly machinery component 50 homolog
Beta-lactoglobulin
Polypyrimidine tract-binding protein 1
Dehydrogenase/reductase SDR family member 4
Elongation factor 1-gamma
Complement component 1 Q subcomponent-binding protein,
mitochondrial
Cytochrome c
GrpE protein homolog 1, mitochondrial
Cathepsin K
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex
subunit 13
Zinc-binding alcohol dehydrogenase domain-containing
protein 2
Zeta-crystallin
Protein-glutamine gamma-glutamyltransferase 2
Transgelin
Adrenodoxin, mitochondrial
7-dehydrocholesterol reductase
Hemoglobin subunit alpha
Ras-related C3 botulinum toxin substrate 1
40S ribosomal protein S9
Mitochondrial carrier homolog 2
Peroxiredoxin-1
Ras-related protein Rab-5A
Succinyl-CoA ligase [ADP-forming] subunit beta,
mitochondrial

10
10
10
7
11
9
3
4
4
6

7
7
7
10
6
8
13
12
12
10

0.016
0.0075
0.031
0.54
0.00082
0.098
0.0012
0.018
0.006
0.26

5
5
3
7
4
5
8
7
3
9
6

10
11
12
8
11
9
7
8
11
6
8

0.17
0.058
0.0032
0.36
0.024
0.24
0.08
0.42
0.006
0.015
0.51

5
6
1
5

9
9
13
9

0.18
0.39
< 0.00010
0.14

4
3
3
7
3
5
6
0
6
2

10
10
10
6
10
8
7
13
7
10

0.041
0.015
0.0082
0.062
0.02
0.47
0.28
< 0.00010
0.47
0.0019

2
7
4
3

11
5
9
9

0.00013
0.088
0.072
0.035

5

8

0.33

4
5
8
4
6
7
8
4
3
3
4
6

9
7
4
7
6
4
4
7
8
8
7
5

0.072
0.38
0.0019
0.31
0.2
0.0085
0.0079
0.24
0.037
0.077
0.18
0.2

3

8

0.049
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ERAP2
VATB2
GBB1
GELS
RAP1A
FA5
RS3
IDH3B
1433E
STT3A
UCRI
MUTA
NDUS8
RL11
RS16
MVP
ATPK
FAF2
DAD1
NDUB7
MMAB
THTR
NDUS7
NNRD
TPIS
HSDL2
RS8
HIBCH
SND1
APMAP
NDUAA
TKT
ANXA4
ODBB
FAHD2
GSTM1
SSRA
STML2
H31
ANXA6
VAPA
RHOA
RL13
RS5
NDUB4
PEBP1
NPM
SSRD
TCPG
RS18
ODB2

Endoplasmic reticulum aminopeptidase 2
V-type proton ATPase subunit B, brain isoform
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit
beta-1
Gelsolin
Ras-related protein Rap-1A
Coagulation factor V
40S ribosomal protein S3
Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial
14-3-3 protein epsilon
Dolichyl-diphosphooligosaccharide--protein
glycosyltransferase subunit STT3A
Cytochrome b-c1 complex subunit Rieske, mitochondrial
Methylmalonyl-CoA mutase, mitochondrial
NADH dehydrogenase [ubiquinone] iron-sulfur protein 8,
mitochondrial
60S ribosomal protein L11
40S ribosomal protein S16
Major vault protein
ATP synthase subunit f, mitochondrial
FAS-associated factor 2
Dolichyl-diphosphooligosaccharide--protein
glycosyltransferase subunit DAD1
NADH dehydrogenase [ubiquinone] 1 beta subcomplex
subunit 7
Cob(I)yrinic acid a,c-diamide adenosyltransferase,
mitochondrial
Thiosulfate sulfurtransferase
NADH dehydrogenase [ubiquinone] iron-sulfur protein 7,
mitochondrial
ATP-dependent (S)-NAD(P)H-hydrate dehydratase
Triosephosphate isomerase
Hydroxysteroid dehydrogenase-like protein 2
40S ribosomal protein S8
3-hydroxyisobutyryl-CoA hydrolase, mitochondrial
Staphylococcal nuclease domain-containing protein 1
Adipocyte plasma membrane-associated protein
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex
subunit 10, mitochondrial
Transketolase
Annexin A4
2-oxoisovalerate dehydrogenase subunit beta, mitochondrial
Fumarylacetoacetate hydrolase domain-containing protein 2
Glutathione S-transferase Mu 1
Translocon-associated protein subunit alpha
Stomatin-like protein 2, mitochondrial
Histone H3.1
Annexin A6
Vesicle-associated membrane protein-associated protein A
Transforming protein RhoA
60S ribosomal protein L13
40S ribosomal protein S5
NADH dehydrogenase [ubiquinone] 1 beta subcomplex
subunit 4
Phosphatidylethanolamine-binding protein 1
Nucleophosmin
Translocon-associated protein subunit delta
T-complex protein 1 subunit gamma
40S ribosomal protein S18
Lipoamide acyltransferase component of branched-chain
alpha-keto acid dehydrogenase complex, mitochondrial

8
5

3
6

0.00023
0.39

3
7
4
3
4
1
3

8
4
7
7
6
8
7

0.15
0.02
0.21
0.083
0.45
0.00083
0.068

6
3
6

4
7
4

0.044
0.089
0.044

3
3
5
9
3
5

6
6
4
0
5
4

0.11
0.21
0.13
< 0.00010
0.4
0.18

5

4

0.093

4

5

0.56

2
2

7
6

0.015
0.095

3
1
6
2
2
2
2
2

5
7
2
6
6
6
5
6

0.47
0.0064
0.00032
0.021
0.12
0.12
0.16
0.03

1
5
2
3
2
3
3
0
6
2
4
4
2
2

6
2
5
5
5
5
5
7
1
5
3
3
5
5

0.014
0.015
0.2
0.35
0.1
0.35
0.35
< 0.00010
0.00042
0.26
0.14
0.25
0.058
0.13

4
3
0
1
5
3

3
4
7
6
2
3

0.25
0.58
< 0.00010
0.0083
0.0037
0.34

0

6

< 0.00010
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HA1A
CP51A
QCR7
TRFE
MTX1
1433G
ARP2
HTRA1
EF1B
PRAF3
NOP56
ASAH1
IDH3G
CASA2
LDHB
RSSA
PAI1
PARK7
FAS
NAGAB
AP1B1
ERP44
LRC59
MANF
ETHE1
PABP1
EMC2
SRSF1
ARP3
APOD
GT251
ATPD
ETFD
HEMH
SNAA
1433T
PPGB
PRDX2
VPS35
LUM
RL6
PCBP1
AMPL
PPIC
ODPX
RS25
TIMP1
KRT81
NDUB8
TPP1
YBOX1
GBB2
HNRH2
PGAM1
RGN
NDUC2

BOLA class I histocompatibility antigen, alpha chain BL3-6
Lanosterol 14-alpha demethylase
Cytochrome b-c1 complex subunit 7
Serotransferrin
Metaxin-1
14-3-3 protein gamma
Actin-related protein 2
Serine protease HTRA1
Elongation factor 1-beta
PRA1 family protein 3
Nucleolar protein 56
Acid ceramidase
Isocitrate dehydrogenase [NAD] subunit gamma,
mitochondrial
Alpha-S2-casein
L-lactate dehydrogenase B chain
40S ribosomal protein SA
Plasminogen activator inhibitor 1
Protein DJ-1
Fatty acid synthase
Alpha-N-acetylgalactosaminidase
AP-1 complex subunit beta-1
Endoplasmic reticulum resident protein 44
Leucine-rich repeat-containing protein 59
Mesencephalic astrocyte-derived neurotrophic factor
Persulfide dioxygenase ETHE1, mitochondrial
Polyadenylate-binding protein 1
ER membrane protein complex subunit 2
Serine/arginine-rich splicing factor 1
Actin-related protein 3
Apolipoprotein D
Procollagen galactosyltransferase 1
ATP synthase subunit delta, mitochondrial
Electron transfer flavoprotein-ubiquinone oxidoreductase,
mitochondrial
Ferrochelatase, mitochondrial
Alpha-soluble NSF attachment protein
14-3-3 protein theta
Lysosomal protective protein
Peroxiredoxin-2
Vacuolar protein sorting-associated protein 35
Lumican
60S ribosomal protein L6
Poly(rC)-binding protein 1
Cytosol aminopeptidase
Peptidyl-prolyl cis-trans isomerase C
Pyruvate dehydrogenase protein X component
40S ribosomal protein S25
Metalloproteinase inhibitor 1
Keratin, type II cuticular Hb1
NADH dehydrogenase [ubiquinone] 1 beta subcomplex
subunit 8, mitochondrial
Tripeptidyl-peptidase 1
Nuclease-sensitive element-binding protein 1
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit
beta-2
Heterogeneous nuclear ribonucleoprotein H2
Phosphoglycerate mutase 1
Regucalcin
NADH dehydrogenase [ubiquinone] 1 subunit C2

0
5
5
5
2
2
1
3
0
0
2
2

6
1
2
1
5
4
5
3
6
6
3
4

< 0.00010
0.00027
0.0065
0.00027
0.11
0.39
0.059
0.54
< 0.00010
< 0.00010
0.55
0.35

0
4
2
2
1
1
4
2
3
2
2
1
2
1
2
0
0
0
4
3

5
1
3
3
4
4
2
3
2
3
4
4
3
4
3
5
5
5
1
2

0.00013
0.002
0.43
0.43
0.041
0.041
0.033
0.43
0.2
0.57
0.25
0.12
0.52
0.12
0.32
0.00039
0.00039
0.00039
0.0074
0.21

1
1
1
1
2
2
3
0
0
0
4
2
2
2
2
0

4
3
4
3
3
3
2
4
4
4
1
3
2
3
3
4

0.025
0.21
0.085
0.21
0.6
0.6
0.089
0.00069
0.00069
0.00069
0.0026
0.49
0.51
0.49
0.49
0.0012

0
0
0

4
4
4

0.0012
0.0012
0.0012

0
0
4
3
2

4
4
0
1
2

0.0012
0.0012
< 0.00010
0.025
0.21
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HP1B3
SC11A
RS3A
ODBA
NLTP
CN37
TAGL2
EF1D
KBL
NUCB1
VA0D1
CHP1
AASS
SF3B3
NNRE
C4BPA
MOES
TMX1
RL5
ISOC2
PLAK
ATP5L
MDHC
MAP4
RL24
NDUA4
DNPEP
CLPP
HXK1
FIS1
FUCO
RL30
PP1A
HMGB1
NDUB9
NB5R1
NDUB6
SCO1
SURF4
RBBP7
CASK
IDHC
PRDX6
GSTP1
NDUA2
AL9A1
WDR1
ITB5
COF1
IVD
RT07
FKB10
CATB
IF2A

Heterochromatin protein 1-binding protein 3
Signal peptidase complex catalytic subunit SEC11A
40S ribosomal protein S3a
2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial
Non-specific lipid-transfer protein
2',3'-cyclic-nucleotide 3'-phosphodiesterase
Transgelin-2
Elongation factor 1-delta
2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial
Nucleobindin-1
V-type proton ATPase subunit d 1
Calcineurin B homologous protein 1
Alpha-aminoadipic semialdehyde synthase, mitochondrial
Splicing factor 3B subunit 3
NAD(P)H-hydrate epimerase
C4b-binding protein alpha chain
Moesin
Thioredoxin-related transmembrane protein 1
60S ribosomal protein L5
Isochorismatase domain-containing protein 2, mitochondrial
Junction plakoglobin
ATP synthase subunit g, mitochondrial
Malate dehydrogenase, cytoplasmic
Microtubule-associated protein 4
60S ribosomal protein L24
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex
subunit 4
Aspartyl aminopeptidase
ATP-dependent Clp protease proteolytic subunit,
mitochondrial
Hexokinase-1
Mitochondrial fission 1 protein
Tissue alpha-L-fucosidase
60S ribosomal protein L30
Serine/threonine-protein phosphatase PP1-alpha catalytic
subunit
High mobility group protein B1
NADH dehydrogenase [ubiquinone] 1 beta subcomplex
subunit 9
NADH-cytochrome b5 reductase 1
NADH dehydrogenase [ubiquinone] 1 beta subcomplex
subunit 6
Protein SCO1 homolog, mitochondrial
Surfeit locus protein 4
Histone-binding protein RBBP7
Kappa-casein
Isocitrate dehydrogenase [NADP] cytoplasmic
Peroxiredoxin-6
Glutathione S-transferase P
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex
subunit 2
4-trimethylaminobutyraldehyde dehydrogenase
WD repeat-containing protein 1
Integrin beta-5
Cofilin-1
Isovaleryl-CoA dehydrogenase, mitochondrial
28S ribosomal protein S7, mitochondrial
Peptidyl-prolyl cis-trans isomerase FKBP10
Cathepsin B
Eukaryotic translation initiation factor 2 subunit 1

2
2
1
3
2
0
0
0
0
4
2
1
3
2
2
0
0
0
0
0
3
1
1
2
1

2
2
3
1
1
4
4
4
4
0
2
2
1
2
2
3
3
3
3
3
0
2
2
1
2

0.59
0.41
0.36
0.085
0.14
0.0021
0.0021
0.0021
0.0021
< 0.00010
0.31
0.45
0.045
0.31
0.55
0.0037
0.0037
0.0037
0.0037
0.0037
0.00021
0.56
0.56
0.22
0.31

2
2

2
1

0.44
0.079

0
3
3
2
2

3
0
0
1
1

0.0065
0.00049
0.00049
0.33
0.33

0
0

3
3

0.011
0.011

0
0

3
3

0.011
0.011

0
0
0
3
3
1
1
1

3
3
3
0
0
1
2
1

0.011
0.011
0.011
0.0011
0.0011
0.47
0.26
0.47

1
2
2
0
0
0
0
2
0
0

1
0
0
2
2
2
2
1
2
2

0.47
0.0027
0.0027
0.02
0.19
0.02
0.02
0.13
0.02
0.02
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PSA6
RL8
ERG24
ZN326
NCEH1
CAV1
(+27)
AOFA
FKB11
SPCS3
ACTN2
CFDP2
DPYL2
PUR9
ERO1A
HEXA
U5S1
AP2A2
OCTC
CISD2
02-Sep
PSD11
SRSF3
RBM14
C560
RM01
UK114
EFHD2
TMED1
MPPB
F162A
MFGM
CAP1
DCTN2
HS105
PARP1
C1TM
GPX1
FUND2
COF2
NUP93
PNPH
TCPQ
CBR4
TIM50
PPIA
1433B
RS7
DHPR
PSPC1
RL10A
RL27
RS13
COX5B
RM12
ABHDB
ORN
CALD1

Proteasome subunit alpha type-6
60S ribosomal protein L8
Delta(14)-sterol reductase
DBIRD complex subunit ZNF326
Neutral cholesteryl ester hydrolase 1

1
1
2
2
1

1
2
0
0
1

0.64
0.36
0.0062
0.0062
0.48

Caveolin-1
Amine oxidase [flavin-containing] A
Peptidyl-prolyl cis-trans isomerase FKBP11
Signal peptidase complex subunit 3
Alpha-actinin-2
Craniofacial development protein 2
Dihydropyrimidinase-related protein 2
Bifunctional purine biosynthesis protein PURH
ERO1-like protein alpha
Beta-hexosaminidase subunit alpha
116 kDa U5 small nuclear ribonucleoprotein component
AP-2 complex subunit alpha-2
Peroxisomal carnitine O-octanoyltransferase
CDGSH iron-sulfur domain-containing protein 2
Septin-2
26S proteasome non-ATPase regulatory subunit 11
Serine/arginine-rich splicing factor 3
RNA-binding protein 14
Succinate dehydrogenase cytochrome b560 subunit,
mitochondrial
39S ribosomal protein L1, mitochondrial
Ribonuclease UK114
EF-hand domain-containing protein D2
Transmembrane emp24 domain-containing protein 1
Mitochondrial-processing peptidase subunit beta
Protein FAM162A
Lactadherin
Adenylyl cyclase-associated protein 1
Dynactin subunit 2
Heat shock protein 105 kDa
Poly [ADP-ribose] polymerase 1
Monofunctional C1-tetrahydrofolate synthase, mitochondrial
Glutathione peroxidase 1
FUN14 domain-containing protein 2
Cofilin-2
Nuclear pore complex protein Nup93
Purine nucleoside phosphorylase
T-complex protein 1 subunit theta
Carbonyl reductase family member 4
Mitochondrial import inner membrane translocase subunit
TIM50
Peptidyl-prolyl cis-trans isomerase A
14-3-3 protein beta/alpha
40S ribosomal protein S7
Dihydropteridine reductase
Paraspeckle component 1
60S ribosomal protein L10a
60S ribosomal protein L27
40S ribosomal protein S13
Cytochrome c oxidase subunit 5B, mitochondrial
39S ribosomal protein L12, mitochondrial
Alpha/beta hydrolase domain-containing protein 11
Oligoribonuclease, mitochondrial
Non-muscle caldesmon (Fragment)

0
0
0
0
0
0
2
2
2
2
2
0
0
0
0
1
0
0

2
2
2
2
2
2
0
0
0
0
0
2
2
2
2
1
2
2

0.035
0.035
0.035
0.035
0.035
0.035
0.014
0.014
0.014
0.014
0.014
0.061
0.061
0.061
0.061
0.37
0.061
0.061

0
0
0
0
0
0
0
1
1
0
1
1
1
0
0
0
1
0
1
0

2
2
2
2
2
1
1
0
0
1
0
0
0
1
1
1
0
1
0
1

0.061
0.061
0.061
0.061
0.061
0.11
0.11
0.034
0.034
0.11
0.034
0.034
0.034
0.11
0.11
0.11
0.034
0.11
0.034
0.11

1
1
1
0
1
0
0
0
0
0
1
0
0
0

0
0
0
1
0
1
1
1
1
1
0
1
1
1

0.034
0.034
0.034
0.11
0.034
0.11
0.11
0.11
0.11
0.11
0.034
0.11
0.11
0.11
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GILT
ARP5L
ARPC2
KAD4
TMX2
FRIL
PYRD
ACOX1
ESTD
ADPGK
COPA
RS19
AL4A1
TCPD
TIM21
TOM40
CATZ
MACD1
ASPH
RL35A
TFAM
RM13
RM43
EFTS
ATAD3
MGST1
NDUS2
ABHGA
ANXA3
BASP1
CP20A
ELMD2
GPX8
RL9
CNN1
UBXN4
ACSF2
COPB2
LGMN
B2MG
PSA1
PSA7
NDUBB

Gamma-interferon-inducible lysosomal thiol reductase
Actin-related protein 2/3 complex subunit 5-like protein
Actin-related protein 2/3 complex subunit 2
Adenylate kinase 4, mitochondrial
Thioredoxin-related transmembrane protein 2
Ferritin light chain
Dihydroorotate dehydrogenase (quinone), mitochondrial
Peroxisomal acyl-coenzyme A oxidase 1
S-formylglutathione hydrolase
ADP-dependent glucokinase
Coatomer subunit alpha
40S ribosomal protein S19
Delta-1-pyrroline-5-carboxylate dehydrogenase,
mitochondrial
T-complex protein 1 subunit delta
Mitochondrial import inner membrane translocase subunit
Tim21
Mitochondrial import receptor subunit TOM40 homolog
Cathepsin Z
O-acetyl-ADP-ribose deacetylase MACROD1
Aspartyl/asparaginyl beta-hydroxylase
60S ribosomal protein L35a
Transcription factor A, mitochondrial
39S ribosomal protein L13, mitochondrial
39S ribosomal protein L43, mitochondrial
Elongation factor Ts, mitochondrial
ATPase family AAA domain-containing protein 3
Microsomal glutathione S-transferase 1
NADH dehydrogenase [ubiquinone] iron-sulfur protein 2,
mitochondrial
Abhydrolase domain-containing protein 16A
Annexin A3
Brain acid soluble protein 1
Cytochrome P450 20A1
ELMO domain-containing protein 2
Probable glutathione peroxidase 8
60S ribosomal protein L9
Calponin-1
UBX domain-containing protein 4
Acyl-CoA synthetase family member 2, mitochondrial
Coatomer subunit beta'
Legumain
Beta-2-microglobulin
Proteasome subunit alpha type-1
Proteasome subunit alpha type-7
NADH dehydrogenase [ubiquinone] 1 beta subcomplex
subunit 11, mitochondrial

0
0
0
1
0
0
0
0
1
0
1
0

1
1
1
0
1
1
1
1
0
1
0
1

0.11
0.19
0.19
0.079
0.19
0.19
0.19
0.19
0.079
0.19
0.079
0.19

0
1

1
0

0.19
0.079

0
0
0
0
0
0
0
1
0
0
1
1

1
1
1
1
1
1
1
0
1
1
0
0

0.19
0.19
0.19
0.19
0.19
0.19
0.19
0.079
0.19
0.19
0.079
0.079

1
1
0
0
1
1
0
0
0
0
1
1
0
0
1
0

0
0
1
1
0
0
1
1
1
1
0
0
1
1
0
1

0.079
0.079
0.19
0.19
0.079
0.079
0.19
0.19
0.33
0.33
0.18
0.18
0.33
0.33
0.18
0.33

1

0

0.18
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Vimentin
***

30
20
10
0
CL - Total

Relative Expression to Fat

Relative Expression to Fat

PLIN3
40

40

*

30
20
10
0

CL - LD

CL - Total

3bHSD

40

*

20
10
0
CL - Total

CL - LD

Relative Expression to Fat

Relative Expression to Fat

P450scc

30

CL - LD

*

15

10

5

0
CL - Total

CL - LD

Appendix A-4 – Quantification of LD-associated protein by Western blot
Relative expression of select proteins in total luteal lysates versus purified LD fractions.
Proteins were normalized to Ponceau S signal of the corresponding lane and the expression of
each protein in fat (not shown in figure) was defined as 1. Graphs display mean ± S.E.M., n
= 4 * P ≤ 0.05, *** P ≤ 0.001 as determined by two-way ANOVA.
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SUPPLEMENTAL DATA FOR CHAPTER 4
Appendix B-1 – Primers used for qPCR
Gene name
ATF3

Primers for qPCR
F: AGCACCTCTGCCACCGGATGT
R: CTTTCAGGGGCTACCTCGGCTTT

FOS

F: TGACACCCTCCAAGCGGAGACA
R: TTGCAGGCAGGTCGGTGAGC

JUN

F: ACGCCGACCCCTACCCAGTTC
R: GGTTGGCGTAGACCGGCTGCG

JUNB

F: CCGGAGCCGCCTCCAGTCTA
R: ATGGTGGCCGTCCGGGTACGA

CCL2

F: TGCTCGCTCAGCCAGATGCAAT
R: GGACACTTGCTGCTGGTGACTCT

CCL8

F: TCTCAGGCTGAAGCCCCCGT
R: ACTGAATCTGGCTGAGCGAGCA

CXCL2

F: GCGCCCGTGGTCAACGAACT
R: AGACTGGCTATGACTTCGGTTTGGT

CXCL8

F: TGTGAAGCTGCAGTTCTGTCAAG
R: TGCACCCACTTTTCCTTGGGGT

ACTB

F: ACACCGCAACCAGTTCGCCAT
R: AAGACGGCCCGGGGAGCATC

GAPDH

F: AGATGGTGAAGGTCGGAGTG
R: GATCTCGCTCCTGGAAGATG

ACTB, actin beta; ATF3, activating transcription factor 3; CCL2,
C-C motif chemokine 2; CCL8, C-C motif chemokine 8;
CXCL8, C-X-C motif chemokine 8; FOS, Finkel-Biskis-Jinkins
murine osteosarcoma viral oncogene homolog; GAPDH,
glyceraldehyde-3-phsophate dehydrogenase; JUN, Jun protooncogene; JUNB, Jun proto-oncogene B
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Appendix B-2 – Differentially expressed transcripts from a short PGF2α time-course

0.5 h

1h

2h

Up-Regulated Transcripts

Down-Regulated Transcripts

ADAMTS1, APOLD1, ATF3, BTG2, CYR61, DNAJB1, DUSP1, EGR1, EGR2, EGR3,
FOS, FOSB, IER2, INSIG1, JUN, JUNB, LOC784931, NR4A1, NR4A2, NR4A3, PLK2,
PPP1R15A, RGS2, RND1, SOWAHC
ZFP36
ABT1, ADAMTS1, ADAMTS4, ANGPT2, APOLD1, ARC, ARL5B, ATF3, BAMBI,
BHLHE40, BTG1, BTG2, C15H11orf96, CCL1, CDC42EP2, CDK8, CDKN1A, CEBPD,
CH25H, COQ10B, CYR61, DLL1, DNAJB1, DNAJB4, DUSP1, DUSP2, DUSP5, EDNRB,
EGR1, EGR2, EGR3, EGR4, ERF, FAM43A, FAM46A, FGF18, FOS, FOSB, FOSL1,
GEM, HOMER1, HSPH1, IER2, IFRD1, INSIG1, JUN, JUNB, JUND, LOC100138911,
NR4A1, NR4A2, LSMEM1, MCL1, NR4A3, MXI1, MYC, NFIL3, NFKBIZ, NPAS4,
PPP1R15A, RGS2, OBFC2A, PCF11, PDE4D, PER1, PEX12, PFKFB3, PHLDA1,
PHLDA2, PLAT, PLK3, PLSCR4, PPP1R10, SOWAHC, PPP1R16B, RAB7B, RASD1,
RCAN1, RFK, ZFP36, RND3, RNF122, SDC4, SEMA7A, SERPINE1, SIK1, SLC20A1,
SLCO4A1, SNAI1, SNAI2, SOCS3, SRF, TAF4B, TMEM2, TRAF1, TRIB1, USP2,
ZC3H12A, ZFAND2A,, MIR2284I,
RCAN1, RFK, ZFP36, RND3, RNF122, SDC4, SEMA7A, SERPINE1, SLCO4A1, SOCS3,
SRF, TAF4B, TMEM2, TRAF1, TRIB1, ZC3H12A, ABL2, AMIGO2, ANGPTL5, AP1S3,
AREG, ARG2, ARID5B, ATP11B, BACH1, BCL6, BDKRB1, BRIX1, BZW1, BZW2,
C1H21ORF91, CBFB, CCDC41, CCDC58, CCDC85B, CCL8, CCT2, CD24, CD24,
CDK17, CNN1, COPS9, CRISPLD2, CSRNP1, CSRP3, DAPP1, DCLK1, DCUN1D3,
DHX15, DNAJA1, DNAJB11, DNAJC21, DPH3, EIF2C2, EIF3J, EIF4A1, ELL2, EPT1,
EREG, ERI1, ERICH1, F2RL1, F3, FAM71F1, FAM8A1, FBXO42, FERMT2, FGF2,
FKBP5, GADD45A, GCH1, GCNT4, GJA1, GMPR, GNE, GOLM1, GPR137B, GPRC5A,
HAT1, HDGFRP3, HRH1, IER3, IL1A, IL1B, IL33, INA, INHBA, JAK2, JMJD1C,
KDM7A, KLF5, KLF6, LDHA, LGALSL, LHFPL2, LMCD1, LOC100138700,
LOC100296849, LOC100336688, LOC784931, LOC100337139, LOC286871,
LOC782470, LOC788082, LONRF3, LYSMD3, MAFF, MAP3K2, MAP3K8, MAP7D2,
MARCH3, MARCH5, METAP2, MMP12, MXD1, NDRG1, NET1, NKAIN2, NOP58,
NPTX2, OLR1, ONECUT2, P2RY6, PDE8A, PFDN6, PIM1, PLAUR, PLPPR4, PMAIP1,
PPP1CC, PPP4R2, PRDM1, PSME4, PTX3, RAB20, RABEP1, RASA2, RBBP8, RDH12,
RGS16, RIOK3, RNF125, RRP15, RSBN1, SAMD8, SERPINB2, SERTAD2, SETD8,
SFPQ, SGMS2, SLC13A3, SLC19A2, SLC2A1, SLC2A3, SLC37A3, SLC41A2, SLC4A7,
SMARCA1, SMARCA5, SNX18, SOX4, SPSB1, SPTY2D1, SSFA2, STK17B, STK38L,
STX11, SUB1, SUCLA2,, TBC1D9, TEAD4, TFPI2, TIAM2, TIGAR, TLE3, TMEM30B,
TMEM65, TNFSF18, TNFSF9, TWF1, UBALD1, UFM1, USP53, UTP15, XCL2, XIRP1,
YOD1, YWHAZ, ZBTB5, ZFAND5, ZNF385B, ZNF644, ZSWIM6DAZL, LOC782090,
PRRG4

LOC100337120, LOC783362, MIR2450B

ARHGAP25, CARD6, LOC100298387

ABCA7, ABCC5, ABLIM1, ADAP2, AGTR1, AHDC1, AKIP1, AMIGO1, AMOT, AOC3,
ARHGAP20, ARHGEF10L, ARHGEF11, ARMCX6, ARRB1, ATAT1, ATP1B2, BCL9L,
BCOR, BLES03, BORCS5, C13H20ORF27, C16H1orf115, C25H7ORF26, C28H10orf54,
C5H12ORF4, CACNB2, CALB2, CAMK2G, CBX7, CCDC125, CCDC14, CD34,
CEP295NL, CFAP126, CNNM3, CRTC1, CTC1, CYYR1, DAPK2, DISP1, DMD,
DNASE1, DNM3, DPF3, EVA1B, FAM13C, FAM193B, FAM198B, FAM222B,, FIS1,
FLT3LG, FLVCR2, FOXL2, FSD1L, GAB1, GLTPD1, GRIA1, GRIN2A, HLX, HOXD3,
HOXD4, IFT52, IRF2, ISYNA1, JUB, KANK2, KANK3, KCNN3, KIAA0232, KIAA1462,
LDB1, LDLRAP1, LENG8, LIN37, LIPE, LMAN2L, LOC100335495, LOC100336724,
LOC100337111, LOC100337178, LOC100337457, LOC509283, LOC510193,
LOC511229, LOC514257, LOC515697, LOC787074,, LRIG3, MAMSTR, MAPRE3,
MFSD9, MID2, MIR2450A, MIR2475, MIR2485, MPPED2, MSRA, MSS51, MTMR11,
MTP18, MTSS1, NAIF1, NFIB, NHSL1, NLRX1, NOTCH3, NPHP3, NPR3, NR1D1,
NR2C2, NR2F1, NR5A2, NUMA1, OGT, PCDH12, PDRG1, PER3, PHACTR4, PHLDB2,
PIEZO2, PLEKHA2, PNMA1, PODXL, PPARGC1B, PPP1R3B, PPP2R4, PRR12,
PTGDS, RAB7L1, RARG, RASGRP3, REM1, RFTN2, RFX3, RMND5B, LOC100337120,
RNF113A, RNF214, RUBCN, RUNDC3B, RUSC2, RXRB, SDPR, SEPW1, SETDB1,
SF4, SFRS14, SFRS8, SLC29A3, SLC39A14, SMIM10, SNCAIP, LOC783362, SPRY4,
ST5, ST6GAL1, STARD9, TANC1, TANC2, TBC1D13, TBC1D30, TCN2, TEK, TET1,
THAP11, TM4SF1, TMEM14C, TMEM42, TNFRSF19, TNFSF10, TNRC6C, TNS3,
TOR3A, TRIM62, TRIM65, TRIM68, TUBGCP5, USHBP1, VAMP2, VAMP5, VIPR1,
WDR59, YPEL3, ZBTB4, ZBTB40, ZC2HC1C, ZC4H2, ZEB2, ZFP2, ZMYM3,
ZMYND15, ZNF12, ZNF22, ZNF362, ZNF43, ZNF462, ZNF581, ZNF585A, ZNF629,,
ZNFX1APBB3, CABLES1, LOC100138414, LOC100336686, LOC616365, MIR584-7,
SH3TC2, TRERF1, VSIG2, ZAR1L, ARHGAP25
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4h

4h

4h

ARC, ARL5B, ATF3, BAMBI, BHLHE40, BTG1, BTG2, C15H11orf96, CCL1, CDK8,
CDKN1A, CEBPD, CH25H, COQ10B, DNAJB1, DUSP1, DUSP2, DUSP5, EDNRB, EGR3,
EGR4, FAM43A, FAM46A, FGF18, FOS, FOSB, FOSL1, GEM, HOMER1, HSPH1, IFRD1,
INSIG1, JUNB, JUND, NR4A1, NR4A2, MCL1, NR4A3, NFIL3, RGS2, OBFC2A, PDE4D,
PHLDA1, PHLDA2, PLK3, PLSCR4, SOWAHC, RCAN1, RFK, ZFP36, RNF122, SDC4,
SERPINE1, SIK1, SLCO4A1, SOCS3, SRF, TAF4B, TMEM2, TRIB1, USP2, ZFAND2A,
ABL2, AMIGO2, ABCE1, ABHD12B, AP1S3, ABTB2, AREG, AEBP2, AGFG1, ARG2,
ARID5B, AHI1, AHSG, AKAP4, AKIRIN1, ALCAM, BACH1, BCL6, ANKRD1, ANO6,
BZW1, BZW2, C1H21ORF91, ARF4, CBFB, ARHGAP28, ARHGAP6, CCDC58, CCL8,
ARL4C, CD24, ASAM, ATAD1, CD24,, CDK17, ATP13A3, CNN1, ATP2A2, ATP2B1,
ATP5I, ATP6V1C1, B3GALNT2, B4GALT5, COPS9, BCAP29, BCAS2, BCHE, BCL2L11,
BCL3, CSRNP1, CSRP3, DAPP1, BIRC3, BMP2, BOLA-DYA, BPIFA2A, BRINP1,
BTBD10, BTG3, DNAJA1, C10H14orf119, C10H15orf65, C12H13orf27, C12H13orf30,
C15H11orf46, DPH3, C16H1ORF21, C17H12orf52, C19H17orf67, EIF2C2,
C23H6orf141, EIF3J, C27H8orf4, EIF4A1, C29H11orf73, C2H2orf76, C3H1orf162, ELL2,
C6H4orf34, C9H6ORF115, CA8, EPT1, EREG, ERI1, CAPZA2, CBARP, ERICH1, F2RL1,
F3, FAM8A1, CCDC80, FERMT2, CCK, CCL2, CCL3, CCL4, FGF2, CCNC, CCNG2,
CCNYL1, CCP110, CCRN4L, CD14, GADD45A, GCH1, GCNT4, CD40, CD44, CD83,
CDC42SE2, CDCP1, CDH1, GJA1, CDKL1, GMPR, CETN3, CFLAR, CGRRF1, CHIC2,
CHKA, CHSY1, CLDN1, CLDND1, CLEC1A, CLEC1B, CLEC2B, GPR137B, COMMD6,
GPRC5A, COX6C, CPNE8, CRABP2, CREB5, CRIPT, HAT1, CRYAB, CSF1, HRH1,
CSRP2, IER3, IL1A, CTLA4, CTNNAL1, CWC22, CXCL13, CXCL2, CXCL5, CXCL8,
CYB5R4, CYP3A4, CYSLTR2, IL1B, IL33, INA, INHBA, DDX3X, DDX5, DENND5A, DES,
KDM7A, KLF6, LDHA, DNAJB6, DNAJB9, DNAJC12, LGALSL, LHFPL2, LMCD1,
DOT1L, LOC100138700, LOC100296849, DRGX, DSTN, DTWD1, DUSP11, DUSP14,
EDN2, EHBP1, EIF1AX, EIF1B, LOC100336688, LOC784931, EIF4E, LOC286871,
ENTPD7, LOC782470, LOC788082, LONRF3, LYSMD3, ESYT3, MAFF, EVI2A, EXOSC1,
F2RL2, MAP3K8, FAM126B, FAM148A, FAM171B, FAM18B, MARCH3, MMP12, MXD1,
FAM92A1, FBXL14, NDRG1, NET1, FGF7, FGFR1OP2, FGR, NPTX2, FKBP14, OLR1,
P2RY6, PDE8A, FSHR, PIM1, PLAUR, GADD45G, GAL, GAS1, GCFC2, PLPPR4,
GDPD1, GLRX2, PPP4R2, GMCL1, GMFB, GMNN, PRDM1, PSME4, GNPNAT1, PTX3,
RAB20, GPR155, GPR65, GPR68, RASA2, RBBP8, GTF2E2, H2AFZ, HAS2, RDH12,
HAUS3, HAUS6, HBXIP, RGS16, HGF, HIGD1D, HINT3, HK2, RIOK3, HMGA1, RNF125,
RRP15, HPCA, HPCAL4, RSBN1, HS3ST5, HSPA13, IBSP, ICOSLG, SAMD8, IFT20,
SERPINB2, IGF2BP2, IGFBP1, IGFBP3, IL10, IL18, IL18BP, SERTAD2, SETD8, IL1R1,
IL1RN, IL21R, SFPQ, IL4R, IL7R, SGMS2, SLC13A3, INHBB, INSIG2, IPMK, IRAK2,
SLC19A2, IRG1, ISCA1, ISG20, ISG20L2, SLC2A1, ITGA2, ITGAV, IVNS1ABP, SLC2A3,
JARID2, SLC37A3, JPH2, SLC41A2, SLC4A7, KBTBD8, KDM6B, KHDRBS3, SOX4,
SPSB1, SSFA2, KLHL32, KRT18, KRT73, KRT8, KRTAP3-1, STK17B, STK38L, STX11,
SUB1,, TBC1D9, LIN7C, LLPH, TFPI2, TIAM2, LMO7, LNPK, LOC100140827,
LOC100174924, LOC100294784, LOC100294785, LOC100294863, LOC100294865,
LOC100295254, LOC100295381, LOC100295586, LOC100295757, LOC100295775,
LOC100296441, LOC100296447, LOC100296475, LOC100296524, LOC100296684,
LOC100296722, LOC100296944, LOC100297075, LOC100297413, LOC100297468,
LOC100298628, LOC100300871, LOC100301462, LOC100335253, LOC100335275,
LOC100335305, TMEM30B, LOC100335936, LOC100336429, LOC100336443,

PPP1R10, AAK1, AARS, AASDH, ABCA1, ABCF3, ABCG2, ABHD14A, ABHD14B,
ACACA, ACAD10, ACAP3, ACBD4, ACD, ACIN1, ACP2, ACP5, ACTN4, ADAMTS17,
ADAMTSL5, ADCK2, ADCY4, ADCY9, ADD1, ADORA2A, ADPRHL2, ADRB1, AEBP1,
AFF1, AFF2, AFF3, AGAP2, AGFG2, AGK, AGPAT1, AGRN, AHNAK, AKAP11, AKAP13,
AKAP8L, AKR1A1, ALAD, ALDH3A2, ALDH3B1, ALG8, ANGEL1, ANKHD1, ANKLE2,
ANXA11, AP1B1, APEG3, APEX2, APLNR, AR, ARAP1, ARAP3, AREL1, ARFGEF2,
ARHGAP17, ARHGAP18, ARHGAP19, ARHGAP23, ARHGEF40, ARHGEF7, ARID1A,
ARID1B, ARMCX5, ARRDC1, ARSB, ARSG, ARX, ASAP1, ASXL2, ATF5, ATF6B, ATF7,
ATF7IP, ATN1, ATP2C2, ATXN2, ATXN7L1, AUTS2, B3GNT3, B3GNT9, B9D2, BAT2,
BAT2L1, BAZ1B, BAZ2A, BCL9, BNC2, BRPF1, C10H15orf41, C11H9orf114,
C14H8ORF70, C22H3ORF37, C23H6ORF47, C28H10ORF35, C28H1orf198, C2H2orf24,
C3AR1, C8H9orf23, C8H9orf91, C9H6ORF203, C9H6ORF70, CABC1, CABIN1,
CAMKK2, CAPN1, CASC3, CASKIN2, CASP9, CBFA2T2, CBL, CBR4, CBX4, CBX6,
CC2D1A, CC2D2A, CCDC106, CCDC6, CCDC8, CCND3, CCNJL, CCS, CDC42BPB,
CDC42EP4, CDON, CEACAM8, CELSR2, CEP110, CEP68, CHD2, CHD8, CHMP1A,
CHMP4C, CHRNB3, CHST7, CIITA, CIRBP, CIZ1, CKAP5, CLASP1, CLIC5, CLMN,
CLN6, CMTM4, CNDP2, CNOT3, CNOT4, CNOT8, COG1, COG7, COG8, COPS7A,
COQ4, CORO2B, CPEB1, CPEB2, CPSF1, CREBBP, CRTC2, CRY2, CSRNP3, CSTF1,
CTNS, CUL7, CUL9, CUX1, CXORF36, CYB5D2, CYB5R3, DAAM2, DAB2, DAB2IP,
DACT1, DAG1, DAGLA, DBP, DCAF4, DCP1B, DCTN1, DDX31, DDX42, DEF6,
DENND1A, DENND4B, DEPDC5, DHRS12, DHX30, DHX37, DHX57, DIP2A, DIP2B,
DIS3L2, DNAJC16, DNAJC17, DNAJC30, DOCK6, DOCK9, DOPEY2, DPAGT1, DSCR3,
DTNBP1, DTX2, DUSP10, DUSP15, DVL3, DYNC1H1, DYSF, EEF2K, EFTUD2,
EGFLAM, EHD2, EHMT2, EIF2B4, EIF2C4, EIF4EBP2, EIF4ENIF1, ELMO1, EMC9,
EMCN, EMD, EML5, ENG, EP400, EPB41, EPHB3, ERAL1, ERAP1, ERCC3, ERCC5,
ERN1, EVC2, EXOC3L, EZH1, FADS6, FAM115A, FAM120B, FAM122A, FAM13A1,
FAM168A, FAM171A2, FAM188B, FAM189B, FAM214B, FAM59A, FAM65A, FAM73B,
FAM83H, FARP1, FASN, FBLIM1, FBLN5, FBN1, FBRS, FBXL12, FBXL6, FBXL8,
FBXO10, FBXO42, FBXW12, FBXW4, FES, FGD1, FHOD1, FIGN, FITM2, FKBP15,
FLAD1, FLOT2, FLYWCH2, FN3KRP, FNTB, FOXJ2, FOXN3, FOXRED1, FOXS1, FRY,
FTSJD2, FUT1, FUT8, FYCO1, FZD4, FZR1, G6PD, GALNS, GALNT10, GALT, GANAB,
GATA4, GATSL3, GBA2, GBF1, GCC1, GCN1L1, GEMIN4, GEMIN5, GGA3, GIPC1,
GIT2, GLE1, GLG1, GLTSCR1L, GNA14, GON4L, GPAM, GPIHBP1, GPR4, GPS2,
GREB1L, GRN, GTF2I, GTF3C1, GTF3C4, GYS1, H1F0, H1FX, H6PD, HADH, HAUS4,
HAUS5, HCFC1, HCRTR1, HDAC4, HDAC6, HDGF2, HEATR5B, HEATR7A, HECTD4,
HECW2, HERC2, HEXIM1, HGS, HIG2, HIP1, HIVEP1, HLCS, HOXC6, HOXD9, HPS1,
HS1BP3, HSD17B14, HSDL1, HSPA2, HSPG2, HUWE1, HYI, ICMT, ID3, IFT122, IFT88,
IGF2R, IGFBP2,, IL11RA, IL23A, ILDR2, ILVBL, INADL, INO80D, INPP5B, INPP5D,
INTS1, INTS3, IPO13, IQGAP2, ITGA9, ITPR3, ITSN1, JMJD2A, KANK1, KANSL1,
KANSL3, KBTBD4, KCTD21, KDM2A, KDR, KEAP1, KIAA0100, KIAA0182, KIAA0355,
KIAA0753, KIF13A, KIF16B, KIF3B, KLF12, KLHL18, KLHL25, KLHL26, KMT2B, KPTN,
LAMB2, LARP1, LASS1, LATS1, LGALS9, LHPP, LOC100137838, LOC100138392,
LOC100295097, LOC100295263, LOC100296493, LOC100298868, LOC100299799,
LOC100335642, LOC100336406, LOC100336508, LOC100336568, LOC100336586,
LOC100336604, LOC100336756, LOC100336769, LOC100336841, LOC100336856,
LOC100336912, LOC100337052, LOC100337072, LOC100337080, LOC100337088,
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4h

4h

LOC100336452, LOC100336518, LOC100336625, LOC100336666, TNFSF18,
LOC100337076, TWF1, LOC100337126, UBALD1, UFM1, LOC100337445, LOC407171,
LOC508459, LOC509071, LOC509094, XCL2, LOC509506, LOC509911, XIRP1, YOD1,
YWHAZ, LOC515823, LOC521081, LOC522171, LOC523389, LOC524181, LOC524703,
LOC613460, LOC613882, LOC613970, LOC614643, LOC615482, LOC616520,
LOC618696, LOC619061, LOC781102, LOC781142, LOC781416, LOC781462,
LOC781612, LOC781807, LOC782021, LOC782266, LOC782348, LOC782402, ZFAND5,
LOC782639, LOC782740, LOC782950, LOC783459,, LOC784207, LOC784704,
LOC785366, LOC785449, LOC785455, LOC785745, LOC786131,, ZNF385B,
LOC787187, LOC788284, LOC788496, LOC789095, LOC789126, LOC789920, ZSWIM6,
#N/A, LRP12, LRRC58, LRRC8B, LRRN3, LSM1, LY96, MAN1A1, MANF, MAP1LC3C,
MAP2K3, MAP4K5, MAPK6, MAPKSP1, MARCKSL1, MEMO1, METRNL, MEX3C,
MGC127989, MGC143035, MICAL2, MIER1, MIR19A, MIR21, MIR2434, MIR2469,
MMP1, MMP1, MOSPD2, MRPL39, MRPL42, MRPS16, MRPS18C, MSC, MT2A, MTCL1,
MTMR12, MUSK, MYH1, MYL3, Mynn, MZT1, NAB1, NCALD, NDUFAF2, NEXN,
NFKB1, NFKBIA, NIPAL1, NMU, NOS1AP, NRCAM, NRG1, NUCB2, NUDCD1, NUDT10,
NUPL2, OAF, ODF2L, OSBPL11, OSTM1, OXT, PAG1, PAK1IP1, PAPD7, PCDH11X,
PCNP, PDCD10, PDE4B, PDGFC, PDLIM4, PDP1, PELI1, PENK, PEX13, PICALM,
PIGP, PIK3CA, PITPNC1, PKIB, PKNOX1, PLA2G7, PLEK, PLIN2, RND1, PLN, PLOD2,
PNP, POLB, POLE4, POLR2K, PPAPDC3, PPARG-TSEN2, PPM1N, PPP1CB, PPP1R2,
PPP1R3C, PPP4R4, PRKCD, PRORSD1, PSMD14, PSTPIP2, PTGER2, RAB19, RAB40B,
RABGGTB, RAI14, RASGEF1A, RASSF8, RBM7, RCHY1, RCN2, RDH11, RERG, RGCC,
RHEB, RIPK4, RNF19B, RNFT1, RPF2, RPIA, RPL34, RPS12, RPS21, RPS23, RRAD,
RRAS2, RSL24D1, RUBCNL, RUNX1, S100A12, S100A8, S100A9, S1PR3, SAMD4A, SDS,
SEC61G, SELK, SEMA3C, SERPINA11, SERTAD4, SF3B14, SGPP1, SGTB, SH3GL3,
SHTN1, SLC12A2, SLC20A2, SLC25A25, SLC25A33, SLC26A2, SLC33A1, SLC34A2,
SLC38A1, SLC39A8, SLC46A2, SLITRK2, SLMO2, SMG9, SNAP25, SNRPD1, SNRPG,
SNX13, SNX31, SNX4, SOCS1, SPCS3, SPHK1, SPP1, SRD5A1, SRXN1, SSTR1, STAMBP,
STEAP1, STK17A, SUCO,, TANK, TBCA, TERC, TET3, TFB2M, TGFBR1, TGIF1, THAP5,
THBD, THBS1, THEX1, TIAM1, TIMM17A, TIMM8A, TLR2, TMC1, TMEM126A,
TMEM136, TMEM14A, TMEM165, TMEM188, TMEM189-UBE2V1, TMEM26,
TMEM41B, TMEM45A, TMEM64, TMF1, TMOD1, TMX1, TNFAIP3, TNFAIP8L3,
TNFRSF12A, TNFRSF6B, TNFSF4, TPM4, TRAM1, TREM1, TRH, TRPC4, TRPM6,
TRPM7, TSPAN12, TUBB2A, TXN, TXNRD1, UAP1, UBE2B, UBE2N, UBE2W, UBE3A,
UCHL3, UPRT, UXT, VAT1L, VBP1, VNN2, WASF1, WDR44, WDR89, XBPP1, YWHAQ,
ZBTB43, ZNF469, ZNRD1, ACBD7, BCL2A1, CHSY3, GPR87, LOC100294744,
LOC100297034, LOC100297127, LOC100337296, LOC509074, LOC514319, LOC520180,
LOC616887, LOC782358, LOC785867, LOC787306, LOC788009, LOC789734, LRRC31,
MBL2, NPPB, PAG6, PAG9, PAQR9, PDE1C, SERPINI1, TMIGD1, TRIM9, VSX1,
WFDC11, WNT10B

LOC100337236, LOC505156, LOC505719, LOC508153, LOC511497, LOC526631,
LOC526847, LOC529423, LOC534002, LOC539110, LOC539229, LOC540312,
LOC616014, LOC616063, LOC616198, LOC619000, LOC783493, LOC786942,
LOC788379, LPCAT1, LPHN1, LRFN3, LRIF1, LRP1, LRRC41, LRRK1, LRSAM1, LTBR,
LYSMD4, MACF1, MAEA, MAMLD1, MAN2A2, MAP2K2, MAP3K4, MAP3K6, MAP4K2,
AGTR1, MAPK7, MAPRE2, AHDC1, AKIP1, AMIGO1, MARK2, MARVELD1, MAVS,
MAZ, MBD6, MBNL2, MCM9, MDC1, MDN1, MECP2, MED12, MED16, MED22,
MED25, MEF2C, MEPCE, AMOT, MFNG, AOC3, MGC134093, MGC159500, MGME1,
MIB2, MICAL1, MID1IP1, ARHGAP20, MINK1, MIR1287, MIR2303, MIR2416, MIR2454,
ARHGEF11, ARMCX6, MKKS, MKS1, MLH3, MLL, MLL2, MLLT10, MMP15, MMP2,
MMS19, MOBKL2A, MON1B, MORC2, MOSPD3, MOV10, MPDZ, MPP5, ATAT1,
MRPS24, MSH6, ATP1B2, BCL9L, MTF1, MTHFD1, BCOR, MTMR14, MTMR15,
MTMR4, MTOR, BLES03, MTRR, BORCS5, MTSS1L, MUL1, MUM1, MXD4, MYCBP2,
MYH11, MYL9, MYO18A, MYOF, MYST2, MYST4, NAAA, NADSYN1, NAGK,
C16H1orf115, NAV2, NBEAL2, NCKAP5L, NCOA2, NCOA6, C25H7ORF26, NDST2,
C28H10orf54, NEU3, NFATC1, NFIA, NFIC, NFIX, NFYC, NHSL2, NIPSNAP1,
NIPSNAP3A, NISCH, CAMK2G, NOL4L, CBX7, NOSIP, CCDC125,, NOVA2, NPEPL1,
CCDC14, NPNT, CD34, NR0B2, CFAP126, CNNM3, CRTC1, NR2F2, NR5A1, CTC1,
NSD1, NUAK1, CYYR1, NUP214, NUP62, NUP85, OGFOD2, DAPK2, OIT3, DMD,
ORAI1, OSBP, OSBPL7, OXSM, DNASE1, PACS1, PALD1, PAN2, PAPSS1, PARG,
PARP1, PARP4, PATL1, PATZ1, PBX1, DNM3, PCDHGA5, PCGF2, PCIF1, PCNT,
PCNXL3, PCYOX1L, PCYT1B, PDE4DIP, PDE7B, DPF3, PDPR, PDZD2, PEAK1,
PELP1, FAM13C, PEX1, PEX10,, FAM193B, PFKM, PGAP2, PGAP3, PGM5, FAM198B,
PHC3, PHF14, PHF15, PHF20, PHF21A, FAM222B,, PIK3C2B, PIK3CG, PIK3R1, PIM2,
PIM3, PIP4K2B, PITPNM2, PJA2, PKD2L1, PKNOX2, FLT3LG, PLCG1,, PLEKHM3,
PLIN3, PLOD3, PLPP6, FOXL2, PLXNA2, PLXNB2, PLXND1, FSD1L, PMF1, PNKD,
GAB1, PNPLA2, PNPLA6, POFUT1, POGZ, POLD1, POLD2, POLDIP3, POLL, POLR1A,
POLR1E, POLR3A, POLR3B, POM121C, POMT1, POU6F1, PPARA, PPIL2, PPP1CA,
PPP1R13B, HLX, PPP1R9A, HOXD3, PPP2R5D, IFT52, PRDM10, PRDM6, PRELP,
PRICKLE1, PRKAB1, PRKACA, PRKCE, PRKCSH, PRKD2, PRKDC, PRPF19, IRF2,
PRR14, PRR3, ISYNA1, PSMF1, PTCH1, JUB, PTH1R, PTHLH, PTPN14, PTPN23,
PTPRF, PTPRG, PTPRS, KANK2, PXN, PYGB, RAB11B, RAB11FIP5, RAB1B, KANK3,
RAB37, RAB3A, RABGGTA, RAD52, KIAA1462, LDB1, LDLRAP1, LENG8, RBM47,
RBM5, LIN37, RECQL5, LIPE, REV3L, RFFL, LMAN2L, RFX1, RGL1, RHBDF1,
RHOBTB1, RHOG, RNASEN, LOC509283, RNF123, RNF135, RNF145, RNF169,
LOC511229, RNF26, RNF31, RNF40, RNF44, RPAP1, RPRD2, RPS6KA5, RPTOR,
RREB1, LOC515697,, RUNX1T1, LRIG3, RWDD3, MAMSTR, SAP130, SAP30BP, SAP30L,
SARS2, SART3, SCAF1, MFSD9, SEC16A, SEC24C, SELO, SEMA6D, SEPN1, SEPT4,
SEPT8, SERPINA14, SETD1B, MPPED2, SF3A1, SF3A2, MSRA, MTP18, SFXN2, MTSS1,
SHPRH, SIAH2, SIN3B, SIPA1, SIRT2, SLC10A5, NAIF1, SLC19A1, NFIB, SLC24A3,
SLC27A1, NHSL1, NLRX1, NOTCH3, SLC2A9, SLC35A4, SLC35E2, NPHP3, SLC37A4,
NPR3, SLC41A1, SLC46A3, SLC47A1, NR2C2, SLC7A8, SLC8A1, SLC9A1, SLC9A3R2,
SLCO2B1, NR2F1, SMARCA2, NR5A2, SMARCC2, SMARCD2, SMC1A, SMG1, SMG6,
NUMA1, SMPD2, SMYD4, SNRNP200, PCDH12, SOGA1, SORBS3, SOS1, PER3, SPG11,
SPIDR, SPRY3, PHACTR4, PHLDB2, SPTAN1, SPTBN1, PIEZO2, SRCAP, SRGAP2,
SRRM1, SRRM2, PLEKHA2, PNMA1, PODXL, STAP2, PPARGC1B, STAT1, STAT2,
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STBD1,, PPP1R3B, STK36, PPP2R4, STOML1, PRR12, PTGDS, RAB7L1, SUN2, SYNE2,
SYNPO2, SZT2, TAB1, TACC2, TAF4, TAF6L, TAF8, RARG, RASGRP3, TAOK2, TAPBP,
TBC1D16, TBC1D2B, TBC1D4, TBC1D8, RMND5B, TBC1D9B, TBCD, TBXA2R,
TCF7L2, LOC100337120, TCP11L1, TDRD7, RNF214, TENC1, RUBCN, TGFBR2, TH1L,
RXRB, TIE1, TIRAP, TJP1, TLDC1, TLN1, SETDB1, TMCC1, TMCO4, TMCO6,
TMEM106A, TMEM127, TMEM138, TMEM204, TMEM214, TMEM265, SFRS14,
TMEM41A, SFRS8, TMEM51, TMEM52, TMEM62, TMEM63A, SLC29A3, TMEM88,
TMEM8A, TMEM94, SMIM10, LOC783362, TNKS, TNRC6A, TNRC6B, SPRY4, TNS1, ST5,
ST6GAL1, TP53, TPCN1, TPCN2, TRAFD1, TRAPPC1, TRAPPC9, TRIB2, TRIL, TRIM11,
TRIM21, TRIM25, TRIM41, TRIM44, TRIM45, STARD9, TANC1, TRIP10, TRM1L, TRPV2,
TRRAP, TSC2, TSC22D3, TSNARE1, TSPAN11, TSPAN4, TSPAN5, TSPAN9, TTC21B,
TTC28, TTC39A, TTC5, TTI1, TTLL12, TTLL4, TUBG1, TBC1D13, TULP4, TXNIP,
UAP1L1, TCN2, UBAP2L, UBE4B, UBIAD1, UBR4, UFSP1, UNC119, UNC93B1, UNG,
UNK, UPF1, TET1, USP19, USP20, USP21, USP22, USP24, USP48, THAP11, VAC14,
TMEM42, VAV3, VIPAS39, TNFRSF19, VIPR2, VMAC, VPS11, VPS13D, VPS37C, VPS39,
VPS52, VRK3, WDR11, WDR20, WDR34, WDR6, WDR76, WDR81, WDR91, WFDC5,
WIPF3, WIZ, WNK1, WWC3, WWP2, TNRC6C, XDH, TNS3, XPC, XPNPEP3, XRCC1,
TOR3A, TRIM62, TRIM65, ZBED5, ZBTB16, ZBTB20, ZBTB24, TRIM68, ZBTB45,
USHBP1, ZBTB6, ZBTB7B, VAMP2, ZC3H4, ZC3H7B, ZC3HC1, ZCCHC11, VIPR1,
ZER1, WDR59, ZFHX3, ZFP3, ZFP62, ZFYVE26, ZHX3, ZBTB4, ZBTB40, ZMYND8,
ZC2HC1C, ZNF142, ZC4H2, ZNF346, ZEB2, ZNF384, ZNF385A, ZNF395, ZNF414,
ZNF423, ZMYM3, ZNF445, ZNF449, ZNF470, ZNF503, ZNF512B, ZNF518B, ZNF22,
ZNF592, ZNF605, ZNF618, ZNF362, ZNF652, ZNF687, ZNF689, ZNF704, ZNF710,
ZNF768, ZNF828, ZRANB3, ZNF585A, ZNF629, ZNF827, CCR10, CD6, CDK18, CEP135,
ZNFX1, IQSEC2, LOC508648, LOC100138414, LOC100336686, LOC616365, PLEKHH1,
PMS2, SLFNL1, TRERF1, WDR62, YDJC, ZKSCAN2, ARHGAP25, CARD6
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Appendix B-3 – Biological process annotation of differentially expressed genes from
each time point
(A) Percent of mapped genes with “transcription factor activity, RNA polymerase II core
promoter proximal region sequence-specific binding” or “protein binding” annotations based
on DAVID molecular function analysis (GOTERM_MF_ALL) of all differentially expressed
genes from each time point. (B) Percent of mapped genes with “transcription factor
(PC00218)”, “hydrolase (PC00121)”, or “transferase (PC00220)” annotations based on
Panther Protein Class analysis of differentially expressed genes from each time point.
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Appendix B-5 – Physiological characteristics of the study animals

A
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Appendix B-4 – Physiological characteristics of the study animals
Mid-cycle cows (n = 3/time point) were treated with 25 mg PGF2α for 0.5, 1, 2,
and 4 hours or saline (n = 4). Symbols indicate individuals or each ovary, with
mean ± SEM overlaid. (A) Age (in years) of cows at ovariectomy. (B) Number
of antral follicles present on each ovary from study animals. (C) Total weight of
each ovary from study animals. (D) Weight of corpus luteum (CL) from each
study animal. (E) Previous number of calves from each study animal. (F) Serum
progesterone concentrations of cows 0.5 - 4 hour post-PGF2α treatment (n =
3/time point). * P ≤ 0.05, ** P ≤ 0.01 compared to saline-treated animals using
one-way ANOVA followed by Bonferroni's multiple comparison test.

Appendix B-4 – Physiological characteristics of the study animals
Mid-cycle cows (n = 3/time point) were treated with 25 mg PGF2α for 0.5, 1, 2,
and 4 hours or saline (n = 4). Symbols indicate individuals or each ovary, with
mean ± SEM overlaid. (A) Age (in years) of cows at ovariectomy. (B) Number
of antral follicles present on each ovary from study animals. (C) Total weight of
each ovary from study animals. (D) Weight of corpus luteum (CL) from each
study animal. (E) Previous number of calves from each study animal. (F) Serum
progesterone concentrations of cows 0.5 - 4 hour post-PGF2α treatment (n =
3/time point). * P ≤ 0.05, ** P ≤ 0.01 compared to saline-treated animals using
one-way ANOVA followed by Bonferroni's multiple comparison test.
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Appendix B-6 – Differentially expressed transcripts included within each SOM

Immediate-Early
Response

Up-Regulated Transcripts (33)
ABT1, ADAMTS1, ADAMTS4, ANGPT2, APOLD1, CCND1, CDC42EP2, CIRH1A,
CYR61, DLL1, DNAJB1, DNAJB4, EGR1, ERF, FOS, FZD4, IER2, JMJD6, JUN,
KLF16, LOC100138911, LOC786156, NFKBIZ, NR4A2, PCF11, PDE7B, PER1,
PLK2, PPP1R10, PPP1R16B, RAB7B, RABGEF1, RGS2, RND1, SNAI1, SNAI2,
ZC3H12A

Down-Regulated Transcripts (144)
ABCA7, ABCC5, ABLIM1, ADAP2, AHDC1, AKIP1, AOC3, ARHGEF10L, ARMC2,
ARMCX6, ARRB1, ATP1B2, BCAR3, BLES03, C13H20ORF27, C4H7orf23,
C8H9orf23, CACNB2, CALB2, CBX7, CCDC125, CCDC14, CDC42EP1, CIRBP,
CLEC3B, DGCR6L, DISP1, EML5, FAM193B, FAM82A1, FGD6, FIS1, FLVCR2,
GLTPD1, GRIA1, GTF3C4, HES2, HLX, HOXD4, HSPA12B, IFT52, KCNN3, LBH,
LDB1, LENG8, LIMS2, LIN37, LMAN2L, LOC100125412, LOC100139577,
LOC100335299, LOC100335495, LOC100336920, LOC100337457, LOC508354,
LOC510193, LOC513640, LOC514257, LOC514704, LOC514750, LOC515356,
LOC522449, LOC540918, LOC616821, LOC618094, LOC618454, LOC786352,
LOC787074, LOC789977, LOH12CR1, MAPK7, MAPRE3, MAST3, MFSD8,
MFSD9, MGC139026, MGC151567, MGC165685, MIR2450A, MRM1, MSRA,
MTMR11, MUSTN1, NHSL1, NPHP3, NPR3, NR1D1, OGT, PATZ1, PDRG1,
PHF14, PHLDB2, PIGS, PNMA1, PRR3, PRRG3, RAB30, RAB3A, RASA3, REM1,
RERE, RFTN2, RFX3, RMND1, RMND5B, RNF113A, SAP30L, SDPR, SF4,
SLC25A42, SLC39A14, SNCAIP, ST5, STK19, SUFU, TADA3, TANC2, TBC1D30,
TEK, THUMPD2, TMEM145, TMEM42, TNFSF10, TP53I11, TRIM41, TRIM65,
TSC1, TUBGCP5, URGCP, VAMP2, VAMP5, WDR59, YPEL3, ZC4H2, ZFP2,
ZFP62, ZMYND15, ZNF26, ZNF260, ZNF319, ZNF366, ZNF43, ZNF462, ZNF581
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Early
Response

Up-Regulated Genes (136)
AATF, ACSL3, AMD1, ANKMY2, ANKRA2, ARC, ARL4C,
ARL5B, ATF3, B3GALNT2, BAMBI, BCL6, BRIX1, BTAF1,
BTG2, C27H8orf4, CCDC85B, CCNYL1, CCRN4L, CCT2, CDK8,
CEBPD, CH25H, CRISPLD2, CSRNP1, DCLK1, DCUN1D3,
DHX15, DNAJB11, DNAJC21, DUSP1, DUSP2, EDNRB, EGR3,
EGR4, EIF3B, EIF3J, EIF4A1, FAM49B, FBXO33, FGF18,
FHOD3, FKBP5, FOSB, FOSL1, GADD45A, GADD45G, GJA1,
GNE, GOLM1, GPRC5B, HAT1, HSPH1, IFRD1, IGFBP3,
INSIG1, JUNB, JUND, KIAA0020, KLF5, KLF6, LOC100174924,
LOC100295476,
LOC100295973,
LOC100296226,
LOC100297981,
LOC100299027,
LOC100336279,
LOC100337254, LOC524703, LOC529462, LOC539374,
LOC541159,
LOC613882,
LOC784070,
LOC785063,
LOC785529, LOC787610, LTV1, LYSMD3, MAP3K2, MAP7D2,
MCL1, MGC137708, MGC142811, MGC148992, MXI1, MYC,
MYL6B, NAB1, NEXN, NFIL3, NOP58, NPPC, NR4A1, NR4A3,
ONECUT2, PDE4B, PEX12, PFDN6, PFKFB3, PHLDA1,
PHLDA2, PLAT, PLSCR4, PPP1CC, PPP1R15A, RABEP1,
RASD1, RDH12, RFK, RND3, RNF122, SEMA7A, SFPQ,
SLC20A1, SLC2A3, SLC4A7, SLCO4A1, SMARCA1, SMARCA5,
SMOC1, SNX18, SPTY2D1, STC1, TEAD4, TIGAR, TLE3,
TMEM2, TMEM65, TP53BP2, TRAF1, TRIB1, ZBTB10, ZBTB5,
ZFP36

Down-Regulated Genes (240)
AASDH, ABCA1, ABCC3, ABHD14B, ACP2, ADCK2, AFF2, AKAP11, AKAP8L, AKR1A1, ALDH3A2, ALG8,
AMIGO1, ANAPC5, ANGEL1, APEX2, ARHGAP19, ARHGAP20, ARHGAP25, ASB16, ATF7IP, ATXN7L1,
C10H15orf41, C14H8ORF70, C23H6ORF47, C28H10ORF35, C2H2orf24, C9H6ORF203, CARD6, CC2D1A,
CC2D2A, CCDC8, CCND3, CDON, CEP68, CHD8, CHST7, CIAO1, CLN6, CNOT8, COG1, COG8, CPT2,
CSTF1, DACT1, DAG1, DBP, DCAF4, DDX31, DENND1A, DEPDC5, DNAJC16, DNAJC30, DPAGT1, DSCR3,
DUSP10, EHMT2, EIF2C4, EIF4EBP2, ERAP1, ERCC3, ERCC5, FAM120B, FAM122A, FAM33A, FAM73B,
FARP1, FBXL12, FBXO10, FIGN, FITM2, FKBP15, FLAD1, FN3KRP, FOXL2, GATSL3, GEMIN4, GON4L,
GPAM, H1F0, HAUS4, HDAC6, HDGF2, HEATR5B, HEXIM1, HIG2, HLCS, INPP5B, IRF2, JMJD2A, KBTBD4,
KCTD21, KEAP1, KIAA1539, KIF3B, LATS1, LNPEP, LOC100138392, LOC100140430, LOC100295097,
LOC100295263, LOC100336406, LOC100336473, LOC100336856, LOC506615, LOC508153, LOC508720,
LOC509858, LOC512910, LOC516630, LOC539472, LOC540169, LOC616198, LOC618190, LOC787062,
LRIG3, MAP3K7IP1, MAPK8IP3, MARVELD1, MCM9, MEN1, MEPCE, MGC134150, MGC139126,
MGC155141, MGC159500, MICAL1, MID1IP1, MKKS, MKS1, MRPS24, MSH6, MTHFD1, MTRR, MUM1,
MYCBP2, MYST2, NCKAP5L, NDST2, NEK4, NEU3, NFYC, NGRN, NIPSNAP3A, NPEPL1, NR0B2, NR1H4,
NR2F2, NR5A1, NSD1, NUP62, PAPSS1, PARG, PCDHGA5, PCIF1, PDE4DIP, PGAP2, PHF15, PHF20,
PIK3C2B, PIP4K2B, PJA2, PNPLA6, POFUT1, POLDIP3, POLR1E, POLR3B, PRICKLE1, PRUNE, PSKH1,
PTCH1, PTHLH, PYGB, RECQL5, RGL1, RHOBTB1, RNF135, RNF145, RNF169, RNF26, RNF31, RNF44,
RNPEPL1, RPRD2, RWDD3, SEMA6D, SETD1B, SF3A1, SLC16A14, SMARCD2, SMPD2, SOS1, STBD1,
STOML1, SYNPO2, TAF8, TBC1D13, TBC1D4, THAP11, TMEM164, TMEM214, TMEM62, TNFAIP8, TRIM21,
TRIM62, TRIM68, TRIP6, TRM1L, TSPAN11, TTC21B, TTC5, TTLL12, TUBG1, TXNIP, UBIAD1, UNG, USP19,
USP20, USP21, VPS11, VPS52, WDFY2, WDR11, WDR20, WDR76, XPNPEP3, XRCC1, ZBED5, ZBTB24,
ZBTB45, ZBTB6, ZBTB7B, ZFP3, ZNF142, ZNF22, ZNF346, ZNF449, ZNF624, ZNF652, ZNF689
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Delayed-Early
Response

Up-Regulated Genes (286)

Down-Regulated Genes (288)

ABCE1, ABL2, AGFG1, AHI1, AMIGO2, AP1S3, AREG, ARG2, ARID5B, ASAM,
ATP11B, ATP13A3, ATP2A2, BACH1, BCAS2, BCL2L11, BCL3, BHLHB2,
BTBD10, BTG1, BTG3, BZW1, BZW2, C12H13orf30, C15H11orf46,
C1H21ORF91, C9H6ORF115, CBFB, CCDC41, CCDC80, CCL3, CCNC, CD83,
CDC42SE2, CDK17, CDKN1A, CHAC1, CHIC2, CHKA, CHSY1, CLDND1, CNN1,
COQ10B, CSRP2, CSRP3, CWC22, CXCL5, DAPP1, DDX39, DDX3X, DDX5,
DNAJA1, DNAJB6, DNAJB9, DPH3, DUSP5, EDN2, EIF1B, EIF2C2, ELL2,
ENTPD7, F2RL1, F2RL2, F3, FAM8A1, FBXL14, FERMT2, FGF2, FGF7, GAS1,
GCH1, GDF11, GDPD1, GEM, GLRX2, GPR137B, GPR155, GPR68, GPRC5A,
GTF2E2, H2AFZ, HAUS3, HGF, HIGD1D, HK2, HMGA1, HOMER1, HPCA,
HSPA5, ICOSLG, IER3, IFNAR1, IL1A, IL1R1, IL33, CXCL8, INA, INHBA, IRAK2,
ISG20L2, ITGA2, ITGAV, IVNS1ABP, JAK2, JARID2, JMJD1C, JPH1, JPH2,
KBTBD8, KRT18, KRT8, LDHA, LHFPL2, LIN7C, LMCD1, LOC100139161,
LOC100270684,
LOC100296849,
LOC100297185,
LOC100297291,
LOC100298623,
LOC100336688,
LOC100336779,
LOC100337139,
LOC100337302, LOC286871, LOC510442, LOC510487, LOC513388,
LOC515823, LOC521504, LOC533324, LOC538547, LOC540234, LOC540868,
LOC617407, LOC617986, LOC768081, LOC782348, LOC782470, LOC782740,
LOC784446, LOC784704, LOC785868, LOC786258, LOC788082, LONRF3,
LRP12, LRRC8B, LRRN3, LSM1, LYPD2, MANF, MAP1LC3C, MAP2K3,
MAP3K8, MARCKSL1, METAP2, MEX3C, MGC165939, MIR21, MIR220C-1,
MMP12, MT2A, MUSK, MXD1, Mynn, NAP1L5, NDRG1, NET1, NFKB1, NIPAL1,
NKAIN1, NP, NUPL2, OAF, OBFC2A, OSBPL11, P2RY6, PAK1IP1, PCP4L1,
PDE8A, PDP1, PELI1, PICALM, PIK3CA, PIM1, PITPNC1, PKNOX1, PLAUR,
PLIN2, PLK3, PLOD2, POLB, PPM1D, PPP1CB, PPP4R2, PPP4R4, PSME4,
PTX3, RAB20, RAI14, RASA2, RASSF8, RBBP8, RCAN1, RERG, RGS16, RHEB,
RIOK3, RNF125, RNF19B, RNF24, RPF2, RPS12, RRP15, RSBN1, RSL24D1,
RUNX1, S1PR3, SAMD8, SBNO2, SDC4, SELI, SERPINA11, SERPINB2,
SERPINE1, SERTAD2, SETD8, SGMS2, SLC13A3, SLC20A2, SLC25A33,
SLC26A2, SLC2A1, SLC37A3, SLITRK2, SMG9, SNAP25, SOCS1, SOCS3, SOX4,
SPCS3, SPP1, SPSB1, SRF, SRXN1, SSFA2, STEAP1, STK17B, STK38L, STX11,
SUCLA2, TAF4B, TBC1D8B, TBC1D9, TFPI2, THBD, THBS1, TIAM1, TIMM17A,
TIMM8A, TMEM30B, TMF1, TNFRSF12A, TRAM1, TUFT1, TWF1, TXN, UBE2B,
UBE2N, UBE3A, UTP15, VAT1L, XCL2, XIRP1, YOD1, YWHAZ, ZBTB43,
ZFAND2A, ZFAND5, ZNF385B, ZNF644, ZNRD1, ZSWIM4, ZSWIM6

ACBD4, ACD, ACP5, ACTN4, ADCY4, ADCY9, ADORA2A, ADPRHL2, ADRB1,
AGAP2, AGFG2, AGTR1, AHNAK, ALAD, AMOT, ARHGAP17, ARHGAP23,
ARID1A, ARRDC1, ATF7, ATP2C2, B3GNT3, BCL9L, BCOR, BRPF1,
C22H3ORF37, C25H7ORF26, C28H1orf198, C5H12ORF4, C8H9orf91, CABC1,
CAMK2G, CASP9, CBFA2T2, CBR1, CBX6, CD34, CDC42EP4, CEACAM8,
CHAD, CHMP1A, CHMP4C, CMTM4, CNNM3, COL4A3BP, COPS7A, CRTC2,
CTNS, CYYR1, DCP1B, DEF6, DHRS12, DIP2A, DMD, DNAJC17, DNASE1,
DTNBP1, DYSF, EIF4ENIF1, ENG, ERAL1, EVC2, EZH1, FAM115A, FBXO42,
FBXW4, FLT3LG, FOXN3, FOXO4, FOXRED1, FOXS1, FUT1, FYCO1, GAB1,
GATA4, GGA3, GNA14, GPIHBP1, GPR111, GPS2, GTF2I, H6PD, HAUS5,
HCRTR1, HIP1, HPS1, HS1BP3, HSDL1, ID3, ILDR2, ILVBL, INPP5K, IPO13,
JUB, KANK1, KANK2, KANK3, KDR, KIAA1462, KIF13A, KIF16B, KLHL26,
LASS1, LDLRAP1, LGALS9, LIPE, LOC100294795, LOC100296837,
LOC100302527,
LOC100335169,
LOC100335642,
LOC100336568,
LOC100336724,
LOC100336733,
LOC100336756,
LOC100337051,
LOC100337052, LOC100337088, LOC505156, LOC505719, LOC507983,
LOC511229, LOC512933, LOC518003, LOC522631, LOC523424, LOC531539,
LOC540132, LOC540480, LOC614014, LOC615144, LOC616063, LOC617808,
LOC783807, LOC785034, LOC785776, LOC786652, LOC789017, LPHN1,
MAMSTR, MAP4K2, MBNL2, MEF2C, MFNG, MICALL1, MINK1, MIR2416,
MLLT10, MMP15, MMS19, MOBKL2B, MPDZ, MTF1, MTMR4, MTSS1, MYH11,
NAAA, NBEAL2, NFATC1, NFIB, NHSL2, NIPSNAP1, NME6, NOVA2, NR1H3,
NR2C2, NR2F1, NR5A2, NUMA1, OSBPL7, PACS1, PCDH12, PEX10, PFKM,
PGM5, PHACTR4, PHF21A, PIK3CG, PITPNM2, PKDCC, PLCG1, PLEKHA2,
PNKD, PNPLA2, PODXL, POLD2, PPARA, PPP1R3B, PPP1R9A, PRDM10,
PRPF19, PRR12, PRR14, PTH1R, PTPN23, RAB11FIP5, RAB7L1, RABGGTA,
RAD52, RARG, RASGRP1, RASGRP3, RBM5, RHOG, RNF213, RNF214, RPAP1,
RXRB, SAP30BP, SEMA4C
, SETDB1, SF3A2, SHANK3, SIPA1, SIRT2, SLC24A3, SLC29A3, SLCO2B1,
SMARCA2, SORBS3, SPRY3, SPRY4, SPTBN1, ST6GAL1, STAB1, STAP2,
STARD9, STAT1, STAT2, STK36, STYXL1, TAF6L, TAOK2, TARBP1, TBC1D16,
TBC1D2B, TBC1D9B, TBXA2R, TCEA2, TCN2, TCP11L1, TDRD7, TENC1,
TGFBR2, TIRAP, TMCO6, TMEM106A, TMEM204, TMEM51, TMEM88,
TNRC6C, TNS1, TOR3A, TPCN2, TRIB2, TRIM11, TRIM26, TRIP10, TSC22D3,
TSPAN4, UBA7, UFSP1, UNC119, UNC93B1, UNK, USHBP1, VMAC, WDR91,
WIPF3, WWP2, XDH, ZBTB4, ZBTB40, ZC3HC1, ZER1, ZMYM3, ZMYND8,
ZNF362, ZNF384, ZNF395, ZNF423, ZNF445, ZNF592, ZNF687, ZNF704,
ZNF768, ZNF827, ZNFX1
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Late-Response

Up-Regulated Genes (321)
ABHD12B, ABTB2, AEBP2, AHSG, AKAP4, AKIRIN1, ALCAM, ANKRD1, ANO6,
ARF4, ARHGAP28, ARHGAP6, ATAD1, ATP2B1, ATP5I, ATP6V1C1, B4GALT5,
BCAP29, BCHE, BIRC3, BMP2, BTBD1, C12H13orf27, C16H1ORF21,
C17H12orf52, C23H6orf141, C29H11orf73, C6H4orf34, CA8, CAPZA2, CCDC58,
CCK, CCL2, CCL4, CCL8, CCNG2, CD14, CD40, CD44, CDH1, CFLAR, CGRRF1,
CLDN1, CLEC1A, CLEC1B, COMMD6, COX6C, CPNE8, CREB5, CRIPT, CRYAB,
CSF1, CTLA4, CTNNAL1, CXCL2, CYB5R4, CYSLTR2, DENND5A, DNAJC12,
DSTN, DTWD1, DUSP11, DUSP14, EIF1AX, EIF4E, EVI2A, EXOSC1, FAM18B,
FAM92A1, FBXO32, FGFR1OP2, FGR, FKBP14, GAL, GMCL1, GMFB, GMNN,
GMPR, GNPNAT1, GULO, HAUS6, HBXIP, HINT1, HINT3, HPCAL4, HS3ST5,
HSPA13, IBSP, IFT20, IGFBP1, IL18, IL1B, IL1RN, IL21R, IL4R, IL7R, INHBB,
INSIG2, IPMK, IRG1, ISCA1, ITGB8, KIAA1715, KLHL32, LLPH, LMO7,
LOC100137875,
LOC100138864,
LOC100140212,
LOC100140827,
LOC100294784,
LOC100294785,
LOC100294863,
LOC100294880,
LOC100295254,
LOC100295381,
LOC100295586,
LOC100295656,
LOC100295757,
LOC100295775,
LOC100296216,
LOC100296447,
LOC100296475,
LOC100296588,
LOC100296684,
LOC100296722,
LOC100296944,
LOC100297075,
LOC100297131,
LOC100297413,
LOC100297496,
LOC100297676,
LOC100297932,
LOC100298628,
LOC100300164,
LOC100301462,
LOC100335253,
LOC100335275,
LOC100335936,
LOC100336429,
LOC100336518,
LOC100336625,
LOC100337076, LOC100337126, LOC100337445, LOC407171, LOC509094,
LOC516629, LOC520588, LOC521363, LOC532603, LOC538197, LOC613460,
LOC613970, LOC614438, LOC614643, LOC615784, LOC616520, LOC619061,
LOC781142, LOC781416, LOC781612, LOC781807, LOC782021, LOC782162,
LOC782266, LOC782402, LOC782950, LOC783459, LOC783838, LOC784097,
LOC784207, LOC784931, LOC785449, LOC785455, LOC785745, LOC786131,
LOC787187, LOC788496, LOC789095, LRRC57, LRRC58, MAGI3, MAN1A1,
MAP4K5, MAPK6, MAPKAPK3, MAPKSP1, MEMO1, METRNL, MGC127538,
MGC127989, MGC133504, MGC143035, MGC148938, MGC148942, MICAL2,
MIER1, MIR147, MIR2469, MMP1, MOSPD2, MRPL39, MRPL42, MRPS16,
MRPS18C, NCALD, NDUFB1, NUCB2, NUDCD1, ODF2L, OLR1, OSTM1, PAG1,
PAPD7, PCNP, PDCD10, PDGFC, PDLIM4, PEX13, PKIB, PLA2G7, PLN, POLE4,
POLR2K, PPAPDC3, PPP1R2, PPP1R3C, PRDM1, PRKCD, PRR5L, PSMD14,
PSTPIP2, PTGER2, RABGGTB, RBM18, RBM7, RCHY1, RCN2, RDH11, RNFT1,
RPIA, RPL27, RPL34, RPS21, RRAS2, S100A12, S100A9, SAMD4A, SEC61G, SELK,
SELP, SEMA3C, SF3B14, SGPP1, SGTB, SH3GL3, SLC12A2, SLC19A2, SLC25A25,
SLC33A1, SLC38A1, SLC39A8, SLC41A2, SLMO2, SNRPD1, SNRPG, SNX13,
SNX31, SNX4, SOAT1, SPHK1, SRD5A1, STAMBP, STK17A, SUB1, TAF13, TANK,
TBCA, TERC, TET3, TFB2M, TGFBR1, TGIF1, THAP5, THEX1, TMEM126A,
TMEM136, TMEM14A, TMEM165, TMEM188, TMEM189-UBE2V1, TMEM26,
TMEM40, TMEM41B, TMEM45A, TMEM64, TMOD1, TMX1, TNFAIP8L3, TNFSF4,
TPM4, TRPC4, TRPM6, TRPM7, TSPAN12, TXNRD1, TYW3, UAP1, UBE2D1,
UBE2W, UCHL3, UFM1, UPRT, UXT, VBP1, WDR44, WDR89, XBPP1, YWHAQ,
ZCCHC10

Down-Regulated Genes (320)
AACS, AAK1, AARS, ABCF3, ABCG2, ABHD14A, ACACA, ACIN1, ADAMTS17,
ADD1, AGK, AGRN, ALDH3B1, ANKLE2, APLNR, AR, ARFGEF2, ARHGAP18,
ARHGEF7, ARID1B, ARSB, ASXL2, ATF5, ATN1, ATXN2, ATXN7, AUTS2, B3GNT9,
BAT2, BAT2L1, BAZ1B, BAZ2A, BCL9, BNC2, CAPN1, CASC3, CBL, CBR4,
CEP110, CHD2, CKAP5, CLASP1, CLMN, CNDP2, CNST, COL4A2, COQ4, CPE,
CREBBP, CUL7, CUX1, CXORF36, CYB5R3, DAAM2, DAB2, DAGLA, DCLRE1B,
DCTN1, DHX30, DHX37, DIP2B, DOCK6, DOCK9, DUSP15, DVL3, EEF2K,
EFTUD2, EHD2, EIF2B4, ELMO1, EMCN, EMP2, EPB41, FADS6, FAM59A, FASN,
FBLIM1, FBLN5, FBN1, FBXL6, FBXL8, FES, FGD1, FIBIN, FLOT2, FLYWCH2,
FOXJ2, FTSJD2, FUT4, FUT8, GALNS, GALNT10, GANAB, GBA2, GCC1,
GCN1L1, GIT2, GLG1, GPR4, GTF3C1, GYS1, HCFC1, HECW2, HGS, HSD17B14,
HSPG2, IFT122, IFT88, IGF2R, IGFBP2, IL11RA, INADL, INPP5D, INTS1, INTS3,
IQGAP2, ITGA9, ITSN1, KDM2A, KLF12, KPTN, LAMA4, LARP1, LHPP, LNP1,
LOC100137838,
LOC100138783,
LOC100295338,
LOC100296937,
LOC100298629,
LOC100300734,
LOC100336508,
LOC100336586,
LOC100336604,
LOC100336651,
LOC100336769,
LOC100337072,
LOC100337134, LOC100337236, LOC100337329, LOC507299, LOC509490,
LOC510855, LOC511523, LOC511901, LOC512110, LOC512168, LOC512286,
LOC517133, LOC517559, LOC518768, LOC523454, LOC524694, LOC524974,
LOC527362, LOC527591, LOC529211, LOC533444, LOC537748, LOC538506,
LOC539067, LOC616014, LOC767865, LOC783344, LOC785548, LOC785659,
LOC790124, LRRC41, LRRK1, LRSAM1, MAP3K4, MAP3K6, MAPRE2, MCM4,
MDN1, MECP2, MED12, MED22, MGC138976, MIB2, MLH3, MLL2, MMP2,
MOBKL2A, MON1B, MORC2, MOV10, MPP5, MTMR14, MTMR15, MTOR, MUL1,
MXD4, MYO18A, MYOF, MYST4, NAGK, NFIA, NFIC, NFIX, NUAK1, NUP214,
NUP85, OIT3, OLFML1, OSBP, PAN2, PARP1, PARP4, PATL1, PBX1, PCNXL3,
PCYOX1L, PCYT1B, PDZD2, PELP1, PEX1, PIK3R1, PKNOX2, PLIN3, PLOD3,
PLXNB2, PLXND1, PMF1, POGZ, POLD1, POLL, POLR1A, POLR3A, POMT1,
PPIL2, PPP1R13B, PPP2R5D, PRDM6, PRELP, PRKAB1, PRKACA, PRKCSH,
PRKD2, PTPN14, PTPRF, PTPRS, RBM47, REV3L, RHBDF1, RNASEN, RNF123,
RNF40, RPS6KA5, SAP130, SARS2, SART3, SCAF1, SEC16A, SEC24C, SELO,
SEPN1, SETMAR, SF3B4, SFXN2, SLC12A6, SLC19A1, SLC46A3, SLC47A1,
SLC7A8, SLC8A1, SMC1A, SMG1, SMYD4, SNRNP200, SPG11, SREBF1, SRGAP2,
SRRM1, SUN2, TBCD, TH1L, TJP1, TLN1, TMCC1, TMEM41A, TMEM52,
TMEM63A, TMEM8A, TNKS, TNRC6A, TNS3, TRAPPC9, TRIM44, TRRAP, TSC2,
TSPAN18, TTC39A, TTLL4, UAP1L1, UBAP2L, UBE4B, UPF1, USP22, USP24,
USP48, VAC14, VAV3, VPS39, WDR34, WDR81, WFDC5, WIZ, WNK1, XPC,
YLPM1, ZBTB16, ZC3H4, ZCCHC11, ZNF385A, ZNF503, ZNF518B, ZNF787,
ZRANB3, ZZEF1
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BiPhasic
Response

Up-Regulated Genes (26)
CRABP2, DES, FAM148A, FCHSD2, IL18BP, LOC100140276,
LOC100336666, LOC100337178, LOC789021, LY96, MIR2475,
NFKBIA, OXT, PDE4D, PENK, PTBP2, RUNDC3B, RUSC2, SEPW1,
SRGN, TM4SF1, TMEM14C, TNFAIP3, UNC50, USP2, XIST

Down-Regulated Genes (222)
ACAD10, ACAP3, ADAMTSL5, AEBP1, AFF1, AFF3, AGPAT1, AKAP13, ANXA11, AP1B1, ARAP1,
ARHGEF11, ARSG, ASAP1, ATF6B, B9D2, C9H6ORF70, CABIN1, CAMKK2, CASKIN2, CCDC106, CCS,
CELSR2, CIZ1, CLIC5, CNOT3, CNOT4, COG7, CPEB2, CPSF1, CRTC1, CRY2, DAB2IP, DENND4B,
DHX57, DIS3L2, DOPEY2, DPF3, DTX2, EGFLAM, EMD, EP400, ERN1, EXOC3L, FAM13A1, FANCG,
FBRS, FBXW12, FHOD1, FNTB, FRY, FZR1, G6PD, GALT, GBF1, GDPD5, GIPC1, GLE1, GRN, HADH,
HEATR7A, HERC2, HEXDC, HOXC6, HSPA2, HUWE1, IKBKG, INO80D, ISYNA1, ITPR3, KIAA0406,
KLHL18, KLHL25, LAMB2, LOC100297361, LOC100298868, LOC100336841, LOC100336912,
LOC100337120, LOC100337133, LOC100337159, LOC100337193, LOC506074, LOC506315,
LOC508226, LOC508997, LOC510844, LOC511420, LOC513500, LOC515954, LOC520505, LOC522998,
LOC526847, LOC528987, LOC533805, LOC533894, LOC534002, LOC534434, LOC535053, LOC535946,
LOC536128, LOC538693, LOC539015, LOC540077, LOC615274, LOC619120, LOC783362, LOC784903,
LOC788113, LOC789485, LOC789747, LPCAT1, LRFN3, LTBR, MACF1, MAEA, MAMLD1, MAN2A2,
MAP1S, MAP2K2, MARK2, MAVS, MDC1, MED25, MGC128008, MGC151975, MIR1287, MIR2450B,
MIR2454, MLL, MOSPD3, MTP18, MTSS1L, MYL9, NADSYN1, NAV2, NCOA2, NCOA6, NGLY1, NLRX1,
NOSIP, NOTCH1, NPNT, OGFOD2, ORAI1, PCGF2, PDPR, PEX6, PGAP3, PHC3, PIM2, PKD2L1,
PLCB3, PLEKHM3, PLXNA2, PML, POU6F1, PPP1CA, PPP1R12C, PPP2R4, PRKCE, PRKDC, PSMF1,
PTGDS, PTPRG, PXN, RAB11B, RAB1B, RFFL, RPTOR, RUNX1T1, SFRS14, SFRS8, SHROOM4,
SLC27A1, SLC35A4, SLC37A4, SLC41A1, SLC9A1, SLC9A3R2, SMARCC2, SMG6, SNX29, SPTAN1,
SRRM2, SYNE2, TACC2, TAF4, TAPBP, TBC1D8, TCF7L2, TIE1, TMEM127, TMEM138, TNRC6B, TP53,
TPCN1, TRAFD1, TRAPPC1, TRIM25, TRIM45, TRPV2, TSNARE1, TSPAN5, TSPYL4, TTC28, TTLL3,
UBR4, VPS13D, VPS37C, VRK3, WDR6, ZBTB20, ZC3H7B, ZEB2, ZFYVE26, ZHX3, ZNF414, ZNF496,
ZNF605, ZNF618, ZNF828

